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ABSTRACT
In the course of this work a novel strategy has been developed for linking the adjuvant 
Escherichia coli heat-labhe enterotoxin subunit B (LTB) to Simian Immunodeficiency Virus 
(SrV) proteins via an antibody bridge and the systemic and mucosal immunogenicity of 
such SIV-MAb-LTB complexes have been investigated.
A short peptide tag, termed Pk, was joined to the 3’-end of the gene coding for LTB 
and expression studies revealed that the gene product, LTB-Pk, could be efficiently 
synthesised and secreted from non-pathogenic Vibrio sp.60. Analysis of the functional 
properties of LTB-Pk demonstrated that LTB-Pk , like native LTB, was a heat-labile 
oligomer, that could bind to the glycolipid GMl-ganglioside and was immunogenic in vivo. 
In attempts to purify LTB-Pk for immunisation studies, both hydrophobic and ion-exchange 
chromatogi'aphy schedules were analysed, the latter procedure being more efficient. 
Strategies were developed for joining LTB-Pk to one arm of an anti-Pk MAb, (MAb SV5-P- 
k) and Pk-linked SIV proteins to the other arm, and such SIV-MAb-LTB complexes bound 
to GMl-ganglioside in vitro. Systemic immunisation studies suggested that SIV-MAb-LTB 
complexes, using recombinant pl7 as the target antigen, promoted both humoral and cell- 
mediated immunity to the recombinant pl7. In addition, it was later shown that conjugation 
of LTB-Pk to recombinant SIV proteins via an antibody bridge, msWtedIn a mere effieent 
presentation of the recombinant SIV protein to the immune system, than co-administration 
of LTB-Pk with the recombinant SIV protein. However, intranasal administration of pl7- 
MAb-LTB complexes did not induce immunity to recombinant pl7. Subsequently it was 
shown that the recombinant p i7 was highly susceptible to mucosal degradation, suggesting 
the poor mucosal immunogenicity of pl7-MAb-LTB complexes may be related to the 
instability of recombinant pl7 in the mucosal environment. Further investigations into the 
stability of other recombinant SIV proteins in the mucosa, revealed that recombinant p27 
was more resilient to mucosal degradation. p27-MAb-LTB complexes were constructed and 
initial intranasal immunisation studies revealed that both systemic and cell-mediated 
immunity to recombinant p27, could be induced following intranasal administration.
Furthermore, mucosal immunity to recombinant p27 was evident in the lungs of vaccinated 
mice, with anti-recombinant p27 IgG-secreting cells predominating.
ABBREVIATIONS
NUCLEIC ACIDS
1
DNA 2' deoxyribonucleic acid
RNA ribonucleic acid
A adenine (base in DNA/RNA)
G guanine (base in DNA/RNA)
C cytosine (base in DNA/RNA)
T thymine (base in DNA)
U uracil (base in RNA)
ATP adenosine 5' triphosphate
GTP guanosine 5' triphosphate
cAMP cyclic 3’, 5' adenosine monophosphate
mRNA messenger RNA
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D Asp aspartate P Pro proline
E Glu glutamate Q Gin glutamine
F Phe phenylalanine R Arg arginine
G Gly glycine S Ser serine
H His histidine T Thr threonine
I He isoleucine V Val valine
K Lys lysine W Trp tryptophan
L Leu leucine Y Tyr tyrosine
PHYSICAL UNITS
“C temperature in degrees Celsius
g gram mass or centrifugal force
mg milli gram (10"3 g)
Hg micro gram (lQ-6 g)
ng nano gram (10-9 g)
1 litre volume
ml milli litre
micro litre
Ci Curie (measure of radioactivity = 3.7x 10^ ^^  
disintegrations/second)
\iCi micro Curie
M molar concentration
lïiM milli molar
fxM micro molar
kD kilodalton
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PH -logio[H+]
V volts
mA milli amperes
U units of enzyme activity
in^ inches squared
Ib pounds
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Â angstrom (lO-^ ®)
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3R radioisotope hydrogen-3
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AMP 2-amino-2-methyl-1-propanol
IPTG isopropyl-P-D-thiogalactopyranoside
TBE Tris-borate-EDTA buffer
Triton t-Octyphenyloxpolyethoxyethanol
VIRUSES
SV5
RSV
LCMV
HIV#
FMDV
SIV
HSV-2
simian virus type 5 
respiratory symcytial virus 
lymphocytic choriomeningits virus 
human immunodeficiency virus 
foot and mouth disease virus 
simian immunodeficiency virus 
herpes simplex virus-2
MISCELLANEOUS
ADCC
APC
AIDS
ASC
Ab
antibody -dependent cell-mediated cytotoxicity
antigen presenting cell
acquired immunodeficiency virus
antibody secreting cell
antibody
B cells
BSA
BCG
B lymphocytes
bovine serum albumin
bovine bacillus Calmette-Guerin
CD#
CFTR
CTL
CMI
C-terminus
CT
CTB
cluster designation
cysitic fibrosis transmembrane receptor
cytotoxic T cell
cell-mediated immunity
carboxyl terminus
cholera toxin
cholera toxin subunit B
DH diversity gene of immunoglobulin heavy chains
ELISA
ELISPOT
env
ER
e.g.
E.coli
enzyme-linked immunosorbent assay 
enzyme-linked immunospot assay 
envelope
endoplasmic reticulum 
for example 
Escherichia coli
ECL enhanced chemiluminscence
Fab
Fig.
FPLC
Fc
FcR
FCA
FDC
antigen-binding fragment of antibody 
figure
fast protein liquid chromatography 
crystalisable fragment of antibodies 
receptor for the Fc region of antibodies 
Freund's complete adjuvant 
follicular dendritic cell
gag
GMl
gP
GST
group-specific antigen 
GMl -monosialoganglioside 
glycoprotein 
glutathione-S-transferase
H-2
H
HRP
HBcAg
HBsAg
designation for the murine MHC locus; chromosome 17
heavy chain of antibodies
horseradish-peroxidase
Hepatitis B virus core antigen
Hepatitis B virus surface antigen
Ig#
IL-#
IFN-Y
immunoglobulin 
interleukin 
gamma interferon
'H joining gene of immunoglobulin heavy chains
L-broth
L-agar
L
ISCOMS
LT
LTB
Luria broth 
Luria agar
light chain of antibodies 
immunostimulatory complexes 
E.coli heat-labile enterotoxin 
E.coli heat-labile enterotoxin subunit B
MAb
MHC
MDP
MAPS
monoclonal antibody 
major histocompatibility complex 
A-acetylmuramyl-L-analanyl-D-isoglutamine 
multiple antigen peptide system
O.D.
NTA
optical density 
nitrilotriacetic acid
PAGE
Pr.A
PHA
polyacrylamide gel electrophoresis
protein A component of Staphylococcus aureus
phytohaemagglutinin
rIL-2 recombinant interleukin-2
SMAA 
St. aureus
solid matrix-antibody-antigen complex 
Staphylococcus aureus
T cells
TcR
TyrVLP
TH#
TNF#
t-MDP
T lymphocytes 
T cell receptor 
Ty: virus-like particle 
T helper cell 
tumour necrosis factor 
threonyl-MDP
U.V.
Vl
Vh
v/v
WB
w/v
ultra violet
variable region of antibody light chains 
variable regions of antibody heavy chains 
volume per total volume ratio
western blotting
weight per total volume ratio
<
>
%
less than 
greater than 
percent
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INTRODUCTION,
Vaccination remains one of the most effective strategies for protecting man against 
viral infections. Vaccination specifically primes the cells of the adaptive immune system, the 
B and T cells, which enable them to respond quicker and with greater magnitude upon 
subsequent infection, and thereby, decreasing the severity of the disease.
Vaccination technology has advanced remarkably over the years, principally due to 
the developments in DNA technology which have now made it possible to construct subunit 
vaccines that contain only the epitopes important in the priming of B and T cells. This 
project, has adopted the subunit approach, with the aim of developing subunit vaccines that 
prime the immune system to the Simian Immunodeficiency Virus (SIV), and potentially 
Human Immunodeficiency Virus (HIV).
One of the fundamental aspects in the design of any vaccine, is to have a clear 
understanding of the adaptive immune responses, the role they play in the control of virus 
infections and the molecular events that lead to their activation.
The objective of the first two sections of this introduction is to present a generalised 
review of the adaptive immune system, its role in the control of viral infections, and how 
our understanding of this system is influencing vaccine design. In later sections of the 
introduction, a brief review of SIV is presented and some of the current vaccination 
strategies under investigation in the control of the virus infection are discussed. Finally, in 
the last section of the introduction, the major aims of this project are presented.
A. Adaptive Immune Responses To Acute Viral 
Infections.
A .i. Humoral Immunity to Viral Infections,
Immunoglobulins (Igs or antibodies) secreted from activated B cells are the effector 
molecules of humoral immunity. Immunoglobulins can exist in two microenvironments: as 
soluble products in the extracellular fluid (e.g. blood, tissue fluid or mucosal secretions) or 
expressed on the membranes of B cells where they function as antigen-specific receptors. In 
either environment, the immunoglobulin shares the same basic four chain structure and 
antigenic specificity. All immunoglobulin molecules are multifunctional, in that they can 
bind to specific antigenic epitopes through their variable N-terminus and interact with 
effector molecules through their more conserved Fc regions [Hilschman and Craig, 1965].
Antibodies are secreted fiom plasma cells, which are the principal effector cells of 
humoral immunity. Antibodies can control viral infections in different ways. For example, 
they can bind to specific components on the surface of the virus particle preventing 
infectivity (virus neutralisation), they activate the complement system which can lead to viral 
cytolysis and uptake by macrophages. Antibodies may target virus infected cells for lysis by 
either the complement pathway or through antibody-dependent-cellular cytotoxicity 
(ADCC). Thus, antibodies have a principal role in preventing viral infection of the cells.
The extent to which humoral immunity contributes to the overall protection against 
infection, is dependant on the actual infecting viruses. For example, both primary and 
secondary infections with vesicular stomatitis virus are controlled by neutralising antibodies 
[Gobet et a l, 1988] and the spread of enteric viruses from the portal of entry is more severe 
in B cell deficient patients [Rager-Zisman and Allison, 1973]. In contrast, humoral 
immunity seems to play only a minor role in the control of lymphocytic choriomeningitis 
virus (LCMV) [Zinkemagel e ta l, 1976; Byrne e ta l, 1984].
A.1.1. Classification of antibodies.
The basic unit of an immunoglobulin molecule is a four chain structure composed 
of two identical light (L) chains and two identical heavy (H) chains. The difference in 
structure of the amino and carboxy termini is reflected in the functions of the two regions. 
There is high sequence variability at the amino termini of both the heavy (Vh) and light (V^) 
chains and dûs allows immunoglobulins to recognise and bind to a vast variety of structures. 
The conserved C-terminal (Fc region) interacts with effector cells (e.g. macrophages) and 
molecules (e.g. complement).
Nine classes of antibodies have been described in man (IgM, IgGi, IgG2a, IgG2b> 
IgGg, IgG4, IgE, IgD, IgAi and IgA2 ) eight classes in murine systems (the same classes as 
in man but there is only one IgA class), the classes being distinguishable from the different 
structures of their conserved C-terminal regions. In addition each class of antibody can exist 
in two forms, as free antibody secreted from plasma cells or as bound antibody that acts an 
antigen-specific receptor on the B cell surface. Both secreted and bound antibodies from a 
given cell are identical in their specificity fca* a particular antigen, only varying in their 
C-terminal region. Membrane bound immunoglobulins contain an additional transmembrane 
and cytoplasmic anchoring domain, (for a review of antibody structure and function, see 
Male et al., 1987).
A. 1.2. Activation of the B ceil.
Naive B cells that have not previously been exposed to antigen, circulate through 
the body as small resting lymphocytes that are in the Go phase of the cell cycle and bear 
membrane IgM and IgD molecules. Upon antigenic stimulation, resting B cells undergo a 
round of proliferation, termed clonal expansion creating many progeny B cells with 
antibodies having identical antigeiuc specificity. B cell progeny then differentiate into either 
memoiy cells or effector (plasma) cells. B cell proliferation and differentiation occur in 
organised lymphoid structures called lymph nodes, and is tightly regulated (reviewed by 
Clarke and Ledbetter, 1994). Antigenic stimulation is usually not enough on its own to 
induce B cells to proliferate, stimulation of the receptor facilitates the B cell to be more
receptive to signals secreted from activated T helper cells that are required for proliferation.
During B cell proliferation, progeny B cells undergo a process called class 
switching, whereby the class of antibody produced changes (for review of immunoglobulin 
class switching, see Snapper and Mond, 1993). Different classes of antibody have different 
effectCMT roles. For example, the pentameric stmcture of IgM makes it veiy suitable to 
activate the complement system by the classical pathway, IgG can target viruses for lysis 
onto FcR bearing macrophages, IgA antibodies are principal effectors in the mucosal 
associated lymphoid tissue and I ^  antibodies play a major role in allergic reactions. The 
class of antibody that is most effective in viral infections is unknown. However, studies by 
Coutelier et aL, [1987] have shown that infection of mice with various DNA and RNA 
viruses induces a striking dominance in the IgGg  ^isotype. IgG2a antibodies could be 
advantageous for clearing viruses as, because in contrast to IgGj and IgG ,^ they can activate 
both the alternative and classical pathways of complement [Klaus et ai, 1979]. 
Macrophages also have distinct receptors for IgG2a [Unkeless et al., 1981] and IgG2a 
antibodies are reported to be better mediators of ADCC than IgG^ and IgG2y antibodies 
[Steplewski et al., 1985]. Whether such findings are relevant to man is unknown, as few 
studies have been conducted.
A.1.3. Generation of diversity of the B cell receptor.
One point that is paramount in considaing the design of vaccines is to understand 
how B cells recognise antigens. The binding of foreign antigens to variable domains on 
antibodies present on the surface of the B cells represents the initial step in the sequence of 
events leading to activation of B cells and the secretion of effector immunoglobulins. The 
diversity in the number of antigenic structures capable of being recognised by 
immunoglobulin receptors on B cells, is a result of two processes unique to B cells- somatic 
recombination and hypermutation. Immunoglobulin polypeptide chains are encoded in 
multiple gene segments scattered along the chromosome of the germ-Hne genome [Hozumi 
and Tonegawa, 1976; Tonegawa et al., 1977], the actual number of gene segments varying 
between species. For example, in murine systems, the H chain germ-line DNA contains a 
cluster of 100-200 variable (Vh) region segments [Givol et al., 1981], a cluster of 12
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diversity (Dh) segments [Schilling et al., 1980] and a cluster of 4 functional joining (Jh) 
segments [Gough and Bernard, 1981]. In B cells, one each of the Vh segments, Dh 
segments and Jh segments are recombined to form a complete Vh region-coding DNA 
segment [Sakano et al., 1979; Early et al., 1980]. Because the Vh region is encoded by three 
gene segments and the joinings can occur in various combinations, the potential diversity 
generated by this rearrangement is enormous. A similar process occurs in the generation of 
the variable region of light chains, (for review on antibody somatic rearrangment see 
Tonegawa, 1983). This somatic recombination greatly diversifies the genetic information 
carried in the germ-line genome, and ultimately, the structure of the antigen-binding site on 
the immunoglobulin molecule. However, although such diversification in the structure of the 
antigen-binding site increases the number of antigens capable of being recognised, 
adversely, it tends to create receptors with low affinity [Fearon, 1993]. To overcome these 
problems, following piimary stimulation and during clonal expansion of the B cells, 
mutations are introduced somatically into the immunoglobulin gene at an exceedingly high 
rate [Brack et al., 1978; Bernard et al., 1978]. B cells bearing high affinity receptors are 
then selected when antigen becomes limiting and differentiate into either memory B cells or 
antibody secreting plasma cells.
A.1.4. Determinants recognised by the B cell receptor.
There have been several attempts to distinguish the minimum epitope that can be 
recognised by immunoglobulins, in the hope of designing subunit vaccines. Many of the 
approaches have employed the use of short synthetic peptides that compete with native 
protein to bind specific antibody. Protein antigenic determinants that are recognised by 
immunoglobulin receptors have been classified as either sequential or conformational 
[Barlow et al, 1986]. Sequential determinants, sometimes referred to as linear or continuous 
epitopes, consist of amino acid residues that occur locally in the polypeptide chain. In 
contrast, conformational determinants are discontinuous, consisting of residues that occur 
far apart in the polypeptide chain, but are juxtaposed upon folding of the protein molecule. 
Most protein epitopes recognised by immunoglobulm receptors are thought to belong to this
latter category [Barlow et al., 198Q, since epitope accessibility is crucial for 
immunoglobulin interaction and most accessible epitopes are positioned at ’comers' of the 
folded polypeptide chain [Novotny et al., 1986], In support of this proposal. X-ray 
crystallographic images of a complex between lysozyme and a monoclonal antibody specific 
fc«* the protein [Amit et al., 1986] revealed that the epitope recognised by the specific 
monoclonal antibody was composed of two stretches of amino acid residues, namely 
residues 18-27 and 116-129, that came together upon folding of the pmtein molecule. In 
addition the size of the antigen binding site on immunoglobulin molecules is large, 
approximately 700 Â [Amit et al., 1986] and few continuous epitopes of this size have ever 
been found [Barlow et al.„ 1986].
Sevei*al algorithms have been proposed to determine where B cell epitopes exist on 
proteins [Novotny et al., 1987; Blundell et al., 1987; van Regenmortel, 1989(a), 1989 (b)]. 
These include identification of regions that are buried within the protein i.e. hydrophobic 
regions and those regions which are hydrophilic and therefore are likely to be on the surface 
of the protein and thus, potentially antigenic. Although such programs are good at 
identifying some potentially important sites, they also fail to predict others and only result in 
a 50-55% efficiency in identifying the epitopes on the primary sequences [Pellequer et al., 
1991; van Regenmortel et al., 1989(a)]. A classic example was demonstrated by Daniel and 
colleagues [1994] who showed that the combination of nine epitope prediction algorithms 
failed to identify critical epitopes necessary for protection against neurotropic murine 
coronavirus.
A.I.5. Evasion of the humoral response.
The specificity of the interaction between antibodies and their specific antigenic 
determinants can have serious implications in vaccine design. For example, vaccine 
formulations that denature the proteins of interest may not induce the appropriate immune 
response. Viruses themselves can thwart attempts to produce efficient vaccines by having 
many antigenic serotypes. Thus to produce a successful vaccine to many viruses, it may be
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necessary to inccaporate multiple epitopes into the vaccine to deal with virus antigenic 
variation.
A second problem in the design of vaccines, is that not all antibodies are actually 
protective and indeed, some may be harmful. It has been noted that for several viruses, e.g. 
Feline leukaemia viruses [Nick et aL, 1990], flaviviruses [Fagbami et al., 1988] and dengue 
virus [Halstead et al., 1988], that both neutralising and enhancing antibodies exist For these 
viruses, subneutralising concentrations of antibodies can cause an enhancement of infection, 
via binding of antibody-virus complexes to cellular Fc receptors and thus facilitating the 
attachment of virus particles to target cells. Some antibodies against murine retroviruses 
have also been shown to enhance viral replication in vitro [Legrain et al., 1986].
A.2. Cell-Mediated Immune Control o f Viral Infections.
The replication of a vims is dependent on its ability to infect host cells and utilise 
the host’s protein synthesising machinery. Thus, for part of its life cycle, a vims is located 
intracellularly and as a consequence, is hidden from humoral immune system. To overcome 
this problem, the immune system has evolved a second-line of defence that is concerned 
with recognising foreign intracellular antigens; cell-mediated immunity.
Cell-mediated immunity is characterised by T lymphocytes (T cells), which are 
quite distinct from their B lymphocyte counterparts in both their effector mechanisms and 
antigen recognition requirements. Rather than recognising free antigen, T cells have 
receptors (TcRs) that recognise and interact with peptide fragments of degraded proteins, 
presented on the surface of antigen presenting cells (APCs), in association with host cell 
molecules, termed major histocompatibility complex (MHC) proteins [Townsend et al., 
1989].
Different classes of T cells exist, and can be phenotypically distinguished by the 
type of cluster differentiation marker (CD) they cany on their cell surface [Knapp et al., 
1989]. Whereas CD4 CD8+ T cells interact with peptides presented in association with 
MHC class I molecules [Norment et a i, 1988], CD4+CD8' T cells recognise peptides
bound to MHC class II molecules [Gay et al,. 1987] (see fig. 1). This classification of T 
cells into CD8+ and CD4+ cells, in part, reflects the different effector functions of the two T 
cell subsets. For example, CD8+ T cells are normally referred to as having cytolytic activity 
(cytotoxic T lymphocytes; CTL), in that they actively destroy target cells. CD4+ T cells, 
upon activation, secrete soluble substances called lymphokines [Stevens et al., 1988; 
Balkwül et al., 1989] that modulate the immune response, e.g. they provide the appropriate 
signals that allow precursor cytototoxic T cells to differentiate into effector cells [Jennings et 
al., 1991; Horvat et al., 1991], and provide help for B cells to proliferate and differentiate 
into antibody secreting plasma cells [Stevens et al., 1988; Snapper and Paul, 1987]. 
However, these functions are not mutually exclusive. In this respect, certain CD8+ T cells 
secrete lymphokines [Fong and Mossman, 1990]. Similarly, some subtypes of CD4+ T cells 
exhibit cytolytic activity [Del Prete et ai, 1991(a); (b)].
T cells have a critical role to play in the resolution of viral infections and the ability 
to design vaccines that actively prime T cells to a particular virus have the potential to be 
very successful. This means that detailed information on the intracellular routes of antigen 
processing and the relative importance of CD8+ as opposed to CD4+ T cells in the resolution 
of viral infections is important in the design of vaccines. In the following sections, the cells, 
molecules and molecular mechanisms leading to the activation of T cells is presented.
A.2.1. Antigen Presenting Cells (APCs).
One of the major requirements in T cell activation, is that viral proteins must be 
processed and degraded into short peptide fragments that can associate with MHC class I or 
n  molecules. Such events are performed in antigen presenting cells (APCs). Virtually all 
nucleated cells bear MHC class I molecules and therefore have the potential, following viral 
infection, to act as APC for CD8+ T cells. In contrast to the ubiquitous expression of class I 
MHC molecules, MHC class II molecules have a more restricted distribution, being 
principally expressed on the surface of specialised cells of the haemapoietic lineage 
[Cresswell et a i, 1987] i.e. B cells, macrophage and dendritic cells. Considering the central
role CD4+ T cells play in the immune system, this restricted distribution of MHC class II 
molecules may serve as a regulatory mechanism in the immune system.
There have been several attempts to establish whether one ceU-type predominates as 
an APC fw activation of naive T cells, in the hope of designing vaccines that can be targeted 
directly at the appropriate APC. Although such research has greatly facilitated understanding 
of the minimum requirements for a cell to function as an APC, which include the ability of 
the cell to internalise antigen [Stockinger et al., 1992; Gasselin et al., 1992], the processing 
capabilities of the cell [Vidard et al., 1992], the level of expression of adhesion molecules 
[Sanders et al., 1988], the surface charge of the cell [Boog et al., 1989] and the provision of 
additional co-stimulatory signals efficient for T cell activation [Mueller et al., 1989; Lui and 
Janeway, 1992], there is no conclusive evidence that one cell type is more efficient than 
another for activating naive T cells. For example, although studies on B-cell deficient mice, 
which contain fully functional macrophage and dendritic cells, suggest that antigen-specific 
B cells aiTe the predominant activators of unprimed T cells [Kurt-Jones et al., 1988], 
Macatonia and colleagues [1989] suggest that dendritic cells are the most efficient APC. 
Indeed, the general opinion is that dendritic cells are the most efficient APC for activating 
unprimed T cells [reviewed by Knight and Stagg , 1993].
A.2.2. The Major Histocompatibility Complex (MHC).
The major histocompatibility complex molecules have a prominant role to play in T 
cell activation, since peptides must be presented to T cells in association with these 
molecules. Sequencing studies have shown that both MHC class I and II molecules are 
highly polymorphic [Coligan etal., 1981; Brown et al., 1988], there being numerous 
haplotypes. In 1987 (a), Bjorkman and colleagues, resolved the X-ray crystallographic 
image of an MHC class I molecule, HLA-A2 and, such studies revealed that class I MHC 
molecules have a deep groove running between the a l  and o2 domains, whose sides are 
composed of a-helical structures, and the floor consists of eight anti-parallel p-pleated 
sheets. Most of the polymorphism seen in class I MHC molecules is located within the 
groove [Bjorkman et al., 1987(b)] and it was proposed that this groove contained the
peptide binding site. Since these initial studies, the X-ray images of several other MHC class 
I and class U molecules have become available [Garret et ai, 1989; Brown et al., 1993] and 
have supported the observation that peptides are located in the grooves of MHC molecules. 
There have been several attempts at sequencing the amino acids lining the peptide binding 
grooves of various MHC molecules and such studies have shown that the binding grooves 
contain six subsites or 'pockets*. Comparative studies have demonstrated that within 
haplotypically similar MHC molecules these subsites are present in similar locations and 
contain almost identical amino acids. Yet, in MHC molecules of different haplotypes, the 
size, shape and location of the pockets are dissimilar. These observations have led to the 
suggestion that the peptide sequences that bind to certain MHC molecules are restricted, in 
that, only peptides that are capable of interacting with the amino acids located at particular 
regions in the groove of the MHC, will be selected for presentation to T cells. Such an 
observation would imply that similar peptide motifs would bind to haplotyically similar 
MHC molecules, a suggestion that has won support from the work of Falk and colleagues, 
1991. In a series of experiments, naturally occurring peptides were eluted from murine 
MHC class IH-2K^ and H-2K^, then sequenced. It was found that peptides eluted from H- 
2K*^  molecules had similar peptide sequences that were distinct from those eluted from H- 
2K*» molecules. It is now generally accepted that peptide-binding motifs exist and thus it 
may eventually be possible to engineer peptide vaccines that bind to particular MHC 
haplotypes.
Ao2.3. The T cell receptor (TcR).
T cells recognise peptide-MHC complexes through their surface T cell receptor 
[TcR (see Fig.l)]. Most peripheral T cells bear TcR composed of a  p polypeptide chains 
and such receptors are extremely polymorphic. The polymorphism of the T cell receptor 
occurs from somatic rearrangement of gene segments in an analogous fashion to that which 
occurs with antibodies [Chothia et al., 1988; Claverie et al., 1989, reviewed by Davis, 
1990].
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Figure 1. Molecular interactions fh antigen-specific T cell recognition of antigen- presenting cells.The left-hand side of the figure depicts the interactions during the recognition of 
peptides associated with MHC cl#s I molecules by TCR on a CDS"  ^T cell (usually a cytotoxic T lymphocyte). The nght-hand side of the figure illustrates the recognition 
of MHC class Il-peptide complejies by a CD4+ T cell (a helper or possibly a cytotoxic T cell). Die key determinant of /f  cell specificity is the T cell receptor (TCR). The TCR is closely associated with#he CD3 complex and either a CD8 or CD4 molecule. The CD3 complex is involvedgn signal transduction across the plasma membrane following TCR engagement apd so are most likely the CD8/CD4 molecules. (Taken from Hanke and Randall, 1994).
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Despite the fact that ap  TcR bearing T cells are extremely sensitive to low 
antigen concentrations (only 30-100 peptide-MHC complexes on APC are required for T cell 
triggering [Demotz et aL, 1990; Harding et al., 1990], the affinity of TcRs for such 
complexes are very low [Matsui et al., 1991; Weber et al., 1992]. Such observations 
suggest that TcR-ligand interactions are not the driving force for conjugate formation 
between T cells and target cells [Singer et al., 1992] and it has been proposed that multiple 
adhesion molecules expressed on both the APC and the T cell, many of which show 
extremely high affinities for their ligands, must mediate the event [Springer et al., 1990].
For example, it is known that the binding of CD4 to MHC class II [Doyle, et al., 1987] and 
CD8 to MHC class I [Norment et al., 1988] allows the recognition process to progress more 
efficiently and with less antigen [Gabert et al., 1987].
A.2.4. Pathways of Processing and Presentation of Antigens.
Proteins have to be processed into peptide fragments that are capable of interacting 
with both the T cell receptor and the appropriate MHC molecule. Two pathways for 
processing proteins have been suggested depending on whether the resulting peptide 
associates with MHC class I or class II molecules; the endogenous and exogenous pathways 
respectively [Figs. 2 & 3 repectively, Germain, 1986]. In the endogenous pathway, newly 
synthesised proteins are degraded in the cytosol and then transported to the endoplasmic 
reticulum (ER) where they complex with newly synthesised MHC class I molecules (Fig.2). 
The lole that the ER plays in this endogenous pathway is highlighted by the ability to arrest 
MHC class I presentation by use of pharmaceutical products like Brefeldin A, that 
specifically prevent egress of molecules from this cellular compartment [Nuchtem et al., 
1989]. In contrast to the endogenous pathway, the exogenous pathway is concerned with 
the degradation of proteins into peptide fragments that subsequently associate with MHC 
class n  molecules. Such presentation can be inhibited by lysomotropic agents (e.g. 
chloroquinine), but not Brefeldin A, that specifically act by increasing the pH of endosomes, 
suggesting that these cellular compartments play a critical role in the degradation of the 
proteins (Fig.3). The exact compartment where complexing between peptides and MHC
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(Modified from Hanke and Randall, 1994)
Figure 2. MHC class 1 presentation pathway.
The diagram schematically illustrates the life cycle of a virus (in tliis case influenza virus) and how the virus proteins can enter the endogenous (MHC class I) antigen processing pathway in an antigen-presenting cell. Following partial proteolytic degradation, certain virus-derived peptides associate with MHC class I molecules. The MHC-peptide complexes are then transported to the cell surface where they are specifically recognised by T cells bearing T cell receptors.
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Figure. 3. MHC class H presentation pathway.
The diagram schematically illustrates the life cycle of a virus (in this case influenza virus) and how the virus proteins can enter the exogenous (MHC class II) antigen processing pathway in an antigen-presenting cell. Following partial proteolytic degradation, certain virus-derived peptides associate with MHC class II molecules. The MHC-peptide complexes are then transported to the cell surface where they are specifically recognised by T cells bearing T cell receptors.
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class n  complexes occurs is unknown, but it has been noted that the endosomes cross the 
pathway leading to the expression of MHC class II molecules on the surface of the cell.
Thus it has been suggested that complexing with MHC class II molecules occur in 
endosomes themselves [for a review on antigen processing and presentation, see Hanke and 
Randall, 1994].
Recent evidence suggests that the processing of antigens to class II or class I 
presentation may not be so straightforward. For example, exogenous (non-replicating) 
antigens that gain direct entry into the cytosol can be presented in association with MHC 
class I molecules [Moore et a/., 1988]. It has also been suggested that there may be 
specialized APC in vivo capable of capturing exogenous antigen and processing it for MHC 
class I presentation. It has also been demonstrated that certain endogenously synthesised 
proteins can be presented in conjunction with MHC class II molecules [Jarquemada et aZ., 
1990; Michalek et ai, 1992]. Although this latter route of presentation has been attributed to 
the secretion of endogenously synthesised antigen, followed by its subsequent re capture by 
antigen-specific receptors and thus internalisation into the endosomal/lysosomal pathway 
[Yurin et aZ., 1989; Bikoff et al., 1989; Jin et al., 1988; Polydefids et al., 1990; Eager et al.,
1989]], there is evidence to suggest that there are two unique pathways in the processing of 
endogenous antigen to MHC class I- and H-restiicted T cells. For example, Jarquemada et 
al. [1990] have demonstrated that infection of a human B cell-line expressing MHC class I 
HLA-A2 molecules and MHC class H MHC HLA-DRl molecules with recombinant 
vaccinia virus containing influenza A virus matrix protein (Ml), resulted in both MHC class 
n  and class I-restricted T cell lysis of the cell-line. Such MHC class U-restricted lysis could 
be inhibited by chloroquinine, whereas class I-restricted lysis could not The converse was 
true when Brefeldin A was added to the assay, suggesting that endogenous antigens can 
gain access to endosomal/lysosomal compartments via an intracellular route, leading to the 
processing and presentation in a class Il-restricted manner.
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A«2.5. Immune regulation; influence of the immune response 
genes.
Soon after the discovery of MHC restriction it became apparent that many viruses 
and cellular antigens were recognised in association with some but not other MHC 
molecules [Blanden et aL, 1975; Simpson and Gordon, 1977; Mullbacker and Blanden,
1978]. Furthermore, some peptide-MHC complexes were immunogenic in one strain of 
mice but not another. For example, for three different viruses, (vaccinia virus, sendai virus 
and cross-reactive influenza A virus) mice of the haplotype respond to virus 
determinants in association with H-2D% whereas mice of the haplotype did not 
respond to virus antigens in association with [Zinkemagel, 1978; Doherty eta l, 1978]. 
However, using lymphocytes in vitro, it was shown that was capable of 
presenting the CTL epitope to De restricted CTL, thus excluding the notion that the non­
responders fail to present antigen in association with D .^ Data presented by Hill et al [1993] 
is also compatible with the concept of ‘immunodominance* where the responding T-cell 
population appeared to focus the immune response on a limited number of MHC-peptide 
complexes. Thus, in the presence of certain more strongly immunogenic antigens, responses 
to other ^patently more weakly immunogenic antigens was not seen.
The means by which some antigens are favoured over others is unclear, but could 
include (a) affinity of T cell clones for antigen; (b) T-cell precursor frequency and (c) the 
concentration of the relevant epitope on antigen presenting cells. In any case, the 
phenomenon applies that there is competition between T cell clones, either for binding 
antigen presenting cells, for helper factors or other nutrients. Thus, response to weaker 
antigens is only observed if the dominant antigen is limited. The existence of immune 
response hierarchies, however, is of more than passing academic interest Recombinant 
DNA technology now makes it possible to manufacture vaccines expressing limited 
antigenic determinants of the virus of interest The mere identification of a determinant as 
immunogenic in the presence of a particular MHC molecule (e.g. in vitro) does not 
guarantee a response in vivo whenever that particular MHC-peptide combination is 
presented. Potential vaccine vectors, such as recombinant vaccinia virus carry their own
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strong antigenic determinants for all class of immune response. Whether an engineered 
determinant is able to induce an immune response may be dependent on its place in the 
immune response hierarchy, generated by the vector carrying it and the MHC genes of the 
responding animals.
A.2.6. Viral escape of cell-mediated responses.
The importance of cytotoxic CD8+ T cells in the control of viral infections can be 
highlighted by the strategies some viruses use to prevent recognition by CD8+ T cells. For, 
example, certain viinses can interfer with MHC class I surface expression. One of the best 
documented examples of inhibition of MHC class I presentation by viral infection is that of 
adenovirus E19 protein on MHC class I transport [Andersson et al., 1985]. E19 interacts 
with MHC class I molecules within the ER and prevents transport of these molecules to the 
cell surface, thereby preventing presentation of the viral T-cell epitopes on the cell surface of 
the infected cells. Similarly, human cytomegalovirus (HCMV) exerts a strong inhibitory 
effect on the cell surface expression of class I MHC [Browne et al., 1990]. However, 
although downregulation of class I would seem an obvious mechanism to evade CTL, this 
has been shown to improve recognition of viral infected cells by natural killer (NK) cells 
[Karre et al., 1986; Harel-Bellan et al., 1986]. Other ways in which viruses may avoid 
recognition by class I-restricted CTLs is to infect cells (e.g. neuronal cells) which do not 
express class I MHC; a mechanism that is thought to correlate with persistent infection by 
LMCV. Some viruses may also be capable of subverting CTL memory by the selection of 
CTL escape mutants. For example, a longitudinal study of HTV seropositive patients 
revealed there were fluctuations in the specificity of the cytotoxic T cells. This was matched 
by variability in proviral gag DNA epitope sequences and some of the viral variants were not 
recognised by CTL [reviewed by Levy, 1993].
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A.2.7. Cellular immune responses to viruses and implications for 
vaccine design.
As indicated above, cell-mediated immune responses to viruses are complex. For 
example, some CTL responses are class I restricted, whereas others are class II restricted. 
The importance of these two classes in the resolution of virus infection can be different for 
different viruses. For example, following influenza infection, the majority of CTLs are class 
I restricted [Bourgault et al., 1989], yet after measles infections class Il-restricted CTLs 
appear to predominate [Jacobson et al., 1984; 1989]. This difference may, in part, be related 
to the mechanism of viral entry [Long and Jacobson, 1989]. As a consequence, vaccine 
technology may have to be engineered to provoke the appropriate class of CTL.
A.5. Deleterious versus Protective responses.
It is evident from the preceding sections that B and T cells have important roles in 
the control of viral infections. However, knowledge of the relative importance of B and T 
cells in the resolution of a viral infection is critical in the design of vaccines to that virus. 
Although for some viruses it may be possible to induce immunity to some viral diseases by 
inducing high levels of neutralising antibody to a restricted number of antigenic 
determinants, (as is the case for foot and mouth disease; Francis et a l, 1988), for many 
diseases it may be necessary to induce both antibody and cell-mediated immunity. It is clear 
from studies on immunodeficient patients that the relative importance and balance of humoral 
and cell-mediated immune responses may vary from one virus infection to another. For 
example, measles infection normally proves lethal in children with defects in cell-mediated 
immunity, yet, children with agammaglobulinaemia can contract and survive measles in a 
relatively normal fashion [Bumet, 1968; Ewan and Lachmann, 1982]. While is some cases 
it is well established that CTLs play an important role in the protection against infection, for 
some viruses inappropriate CTLs may contribute to the viral pathology. For example, 
transfer of CTLs specific for respiratory syncytial virus (RSV) into immunodeficient mice 
can increase the pathology following subsequent infection [Cannon et al, 1988].
18
In other cases, B cell responses may be harmful. For example, enhancement of 
viral infectivity due to antibodies directed at particularly determinants has been reported in 
several cases, including human immunodeficiency virus [Bolognesi, 1989]. It has also been 
reported that antibody-induced antigenic modulation may be an important factor in the 
establishment of persistent infections in vivo [for review of persistent infection see Randall 
and Russell, 1990]. A fine balance may thus exist between the induction of protective 
immunity and the induction of immunity that will lead to detrimental responses upon 
subsequent infection with virulent virus. Consequently, vaccines may have to be designed 
that induce not only the appropriate type of immunity, i.e. humoral versus cell-mediated, but 
immunity is directed at epitopes that are protective and not epitopes that are deleterious.
A.4. Long lived immunity.
One of the primary goals of vaccination is to create long term memory cells capable 
of responding to their specific antigen, upon subsequent encounters, swifter and with 
greater magnitude. However, little is known about the generation of immunological 
memory. Several concepts have been proposed to account for immunological memory 
including long-lived memory cells [Strober and Dilley, 1973], different thresholds of 
stimulation of naive and lymphocyte memcay cells (which may not be long lived) due to 
altered surface expression of adhesion molecules [Sanders et al., 1988] periodic stimulation 
with cross-reactive antigens [Beverley, 1990], re-stimulation by recurrent infections [Mims, 
1987] or antigen persistence in specialised reservoirs [Tew et al., 1980; Tew and Mandel,
1979] causing continual stimulation of memory clones. These latter concepts have been 
proposed because recent evidence suggesting that non-replicating pathogens need to persist 
if long term memory is to be maintained for both B cells [Gray and Skarvall, 1988] and T 
cells [Gray and Matzinger, 1991]. This leads to the question of how a non-replicating 
antigen persists. At present the only known repositories for antigen are on the surface of 
follicular dendritic cells (FDCs) found in the B lymphocyte follicles of lymph-nodes, which 
can maintain native antigen as immune-complexes for months or years [Tew et al.., 1990] 
and specifically present antigen to B cells. If FDCs are subsequently found to be the only
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cell-type that can store antigen for long periods of time, then an inescapable conclusion of 
such a finding is that the survival of T lymphocyte memoiy must be dependant on the 
production of antibody and on the presence of memory B cells [Gray et al., 1991].
However, for CD8+ T cells, evidence suggests that the clonal burst is more important than 
antigen persistence in the maintenance of CD8+ memory [reviewed by Doherty et ai, 1994]
A.5. Mucosal Immunity to Viruses.
The mucosal surfaces in the body, represented by the respiratory, 
gastrointestinal and urinogenital tracts, are readily infected by a wide variety of RNA and 
DNA viruses. However, parental immunisation schedules that evoke efficient systemic 
immunity, rarely induce protection at the mucosal surfaces. Such evidence has led to the 
proposal that the mucosal immune system is distinct from the systemic immune system and 
highlighted the need for the development of vaccines that induce protective immunity at 
mucosal surfaces. However, the development of effective mucosal vaccines has been 
hindered because, for many years, understanding the immune mechanisms operative at 
mucosal surfaces has proved an enigma. In part, this difficulty in analysing the mucosal 
system has been due to the inherent difficulties in the isolation and characterisation of 
lymphoid cells in the various mucosal-associated tissues. However, since the major route 
for the entry of Human Immunodeficiency Virus (HIV) is through the urino-genital tract and 
rectum, vaccines tliat are likely to induce protective immunity to HTV will have to prime both 
the mucosal and systemic systems. This has re-focused attention once more on deciphering 
the intricacies of the mucosal immune system. In this section, a brief review on the current 
understanding of the immune cells and effector mechanisms operative at the mucosal 
surfaces is presented.
A.5.1. Evidence of a common mucosal immune system.
Inteiest in designing vaccines that stimulate mucosal immunity stems from 
observations that immunisation of one muœsal site often leads to detectable immune 
responses at distant mucosal sites [Mestecky et al., 1987] (and potentially systemic
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immunity too). This seeding of distal mucosal sites is likely to be the result of trafficking of 
locally stimulated mucosal B cells to distinct sites, where they reside as IgA plasma cells 
actively producing antibodies. Such trafficking of antiviral IgA producing cells can occur in 
the gastrointestinal tract mucosa to the respiratory mucosa and perhaps vice versa [Waldman 
et al., 1986; Chen et al., 1987; Hirabayashi et al., 1990]. Although this common mucosal 
system exists, it appears to be relatively inefficient at protecting sites not directly stimulated 
with antigen [Nedrud et al., 1987].
A.5.2. Antigen uptake at the mucosal surfaces.
Accumulating data over the last few years, has indicated that the mucosal immune 
system is anatomically and functionally divided into separated regions, one where antigens 
are encountered, processed and initial B- and T-cell triggering occurs (called inductive sites) 
and areas where immune cells actually function (called effector sites) [McGhee et a i, 1992]. 
In man, the major inductive sites are putated to be the Beyer's patches of the gastrointestinal 
tract [McGhee et al., 1992; Mestecky and McGhee, 1987] and the tonsils in the upper 
respiratory tract [Bernstein et al, 1994], with the lamina propria and salivary/mammary 
glands constituting the effector sites in the gastrointestinal and repiratory tracts, respectively. 
Most studies on the uptake of antigens at the mucosal surfaces have therefore been 
concerned with events occurring at these putative mucosal inductive sites. Such regions are 
equipped with specialised antigen uptake cells, termed follicular-associated epithelium (FAE) 
or M cells [Owens and Jones, 1974]. M cells efficiently pinocytose/endocytose soluble and 
insoluble antigens [Bockman and Cooper, 1973; Pappo and Ermak, 1989], as well as 
micro-organisms [Owen et al, 1986] and sometimes serve as specific sites of viral entry 
e.g. reovirus types 1 and 3 [Wolf et al, 1981] infect mucosal surfaces by binding to specific 
receptOTS on the M cell surface. Upon uptake, antigens are rapidly transported, intact, in a 
'central hollow* or 'pocket region* to the underlying antigen presenting cells which 
subsequently process the antigen for presentation to T cells [Owen et a l, 1977; 1986]. 
Antigens that are capable of adhering to M cells are more efficiently transported tlian their 
non-adherent counterparts [Neutra et a l, 1987]. Such evidence has led to investigations into
21
novel antigenic delivery systems that promote antigen uptake by M cells. Several of these 
novel strategies are discussed in later sections.
Tlie epithelial cells of the effector regions can also act as portals of antigen entry 
[reviewed by McGhee and Kiyono, 1993]. In particular, soluble vaccines are particularly 
adept at reaching the underlying lymphocytes following endocytosis by the overlying 
epithelium. Alternatively, vaccines may transverse tight junctions between epithelial cells 
and intact antigen could trigger B- and T-cell responses. However, the actual role epithelial 
cells play in the induction of mucosal immunity is something that remains to be ascertained.
A.5.3. Humoral immunity at the mucosal surfaces.
The protection of the mucosal surfaces from viral infection is generally assumed to 
be conferred by virus-specific secretory antibodies of the IgA isotype. A prelhninary site for 
IgA-committed B cells seems to be the Peyer's patches [Craig and Cebra, 1971]. Following 
activation, the B-cells migrate from Peyer's patch through the thoracic duct and back to the 
effector sites of the lamina propria where they differentiate into IgA secreting plasma cells 
(reviewed by McGhee and Kiyono, 1994].
The majority of IgA produced enters mucosal secretions via epithelial transcytosis 
mediated by the polymeric Ig receptor (also known as the transmembrane secretory 
component) [Solan et al., 1985]. The mucosal response to primary viral infection is rapid 
and can occur within three days of infection [Rubin et al., 1983]. However, this response is 
not sustained [Bishop et al., 1990; Coulson etal., 1990], which may in part explain why 
mucosal surfaces, as opposed to peripheral system, are more readily re-infected with 
mucosal viruses.
The predominant role that IgA antibodies are thought to have in response to viral 
infection is to neutralise the virus, though it has been noted that unlike IgG antibodies, IgA 
are poor activators of complement and ADCC [Ffaffenbach et al., 1982]. Although the exact 
mechanisms of how IgA neutralisation of viruses occurs is unknown, it has been proposed 
that IgA antibodies may decrease infectivity by aggregating viruses [Outlaw and Dimmock,
1990] or by blocking attachment of viruses to cell receptors [Outlaw and Dimmock, 1991]
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or preventing penetration of attached viruses into the cells [Nguyen et al., 1986]. Receptors 
for the Fc region of IgA have also been found on epithelial cells and thus, IgA may 
potentiate the clearance of viruses by boosting their uptake by epithelial cells and transport to 
the underlying lymphoid cells [Weltzin et al., 1989]. IgA may also neutralise virus inside 
infected epithelial cells by inhibiting virus replication [Outlaw and Dimmock, 1990]. For 
example, experiments on Sendai virus have shown that virus in infected cells could be 
reduced by the addition of virus-specific IgA, presumably through the uptake of IgA into the 
cell by the polymeric receptor [Mazanec et al., 1992].
In vivo responses support in vitro virus neutralisation studies. Mice passively 
immunised intranasaUy with IgA antibodies were protected from intranasal challenge with 
sendai virus [Mazanac et al., 1992]. In a separate study of influenza virus, IgA polymeric 
monoclonal antibody to haemagglutinin administered systeraically, was able to restrict virus 
replication in the upper respiratory tract of the mouse [Renegar and Small, 1991]
Despite the prominent role that the IgA response plays in the protection of the 
mucosal surfaces against viral infection, IgG antibodies have also been suggested as 
contributing to tlie overall reduction of infectivity at this site. In IgA-deficient patients 
mucosal production and secretion of IgG antiviral antibodies can compensate for the 
deficiency in the production and secretion of IgA [Ogra et al., 1974]. Further, serum IgG 
antibodies, produced in response to respiratCMy virus infection, have been shown to restrict 
virus replication in the lung more effectively than in the trachea or nose [Ramphal et al., 
1979; Prince et al., 1985]. Passively transferred IgG can also restrict replication of 
poliovirus to a greater extent in the throat than in the lower intestine [Bodian and Nathanson, 
I960]. Much of the IgG response detectable at mucosal surfaces originates from the 
transudation of semm IgG into the mucosal site [Wagner et al., 1987; Murphy et al., 1982], 
though virus-specific IgG antibodies produced by the mucosa also contribute to the total 
antiviral activity in mucosal secretions [Ogra et al, 1974; McBride and Ward, 1987]. The 
mechanism of antiviral activity of IgG antibodies in the mucosa is related to direct 
neutralisation as opposed to complement-mediated lysis or ADCC, a finding supported by 
the observations that RSV replication is restricted in the lungs of passively immunised
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rodents depleted of complement and that F(ab)2 fragments of IgG, can restrict pulmonary 
virus replication as effectively as whole IgG molecules [Reviewed by Murphy, 1994].
A.5.4. Epitopes recognised by B cells at mucosal surfaces.
Several studies have shown that the epitopes recognised by IgA antibodies and IgG 
antibodies are similar. For example, polyclonal IgA antibodies, like polyclonal IgG 
antibodies recognised the haemagglutinin of influenza virus [Clements eta l, 1986]; the 
gp70 (fusion) and gp90 (attachment) glycoproteins of respiratory syncytial virus [Murphy 
et (Ü., 1986]. However, the antigens of viruses may be modified by mucosal enzymes to 
expose new epitopes on the surface proteins of such vimses. Thus the immunogenicity of 
viruses that replicate at mucosal surfaces may differ from a parentally administered 
inactivated vaccine. For example, poliovirus VP3 protein is cleaved by intestinal enzymes 
following oral administration of live virus, thereby exposing unique epitopes on the protein 
that are recognised by IgA antibodies [Zhaori et al., 1989].
A.5.6. Cell-mediated immunity at the mucosal surfaces.
Although most studies on protective immunity at the mucosal surfaces has centred 
on the role of the secretory antibody response, MHC class I-restricted CD8+ cytotoxic T 
cells can both function as antiviral effector cells against viruses that infect the mucosal 
surfaces. For example, passive transfer of (D8+ cytotoxic T cell clones to animals results in 
the restriction of influenza virus replication in mucosal epithelial cells [McDermott et al.,
1987]. MHC class Il-restricted CD4+ T cells have also been shown to have direct anti-viral 
activity [McDermott et al., 1987; Taylca* et al., 1990] and are proposed to play a role in the 
generation of the secretory IgA antibody response, e.g. IL-5 and IL-6 secreted from 
activated CD4+ Tcells are reported to be important in the switching of B cells to secrete IgA 
[Beagley cfa/., 1988].
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A.5.7. Intraepithélial lymphocytes.
As well as in the Peyer's patches and lymphoid structures of the gut, T- 
lymphocytes are found all along the murine intestinal mucosae. The most striking of these 
cells are the ones located between the epitheHa- the intraepithélial lymphocytes (lEL). In the 
murine system, it has been suggested that T cells carrying the ^ ÔT cell receptor predominate 
here [Koning et al., 1987; Kuziel etal., 1987] (though recent evidence would dispute this 
[reviewed by Guy-grand, 1993]) and as such may be important in the immune surveillance 
of the epithelia. Indeed, the exclusive expression of the )0TcR by intraepithélial T 
lymphocytes and the fact that peripheral T-lymphocytes very rarely express this receptor, 
suggests that the T-lymphocytes in the yôTcR-expressing T lymphocytes specifically home 
to epithelial surfaces in the mucosal system and thus, they must have some critical role here 
[Janeway et al., 1988].
Studies by Bonneville and colleagues, on the murine intestine, have demonstrated 
that such cells also carry the CD8+ molecule [Bonneville et al., 1988] and are thought to be 
cytotoxic in nature [Ernst et al., 1985; Klein et al., 1986]. Also the presence of granules 
containing serine esterases in these intraepithélial cells is compatible with their proposed 
cytotoxic role [Guy-Grand et al., 1991]. It has also been noted that intraepithélial cells are 
capable of secreting certain lymphokines, e.g. interleukin-2 (JL-2), -3 (BL-3), gamma 
interferon (EFN-y), tumour necrosis factor-a (TNF-a) and TNF-p [Viney and McDonald, 
1992; Barret et ah, 1992; Taguchi et ah, 1991].
However, the importance of these unique cells in the murine system does not 
seem to correlate with present findings in humans where the majority of gut intraepithélial T 
lymphocytes, like their peripheral T lymphocyte counterparts, bear the ap  T cell receptor, 
although they are also preferentially CD8+ [Brandtzaeg et al., 1989]. As yet unproved, two 
important functions have been ascribed to the gut intraepithelium T cells, namely MHC- 
restricted or non-restricted cytotoxicity [Ernst et al., 1985] and suppression of mucosal 
hypersensitivity [Brandtzaeg et al., 1988; Doherty etal., 1992]. Nevertheless, the actual role 
these cells play in the surveillance of the mucosal surfaces and the ligands that they
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recognise are still unknown. The importance of immunisation to prime intraepithélial cells is 
something that remains to be investigated.
B. Vaccination,
Multiple factors can influence the efficacy of vaccines namely: the types, number 
and association of antigens used, their shape and conformation, the timing of their 
administration, the addition or absence of adjuvants, and the immune status of the vaccinee. 
It is also important to stress that the route and dose of immunising antigen is important in the 
induction of T and B lymphocyte responses. Small amounts of antigen can fail to induce a 
response but too large a quantity can lead to immune tolerance to the antigen. In light of 
these principals, some of the advantages and disadvantages of various immunisation 
procedure that have been used to make vaccines, or are being proposed as methods of 
making novel vaccines, will now be briefly considered.
B .l. Live, attenuated viral vaccines.
Live, attenuated mutants of wild -type viruses, i.e. viruses that are capable of infecting 
host cells but do not induce the disease characteristic of native virus, offer one of the most 
attractive strategies for producing protective immunity against viral infections. Since 
attenuated viruses are capable of replicating in vivo, any viral protein has the potential to 
be presented to the immune system, thus, evoking a wide spectrum of humoral and cell- 
mediated immunity to both structural and non-stnictural viral proteins. In addition, 
attenuated viruses presumably infect the same types of cells as the wild-type virus, and 
thus could potentially give rise to T cell responses with individuals selecting the 
appropriate T cell epitopes depending on their MHC status. Also, some live attenuated 
viruses may be capable of persisting and restimulating the immune system at regular 
intervals which may obviate the need for booster inoculations.
However, despite the potential advantages of live, attenuated viruses as vaccines, there are 
a number of concerns about the safety of such vaccines. For example, the attenuation
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process is normally achieved by culturing the native virus through a non-natural host 
[Sabin and Bougler, 1973]. This results in the virus accumulating many mutations, the 
mutant viruses that are shown to have the least virulence, in either experimental animals or 
in humans, being selected as potential vaccines. However, such a process makes it 
difficult to decipher what the mutations are and there is a danger that an attenuated virus 
may revert to its virulent form through subsequent mutations during the replication of the 
vaccine virus in the host cells [Almond et al., 1985]. In addition, for certain live 
attenuated viruses, the persistence of the virus can be detrimental to the host. For example, 
the persistence of rubella virus in lymphocytes after vaccination has been linked with the 
onset of arthritis [Chantier, 1981]. Nevertheless, despite these problems, the efficacy of 
such live attenuated viruses as vaccines has been highlighted in a dramatic way by the 
global eradication of smallpox and control of yellow fever as well as the success of such 
vaccines in inducing protection against poliomyelitis, measles and rubella [Hilleman,
1985].
B.2. Whole, killed virus vaccines.
Live viruses can be inactivated by heat treatment and exposure to protein modifying 
agents. Tliese so-called, killed virus vaccines, represent the second most traditional 
approach to immunisation. Killed viruses are incapable of replicating in vivo, thus 
presenting an initial advantage over their attenuated counterparts in that there is no danger 
of disease due to viral reversion. In addition, killed virus vaccines tend to be more stable, 
and tlierefore easier to store than attenuated vaccines. Despite these advantages, there are 
several disadvantages in the use of killed viruses as vaccines. For example, it is paramount 
that all infectious virus particles in the vaccine preparation must be inactivated- a point that 
is highlighted by incidents of paralytic disease in vaccinees given inactivated polio vaccine 
which was found to contain trace amounts of live polio virus [Nathanson, 1963; Peterson 
et al., 1955]. There have also been reports of vaccinees given formalin-inactivated 
respiratory synctia virus (RSV) vaccine exhibiting serious lower respiratory tract 
complications upon subsequent natural infection with native RSV [Kapikian, 1969]. In
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this case, and others [Ranh and Schmidt, 1965; Kim et cU., 1969; Fulginiti et al, 1967; 
Orvell and Norrby, 1977], the process of inactivating the virus seems to be responsible for 
the adverse reactions. For example, studies in cotton rats revealed that formaldehyde 
treatment of RSV led to the cross-linkage and subsequent destruction of virus neutralising 
epitopes on the fusion and attachment glycoproteins of the virus [Prince et a l, 1986]. 
Subsequently, upon infection with native virulent virus, an unusually large antibody 
response was directed at non-protective epitopes on the viral glycoproteins, resulting in 
immune-complex deposition in the lungs and increased lower respiratory tract pathology. 
Thus great care must be taken during the inactivation process to ensure epitopes that are 
critical for protection against infection, are not damaged. Even if critical epitopes are 
preserved, it is possible that the viral proteins in killed virus vaccines will be preferentially 
presented to MHC class Il-restricted T cells due to the lack of endogenous synthesis of the 
viral proteins. In this instance, it is unlikely that killed virus vaccine will be effective 
against viruses that are normally cleared by MHC class I-restricted cytotoxic T cells.
In addition to the problems mentioned above, the inability of killed virus vaccines 
to replicate, also means that larger doses of virus may have to be administered at regular 
intervals for the induction of long term protective immunity. Unfortunately, vaccines that 
have to be given in multiple inoculations are not only unattractive to the general public, but 
also increase the risk of hypersensitivity reactions.
Bc3. Subunit vaccines; a reductive approach to vaccination.
Subunit vaccines, which are characterised by synthetic peptides and purified viral 
proteins, are an attractive and relatively new approach to vaccination. Obvious advantages 
in the use of subunit vaccines, are that they are non-infectious and that they contain only 
the proteins or epitopes important for inducing protective immunity. However, these 
advantages are offset by the disadvantage that such vaccines are generally non- 
inununogenic when administered on their own. This paradox has led to the search for 
suitable adjuvant formulations (e.g. alum, muramyl-dipeptide, Quil. A) or carrier vehicles 
(e.g. ISCOMS, miciospheres, SMAA complexes; below) that can potentiate the
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immunogenicity of the subunit vaccines by maximising presentation of the target viral 
antigens to the immune system. In the following sections, a general review on the more 
recent advances in vaccine technology is presented, but for the moment, the use of 
peptides and purified proteins, themselves, as immunogens is discussed,
B.3.1. Peptides.
Immunisation with short, synthetic peptides corresponding to the appropriate protective 
epitopes of a virus is an attractive vaccination strategy, since potentially, vaccines could be 
designed that stimulated whichever effector function was particularly beneficial in the 
pmtection against virus infection. Naturally, the first step in this approach necessitates the 
availability of an efficient detection system for identifying critical antigenic epitopes 
present on the native virus particle. Although rapid advances have been made in this area 
of immunology, such research has highlighted the problems in using synthetic peptides as 
human vaccines. For example, since most B cell epitopes tend to be discontinuous i.e. 
composites of amino acids from different regions within the same protein [Barlow et al,„
1986], then peptides will have to be constructed that adopt an identical conformation to 
that of native vii-al proteins if they are to be effective [Satterthwaite et ai, 1989]. There 
have been attempts to overcome this problem by adding secondary structures to B cell 
epitopes. For example, the placement of cysteine residues at each end of a peptide 
sequence has been shown to facilitate the formation of disulphide bonds [Schulze-Gahmen 
et ah, 1985; Leonard etaU, 1990] and increased the immunogenicity of the B cell 
epitopes. Another novel strategy that has been shown to enhance the immunogenicity of B 
cell epitopes is the development of Multiple Antigen Peptide Systems (MAPS) [Tam,
1988]. This approach uses a small peptidyl core matrix bearing radially branching 
synthetic peptides as dendritic arms, to which the desired B cell epitopes can be linked.
However, other problems exist in the design of peptide vaccines for the 
stimulation of B cell responses; the necessity for T cell help for efficient B cell activation 
and antibody secretion, means that T cell epitopes may have to be coupled to the B cell 
epitopes, unless of course, the B cell epitopes themselves, contains sequences stimulatory
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for T cells. In addition, the ability of certain viruses to antigenically vary important B cell 
epitopes, suggests that efficient vaccines will have to include multiple B cell epitopes. The 
development of peptide vaccines that stimulate T cells has its own set of problems. For 
example, the consequence of peptide selection by polymorphicaUy distinct MHC in any 
peculation, means that peptide sequences that are immunogenic in one individual may not 
be in another. Consequently, peptide vaccines may need to contain multiple T cell epitopes 
[Rothbard, 1987].
B.3.2. Purified, recombinant viral proteins.
There are a number of potential advantages in using purified viral proteins as 
vaccines. For example, their non-infectious nature means they are unlikely to cause 
disease, and since the proteins contain multiple antigenic determinants, it is possible both 
B cell and T cell responses can be induced. Two practical requirements for purified 
proteins to be incorporated into vaccines are that they can be produced on an industrial 
scale (i.e. there is a need for suitable expression systems that can produce large quantities 
of recombinant protein that resembles natural protein) and that the purification scheme 
conserves sensitive conformational viral epitopes. The importance of a rigorous 
purification scheme is of particular importance for viral proteins expressed in continuous 
cell-lines, where the possibility of contaminating oncogenic DNA in the vaccine 
preparation, may lead to tumours upon vaccination. Prokaryotes, yeasts, baculoviruses 
and mammalian cells have all received attention as potential expiossion systems for viral 
proteins [Luckow et al., 1988, Hanke et aL, 1994; Randall etal., 1993], where the 
expression of viral proteins can be controlled by inserting viral genes downstream from 
strong ccHistitutive or inducible promoters [Kleid et ai, 1981]. Yeasts have been 
particularly successful for the production of recombinant Hepatitis B virus surface 
antigens that have subsequently been used in wide spread vaccination programmes.
Novel protein purification strategies are also currently being investigated. For 
example, through recombinant DNA technology it is possible to delete viral domains that 
normally anchor viral proteins in the cell membrane of the expressing cell, thereby
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facilitating secretion of the protein and therefore making purification simpler [Lasky et ai, 
1986; Whang et ai, 1987]. An alternative strategy, described by Hanke and colleagues 
(below), is to attach small, affinity tags to viral proteins which subsequently can be used 
to purify the recombinant viral protein on anti-tag affinity columns.
However, apart from a few general exceptions [Valenzula et aL, 1982; McAleer et al,
1984], as with peptide-based vaccines, purified proteins on their own, tend to be poorly 
immunogenic in vivo, often having to be administered in conjunction with powerful 
adjuvants or coupled to caniCT systems.
B.4. Novel strategies for potentiating the immune response to 
subunit vaccines.
The rapid advancement in the production of peptide and purified proteins as 
potential subunit vaccines, has been paralleled by developments in novel strategies to 
increase their immunogenicity. Current interest in this field of immunology, has centred on 
the development of improved adjuvant formulations or the manipulation of recombinant 
viruses and bacteria to express and present foreign viral proteins to the immune system. 
Naturally, such research has yielded a vast array of novel vehicles for potentiating the 
immunogenicity of subunit vaccines, and although each has its own particular merits, it is 
outwith the scope of this introduction to be able to describe them all in detail. Thus, the 
rest of this section is concerned with describing adjuvants and carrier systems, currently 
receiving the most attention.
B.4.1. Adjuvants.
Adjuvants, classically defined, are any substance that can augment the immune 
response to a particular antigen when it is administered at the same time as the antigen. 
There is a vast array of chemical, bacterial and immunological products that have been 
ascribed adjuvant properties [Penny et al., 1993; Bernstein et al., 1993; Good et aL, 1988] 
and have recently been reviewed by Gupta and colleagues [1993]. However, most 
adjuvants are highly toxic, inducing several unpleasant side-effects, that make their use in
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man unlikely. As such, there has been a large amount of research into new adjuvants that 
retain the adjuvanticity of existing formulations, but exhibit greatly restricted adverse 
reactions. A few of the more recent advances in human adjuvant research that show 
particular promise, are described below.
(al Mineral compounds.
The use of alum (aluminium hydroxide and aluminium phosphate) as an adjuvant was 
described more than 60 years ago [Glenny, 1926) and even today, it is the only adjuvant 
licensed for use in man. Alum-based products can be prepared either by the precipitation 
or adsorption of the desired protein onto the mineral compound [Randall et a i, 1994], the 
latter strategy being more efficient at producing a uniform vaccine formulation. Although 
alum is generally considered a safe adjuvant, there are variable reports on its efficacy. For 
example, alum-adsorbed inactivated poliomyelitis virus was Mghly immunogenic in vivo 
[Butler, 1962] but adsorption of influenza A virus haemaglutinin onto alum had no 
enhancing effect in clinical trials [Davenport et al., 1968]. Since the mode of action of 
alum is thought to be due to a depot formation [Leeling et al., 1979] which delays 
resorption of the protein from the site of injection (thereby prolonging the period of 
antigenic stimulation), it is generally assumed that the efficacy of alum as an adjuvant for a 
particular protein will be dependant on how well that protein can adsorb to alum [Skea et 
al., 1993 (a); (b)]. This may help explain the discrepancy in the clinical trials described 
previously (i.e. influenza haemagglutinin binds poorly to alum). There have also been 
reports that alum-based vaccines are weak inducers of cell-mediated immunity [Bomford,
1980], and as such, they may be inefficient against viruses whose replication is normally 
controlled by this aim of the immune system. There are other potential problems in the use 
of alum as an adjuvant. For example, it has been shown that following administration, 
alum can induce granulomatous formation at the site of injection [Walls et al., 1977], as 
well as enhancing IgE production [Cogne et al., 1986], and therefore it may have a 
possible role in increasing allergic disease [Bohler-Sommeregger etal., 1986]. Also, the 
recent evidence that suggests aluminium compounds may be neurotoxic, leading to
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neurological disorders like Alzheimer's disease [McLachlan et al., 1989], has caused 
concern over the utility of alum in vaccine formulations.
Two alternatives to alum have recently been suggested; calcium phosphate 
[Goto et al., 1993] and an octadecyl ester of tyrosine, octadecyl tyrosine hydrochloride 
(stearyl tyrosine) [Penny et al., 1993]. Both have been shown to be stable, efficiently 
entrap proteins, can stimulate high levels of IgG (but little IgE), do not induce 
granulomatous formation and since they are composites of natural constituents of the 
body, are readily adsorbed [Relyveld et al., 1986; Penny et al., 1993; Nixon-George et 
al., 1990].
Probably the most famous adjuvant is Freund's complete adjuvant (FCA). This oil-in- 
water emulsion contains mycobacteria in the oil phase, and has been shown to be a potent 
inducer of both humoral and cell-mediated immunity, including cytotoxic T cell responses 
in experimental animals. However, FCA is highly toxic inducing fever, cramps and 
necrosis at the site of injection, which makes it unsuitable for use in man. The active 
component of FCA has been linked to the presence of the mycobacteria, in particular the 
muramyl dipeptide (N-acetylmuramyl-L-analanyl-D-isoglutamine, (MDP)) component of 
the bacterial cell wall [Chedid et al., 1976]. MDP itself is highly immunogenic but, like 
FCA, it is extremely toxic. This has led to several studies to determine if the 
imraunopathological effects of MDP can be separated from the adjuvant properties. Such 
research has shown that a synthetic analogue of MDP, threonyl-MDP (t-MDP) exhibits 
adjuvant activity in experimental animals without inducing severe side-effects [Allison and 
Byars, 1986]. The potential of such adjuvants in man is currently under investigation.
(c) Cytokines.
Cytokines are also being exploited as potential adjuvants, in particular recombinant 
interleukin-2 (rIL-2) [Good et al., 1988], For example, injection of rIL-2 with the hepatitis 
B vaccine, induced humoral immunity to the viral surface protein in individuals who were 
noimally non-responders to hepatitis vaccination [Meuer et al., 1989; Kawamura et al.,
1985]. In contrast to these findings, immunisation of guinea-pigs with IL-2 and herpes
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simplex virus-2 (HS V-2) induced an efficient cell-mediated response to HSV-2 
glycoprotein D but had little effect on antibody production [Weinberg and Merigan, 1988].
However, despite the initial success of cytokines as adjuvants, it does not yet 
establish them as alternatives to conventional adjuvants like alum, and it is important to 
point out that cytokines can induce serious side-effects, even when administered in minor 
amounts. It may be, that in time, after further research into their effectiveness and 
toxicities, cytokines may have a specialist application in vaccine design, e.g. in 
overcoming hyporesponsiveness, or selectively inducing cell-mediated immunity.
B.4.2. Novel carrier systems.
In recent years there has been a major development in the construction of various 
polymeric presentation systems, that optimise the delivery of peptides and purified 
proteins to the immune system. There are two types of, so-called, carrier systems:- 
expression based and non-expression based. Live, recombinant viral and bacterial vectors 
are examples of the former category, whereas non-expression based carriers are 
characterised by immunostimulatory complexes (ISCOMS), liposomes, solid matrix- 
antibody-antigen (SMAA) complexes and Ty-paiticles to name but a few. Carriers may 
serve several functions, they may allow presentation of multiple epitopes of the target 
antigen and/or provide the necessary T cell epitopes for the provision of B cell help. One 
concern with carriers is the effect of carrier induced suppression, where pre-existing 
immunity to the carrier can downregulate the immunogenicity of the target antigen 
[Schutze et a l, 1985]. Thus, several areas of reseaixih into carrier systems for peptides or 
purified proteins, have relied on the development of novel synthetic carriers where no pre­
existing immunity to the carrier exists. In the following sections, a general review of some 
of the current earner systems that are under investigation as potential human vaccines are 
presented.
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B.4.2.1. Live, recombinant viral vectors.
Several different viruses have been proposed as potential live carrier systems for 
viral proteins including vaccinia virus [Andrew et al, 1991], avipox virus [Radaelli et al, 
1994; Radaelli and De Giuli Morghen, 1994], herpesvirus [Roizman and Jenkins, 1985], 
adenovirus [Johnson et aL, 1988], rotavirus [Redmond et al., 1991], and poliovirus 
[Burke et al., 1988; Evans et al., 1989; Dedieu et al., 1992]. Some viral vectors e.g. 
attenuated vaccinia and adenovirus lepUcate in vivo, whereas others e.g. poliovirus 
minireplicons and avipox, are engineered to liave a restricted or abortive replication, but 
they all retain tlie ability to infect. Thus, upon infection, foreign proteins are expressed 
during the normal replication of the virus, thereby potentially inducing both humoral and 
cell-mediated immunity. However, certain problems exist in the use of live, recombinant 
viruses as carriers for viral proteins. For example, the size of the genome can restrict the 
amount of foreign genetic information that can be inserted into the vector. Viruses like, 
vaccinia, that contain a large 231 kilo base-pair genome, can accommodate high amounts 
of foreign DNA [Smith and Moss, 1983] either by inserting the desired sequence 
downstream of a defined vaccinia promoter sequence [Mackett et al., 1982] or by insertion 
into a nonessential loci [Panicali and Paoletti, 1982; Perkus et al., 1985; 1986]. In 
contrast, poliovirus, with its characteristic 7.7 kilo-base RNA genome, can only 
accommodate relatively small inserts [Burke et al., 1988].
Live replicating viruses present the additional problem of finding suitably 
attenuated strains that can act as carriers. As examples, the gene product El A of 
adenovirus can transform cells in culture, causing concern as to whether it may be 
oncogenic in man, and attenuated vaccinia virus strains currently available may induce 
neurological complications e g. encephalopathy in immunosuppressed individuals, as well 
as leading to the exacerbation of dermatological conditions. Although new strategies for 
attenuating vaccinia virus have recently been described, e.g. animal studies have shown 
the inseition of foreign DNA into the thymidine kinase locus is accompanied by the 
attenuation of the recombinant virus, this does not necessarily mean that the virus will be 
attenuated in man [Bidler et al., 1985; Rodriguez et al., 1989; Hu et al., 1986]. Insertion
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of cytcddne genes into the genome of vaccinia virus, in particular IL-2, has also been 
reported as a novel strategy for attenuating the virus. This latter strategy having the 
additional benefit in that the expression of IL-2 in conjunction with the foreign viral 
protein, can over-ride non-responsiveness.
B.4.2.2. Live, recombinant bacterial vectors.
Mycobacterium bovis bacillus Calmette-Guerin (BCG), the human 
tuberculosis vaccine and attenuated strains of Salmonella have both been used as carriers 
for foreign proteins, the latter being used as a carrier for mucosal immunisation (see later). 
BCG has features that make it a particularly attractive live recombinant, bacterial vaccine 
vehicle; BCG, as with other mycobacteria, are excellent adjuvants, with a long-lived safety 
record in man. In addition, BCG engenders a long-lived immune response with a single 
dose, is heat stable, inexpensive to produce and one of the few vaccines that can be given 
at birth. Recent developments in genetic engineering have shown that it is possible to 
insert foreign genes into BCG [Jacobs e ta l, 1987; Snapper et al., 1988] and following 
vaccination, such expression of the resulting foreign proteins can induce both humoral and 
cell-mediated responses [Aldovini and Young, 1991], including MHC class I-restricted 
CD8+ CTL. Strover and colleagues, [1991] showed that foreign genes inserted under the 
control of the heat shock promoter, could lead to high level expression of the foreign 
proteins, and as such only low doses of BCG were needed for immunisation purposes.
However, one problem with the use of BCG or any bacteria for that matter, is the 
inability to express glycosylated viral proteins in native conformation. Since viral 
glycosylated proteins normally contain the antibody neutralising domains, it is 
questionable whether any bacteria expressing the genes for such viral proteins will be 
capable of inducing immunity to these protective epitopes.
B.4.2.3. Super-molecular assemblies.
Several new approaches in the design of carrier systems for peptides and purified 
proteins have been concerned with the development of large molecular assemblies that
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contain multiple copies of one or more foreign epitopes. The repeating units of the 
assembled carrier protein stimulate T lymphocytes efficiently and the use of an efficacious 
adjuvant can further increase both cell-mediated and humoral responses. A brief review of 
some of the most promising carrier systems is presented below.
B.4.2.3.1. Liposomes and ISCOMS.
Liposomes and immunostimulatory complexes (ISCOMS) are examples of lipid- 
based carrier systems. Liposomes are membrane vesicles, formed by the dispersion of 
phospholipids in aqueous media that possess several interesting properties required for in 
vivo carriers. For example, they are relatively non-toxic, exhibit low immunogenicity and 
are biodegradable [Snyder and Vannier, 1984]. ISCOMS on the other hand, aie cage-like 
particles of 30-40nm in size that are composed of the saponin Quil A, cholesterol and 
amphipathic antigen in a molar ratio of 1:1:1 [reviewed by Morein, 1988]. Both liposomes 
and ISCOMS can stimulate a wide spectrum of immune responses. For example, 
liposomes have been reported to protect against influenza [Friede et al., 1994] and can 
induce MHC class I-restricted CD8+ CTL responses [Reddy et al., 1992]. In part this 
adjuvanticity of liposomes is related to the number of layers [Shek etal., 1983], their 
charge [Allison and Gregoriadis, 1974], and their composition [Heath eta l, 1976].
Likewise, ISCOMS have been shown to generate immunity to a wide variety of 
viral proteins, including influenza [Lovgren, 1988], measles [DeVries e ta l, 1988], rabies 
[Osterhaus et a l, 1986], glycoprotein 340 from Epstein Barr Virus [Morgan et a l, 1988] 
and the glycoprotein 120 from HIV [Pyle et al, 1989]. In slight contrast to the safety of 
liposomes, ISCOMS are still restricted to veterinary use. A problem with ISCOMS, that 
prevent their use in man, is the presence of the toxic adjuvant Quil A. Nevertheless, 
several attempts are being made to design non-toxic versions of Quil A that retain the 
adjuvant properties of the parent molecule.
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B.4.2.3.2. Ty; Virus-Like Particles (Ty:VLP).
Certain yeast proteins that spontaneously associate into virus-like particles (VLP) 
[Mellor et al., 1985] are also under consideration as carriers of viral proteins [Griffiths et 
al., 1991]. Such an approach is typified by the TyrVLP system wherein a foreign DNA 
sequence is fused to the TYA gene and can then be expressed in yeasts [Adams et al.,
1991]. For example, fusion of the principal antibody neutralising domain, V3, of Human 
Immunodeficiency Virus-1 (HIV-1) to TytVLP resulted in an effective MHC class I- 
restricted CD8+ CTL response to the viral antigen [Layton et al., 1993]. Ty:VLP particles 
are also showing promise as mucosal vaccines [Lehner et al., 1992].
B.4.2.3.3. Self-aggregating viral proteins.
The hepatitis B virus core antigen (HBcAg) and surface antigen (HBsAg) are 
examples of self aggregating viral proteins that have been suggested to have potential 
carrier activity for foreign antigens [Francis et al., 1990]. For example, HBcAg 
spontaneously self aggregates into characteristic 27nm particles [Almeida et al., 1971], 
and chimeric core particles can be created by tlie insertion of peptide sequences onto the N- 
and C-termini of HBcAg [Clarke et aL, 1987; Stahl et al., 1989]. The HBcAg particle 
itself is highly immunogenic [Hoofnagle et al., 1973], presumably due to the virus 
proteins' polymeric nature as well as the presence of a number of well-defined helper T 
cell epitopes [Milich et al., 1987] and this may contribute to the adjuvant properties of 
HBcAg for fused foreign antigens.
An example of HBcAg as a carrier system is presented by the study of Francis 
and colleagues [1990]. Fusion of the VP2 proteins from human rhinovirus type 2 to 
HBcAg, resulted in both humoral and cell-mediated immunity to VP2 following parental 
administration. Low levels of semm antibody was also detected following intranasal or 
oral vaccination, so such HBcAg-fusions may have potential as mucosal vaccines. 
Similarly, fusion of the V3 domain from HTV-1 to either the N- or C-teiininal of HBcAg 
resulted in the induction of neutralising antibodies to the HTV [Von Brunn et al., 1993]. 
MHC class I-restricted CD8+ CTL can also be induced by immunisation with the target
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epitopes fused to hepatitis virus antigens, e.g. HBsAg [Schlienger et al., 1992], 
suggesting that these novel self aggregating viral proteins have the potential to induce all 
arms of the immune response.
B.4.2.3.4. Solid matrix-antibody antigen (SMAA) complexes.
A novel strategy to vaccine design has been the development of solid matrix- 
antibody-antigen complexes [reviewed by Randall, 1989]. The basis of this scheme is to use 
monoclonal antibodies, linked to a solid matrix (e.g. hodX-)dllçàStaphylococcus aureus, an 
organism that can bind to the Fc region of IgG2a antibodies via the Protein A determinant of 
the bacteria wall, thereby leaving the antigen binding arms of the antibody free to complex 
with its specific antigen, or the adjuvant alum), to first purify the antigen and then to use the 
SMAA complexes as immunogens (see Figure 4). SMAA complexes themselves are 
particulate and can induce both vigorous antibody responses as well as class I-restricted 
CTL [Randall and Young, 1988; Randall et al., 1988]. The potential advantages and 
disadvantages of such a method of antigen presentation have been discussed elsewhere 
[Randall, 1989]. Piincipally the major advantage of such a system is that tlie complexes are 
extremely easy to produce and it is relatively simple to incorporate multiple virus antigens, 
including structural and non-structural proteins into the SMAA complex. Also antigens can 
be derived from virtually any source, be it expression vectors or virus infected tissue culture 
cells, and can simply be incorporated into the SMAA complexes. As alternative to 
conventional adjuvants it has also been suggested that it may be possible to induce an 
immune response to antigens by tar geting the binding of antigens directly to particular host 
cells [Randall, 1989]. This could be achieved by coupling the antigens to monoclonal 
antibodies that recognise cell surface determinants, such as immunoglobulins [Kawamura 
and Berzofsky, 1986] or MHC class I and class II antigens [Snider and Segal, 1987; 1989; 
Carayanniotis and Barber, 1987].
More recently it has been demonstrated that a single monoclonal antibody (MAb) 
specific for a short oligopeptide tag can be used to assemble multiple tag-linked antigens into 
SMAA complexes [Hanke et al., 1992; 1994]. For example, a variety of viral proteins from
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a)
Antigen 1 
MAM \ .
s^oiid
MAb 2
Antigen 2
«sss^a
c)
MAb to . tag /antigen tagantigen
Fab to tag antigen
tagantigen
scFv to
antigen tagantigen
MAb to host cell surface antigen
/Antigen (eg. cholera toxin) incorporated solely to enhance specific type of immune response
Figure 4. Solid matrix-antibody-antigen (SMAA) complexes.Schematic illustration of the construction of solid matrix-antibody-antigen (SMAA) complexes as muitivalent immunogens, (a) Different monoclonal antibodies (MAbs) are attached to independent solid matrices prior to the binding of antigen. The resulting SMAA complexes are mixed together before being used as immunogens, (b) Different MAbs are attached to the same solid matrix prior to the formation of SMAA complexes, (c) A single MAb that recognises a tag antigen, which may be aatached to different microbial antigens, is used in the construction of SMAA complexes, (d) and (e) are the same as (c) only Fab or single chain Fv fragments of antibodies respectively are used in the construction of modified SMAA complexes, (f) is the same as (b) except that the additional MAbs (e.g. to host cell surface antigens) and proteins (e.g. cholera toxin) are also attached to the solid matrix specifically to enhance particular types of immune responses (e.g. mucosal immunity)(Taken from Randall, 1993)
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Simian Immunodeficiency Vims (SIV) have been cloned and expressed, from a modified 
vector pQE9-Pk, in E.coli such that the recombinant proteins have a small histidine (His) tag 
at their N-termini and a small oligopeptide tag, termed Pk, at their C-termini. The Pk tag is 
recognised by monoclonal antibody SY5-P-k [Southern et al., 1991]. These recombinant 
proteins can thus be purified on nickel columns, via the histidine tag, and then on immune- 
affinity columns by the SV5-P-k MAb. The combination of the two affinity purification 
steps significantly improves the purity and selects for full-size proteins. Moreover, using the 
MAb SV5-P-k in the second purification step, Pk-linked antigens can be assembled directly 
into SMAA complexes for use as vaccines [Randall et al., 1993; Hanke et al., 1994].
B.5. Genetic Immunisation.
Probably one of the most novel vaccination strategies to emerge in recent years, is 
the direct inoculation of the foreign gene(s) into living animals [Nabel et al., 1990; Wolff et 
al., 1990]. Such a process is referred to as naked DNA, or genetic, immunisation and 
potentially offers an extremely powerful approach for combating disease caused by vimses. 
One advantage is that the foreign protein is synthesised within the host cells and is thus 
capable of inducing CD8+ CTL. For example, vaccination of experimental animals with 
DNA encoding the conserved internal nucleoprotein of influenza virus A, resulted in CTL- 
induced cross-protection from sublethal challenge with an antigenically distinct isolate of the 
virus [Ulmer et al., 1993]. Another advantage is that the expressed protein will undertake 
the native conformation, an extremely impoitant point when considering the induction of 
neutralising antibodies.
Naturally, as with all vaccines there are drawbacks to genetic immunisation. One 
of these drawbacks is the need for an efficient system that permits maximal uptake of DNA 
into the target cells. So far, the most common method for transfecting DNA into cells in vivo 
is direct immunisation of the genetic material into muscle cells, which are surprisingly 
permissive in their uptake of DNA after treatment with bupivacaine. However, other 
strategies are emerging. For example, inhalation of DNA incorporated into cationic 
liposomes, has been shown to result in the expression of the target protein in both the
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airways of the epithelium and the alveolar cells lining the lungs [Stribling et al., 1992]. 
DNA-coated gold particles can be directly inoculated into tissues of a living animal by use of 
a gene gun [Fynan et al., 1993]. There are also several safety considerations in the use of 
DNA immunisation. For example, it wül be important to determine if inoculated DNA 
integrates into the host chromosome, and whether the genetic material can induce anti-DNA 
antibodies that cioss-react with host DNA.
B.6. Mucosal Immunisation.
The increasing evidence that priming of the mucosal system to a particular antigen 
can sometimes lead to immunity at other mucosal sites as well as systemic immunity, has 
increased research into vaccine strategies that promote immunity at mucosal surfaces. 
However, many strategies employed for systemic immunisations have been tried by the 
mucosal route with limited success. Furthermore, in general it has been extremely difficult to 
induce optimal antigen specific IgA responses following oral immunisation with soluble 
protein antigens. In part, this is due to the problem of degradation of the antigens in the 
acidic environment of the gut and has necessitated large amounts of antigen needing to be 
administered to overcome this problem. However, prolonged feeding of large doses of oral 
protein antigen can also lead to tolerance [Challacombe and Tomasi, 1987].
Several of the vaccine strategies described in the preceding sections have been 
adapted as mucosal vaccines, and are briefly outlined below. Other novel strategies that are 
showing particular promise as mucosal based vaccines are described in greater detail.
B.6.1. Biodegradable polymer microspheres (microcapsules).
Microspheres are biodegradable polymer matrices that can be used to 
encapsulate target antigens and protect the antigen from acidic and enzymatic degradation 
in the gastrointestinal tract. The most studied polymers are those made from lactic and 
glycic acids, e.g. poly lactide-co-glycolide, which are normal constituents in mammalian 
energy metabolism. Such spheres can vary in size depending on the constituents of the 
polymer matrix, and the biodégradation of the polymer is usually the rate controlling step
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in the release of the antigens [Cohen et aL, 1991]. The release of antigen is controlled 
through its diffusion in the matrix pores and the speed of degradation of the matrix. Large 
polymers can release antigen slowly and thus have the potential to restimulate the immune 
system over a long period of time. It has been shown that formalin inactivated whole 
influenza virus A retained its immunogenicity when encapsulated in lactide co-glycolipid 
microspheres [Moldoveneau et a i, 1989] and that such microspheres induced antibody 
responses on the levels similar to parental immunisation with the killed vaccine. In 
addition, it was later found that such vaccination protected experimental animals against 
lethal virus challenge [Moldoveneanu e ta l, 1993]. Miciospheres have been shown to be 
efficiently uptaken by M cells in the Peyers patch, the hydrophobicity of the microsphere 
having important implications on the efficiency of this uptake. Microspheres, therefore 
may be used for both parental and mucosal immunisation.
However, one problem with microspheres is that during their production they 
are exposed to harsh, organic solvents e.g. methylene chloride, and trace amounts of this 
toxic compound have been found inside microspheres [Benoit etal., 1986]. The presence 
of such substances wiU naturally prevent approval of microcapsules for human use. 
Furthermore, such harsh conditions may denature the antigen of interest, destroying 
important epitopes, particularly virus glycoproteins. Consequently, different, more gentle 
strategies are currently being developed for creating the capsules. It will be important to 
characterise the shelf-life of the microspheres and the ideal conditions for their storage. 
The possibility that the polymer will spontaneously hydrolyse and/or the encapsulated 
proteins aggregate in the presence of ambient moisture, remains an additional concern 
[Domb etal., 1987].
B.6.2. Live recombinant bacterial vectors.
Live recombinant bacterial vectors e.g. attenuated Salmonella typhimurium are 
showing promise as novel carriers for delivery of foreign proteins to the mucosal immune 
system [Aggarwal et al., 1990]. Many of the new strains of Salmonella that are currently 
being investigated as potential carriers are auxotrophs [Hoiseth and Stocker, 1981]. As
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such they can only replicate in the body to a limited extent, and are potentially safe for use 
in immunocompromised individuals [Stocker et al., 1983]. Several studies have been 
conducted on the efficacy of attenuated Salmonella strains as carriers for foreign viral 
genes. For example, incorporation of Hepatitis B virus surface protein [Wu et al., 1989] 
and an influenza A virus haemagglutinin epitope [McEwen et al., 1992] into Salmonella 
leads to the induction of humoral immunity to the respective viruses. One problem with 
Samonella as a carrier is that the insertion of foreign genes using antibiotic resistant 
plasmids is undesirable [Schodel etal., 1994].
Recombinant BCG has also been shown to be an efficient oral vaccine delivery 
system [Lagranderie etal., 1993].
B.6.3 Cholera toxin (CT) and Escherichia coli enterotoxin (LT) 
as mucosal adjuvants.
The gastrointestinal toxins, cholera toxin (CT) secreted from Vibrio cholerae and 
the related E.coli heat-labile enterotoxin (LT), which cause severe diarrhoeic disease in 
infected individuals, are proving promising as mucosal adjuvants for unrelated antigens co­
administered at the same time as the toxins [Lycke and Holmgren, 1986; Clements, 1990]. 
Both CT and LT have the same basic structure, composed of two subunits; the A subunit of 
approximately 28kD carriers the enzymatic activity of the toxins (see below) and the B 
subunits, made up of 5 identical polypeptide chains (11.6kD each) arranged as a pentamer, 
functions to bind the toxins onto the surface of target cells via its affinity for the glycolipid, 
GMl-ganglioside, a normal constituent of cell membranes [Clements and Finklestein, 1979; 
Gill et al., 1981]. In addition to GMl-ganglioside, LT (unlike CT) can also bind to certain 
sugars [Holmgren, 1973; 1985]. The A subunit is located in the central core of the B subunit 
pentamer [Sixma et al., 1991; 1993], and upon binding of the toxin to the target cells, enters 
the cell and ADP-ribosylates the a subunit of the Gs regulatory protein [Dominguez et al., 
1987], wliich results in the Gs protein remaining in an activated state. As a consequence of 
this, intracellular cyclic AMP levels rise, resulting in the activation of protein kinase A, 
which is capable of phosphorylating the cystic fibrosis transmembrane receptor (CFTR), a
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regulated chloride ion channel [reviewed by Roidan, 1993]. Phosphorylation of the CFTR 
causes the ion gate to open, resulting in an efflux of chloride ions (and water) into the lumen 
of the gut, causing characteristic symptoms of the disease. CT and LT are extremely potent 
mucosal immunogens, eliciting high levels of IgA antibodies to themselves following 
intragastric administration [Pierce and Gowans, 1975]. Of more significance for vaccine 
technology, both CT and LT have been shown to promote mucosal immunity to unrelated 
antigens administered at the same time as the toxins [Lycke and Holmgren, 1986; Elson and 
Ealding, 1984] .The exact mechanism(s) responsible for the adjuvanticity of the toxins is 
unknown, but several in vitro and in vivo assays have demonstrated that they are capable of 
modulating a variety of immune functions, including enhancement of antigen presentation by 
macrophage [Bromander et al., 1991], as well as promoting the switching of IgM secreting 
B cells, to secrete IgA [Lycke and Strober, 1989]. In addition, CT has been shown to exert 
both enhancing and inhibitory effects on the proliferation of B and T cells in vitro [Woogen 
et al., 1987] and possibly, in vivo. In part, the potentiation of mucosal immunity to 
unrelated antigens is thought to be under control of the immune response genes [Elson and 
Ealding, 1987].
Naturally, the highly toxic nature of the toxins, prevents their use in man, and there 
have been several attempts to determine if the adjuvanticity of the toxins can be separated 
from the toxicity properties i.e.whether the B subunits themselves, which do not contain any 
ADP-ribosylating activity, contain the adjuvant function of the toxins. This has led to several 
research programmes analysing the ability of CTB (or LTB) to promote immunity to either 
co-administered antigens or antigens fused to the subunits by chemical or genetic means 
[Clements, 1990; Sanchez etal., 1988, Klipstein, etal., 1982; Schodel etal., 1991]. The 
results frtxn such work has been largely inconclusive in identifying the adjuvant properties 
of CT and LT. In some instances, the B subunits were shown to enhance the immune 
response [Schodel and Will, 1989; Dertzbaugh et a l ., 1990], but in others, the presence of 
the A subunit was necessary to promote immunity to the target antigen [Lycke and 
Holmgren, 1986; Lycke et al., 1992]. This discrepancy in the results has been attributed to
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contamination of the B subunit preparations, (which are prepared from purified whole toxin) 
with minor amounts of the A subunit [Vajdy and Lycke, 1993].
More recently, the genes of the B subunits of CT and LT have been cloned and this 
has facilitated the construction of a number of plasmid vectors, that permit the addition of 
foreign sequences onto the 3' and 5'-ends of the subunits [Sandkvist et a l, 1987; 
Dertzbaugh et al., 1990]. Although genetic linkage of antigens to LTB (and CTB) has 
obvious advantages over chemical linkage, in that the recombinant proteins are structurally 
defined, there are several problems to be overcome. For example, the ability of LTB and 
CTB to form pentamers is thought to be cmcial for their immunogenicity (and hence 
adjuvanticity), since several studies have suggested that efficient binding of the toxins to 
GMl-ganglioside requires more than one B subunit [Sixma et al., 1992; lida et al., 1989]. 
Certain amino acid additions at the C-terminus of LTB have been shown to prevent 
pentamerisation and subsequently association with GMl-ganglioside [Sandkvist et al., 
1987], although the exact amino acid restraints that lead to this are, at present, unknown. A 
second consideration in the use of CTB or LTB-fusion proteins is the availability of a 
suitable expression vector and purification protocols that can be used to purify the fusion 
proteins without damaging important epitopes on either the toxin subunits or the fused 
antigen. E.coli has, in the past, been employed as an expression system for LTB-fusions, 
but more recently. Vibrio cholerae species have been shown to be amenable to the 
expression of LTB-fusions [Schodel et al., 1991]. One such vector receiving current 
attention is Vibrio sp. 60, a non-pathogenic strain of Vibrio [Leece and Hirst, 1992; Amin 
and Hirst, 1994]. The use of Vibrio species as vectors for LTB- and CTB-fusions, is 
particularly attractive, since this organism, unlike E.coli, can secrete oligomeric toxins (CT 
and LT) [Hirst et al., 1984; Neill et al., 1983] or their B subunits [Sandkvist et al., 1987; 
Schodel et al., 1991], across the outer membrane and into the external culture medium, 
where the fusion protein can be readily harvested from the culture medium. Other bacterial 
vectors have also been shown to be capable of expressing LTB-fusion proteins, e.g. 
salmonella, [Clements and Cardenas, 1993; Sanchez et al., 1988] and this presents the 
opportunity the LTB-fusions may be delivered in situ, by the intestinal colonising bacteria.
46
c .  Simian Immunodeficiency Virus (SIV).
One of the major challenges for virological and immunological research is to 
develop successful and practical vaccines to Human Immunodeficiency Virus (HTV). 
However, from work to date, it is not clear what arc the parameters of protective immunity 
to HTV [reviewed by Levy, 1993]. Furthermore, HIV does not cause disease in any animal 
model system. Consequently, to try and develop vaccines against HTV, other animal model 
systems have been developed. The best characterised of these being infection of macaques 
and rhesus monkeys with Simian Immunodeficiency Virus (SIV).
SIV, like HTV, is a member of the lentivirus subfamily of retroviruses. All 
lentiviruses have a unique virion morphology/ morphogenesis that distinguishes them 
from other retrovmises. Furthermore, lentiviruses are not oncogenic but instead induce 
chronic, debilitating diseases following long term persistent infections. SIV has several 
properties that make it a useful model for HTV infection. For example, it shares biological 
and genetic characteristics with HTV and there is considerable sequence homology in the 
major structural and regulatory proteins of SIV and HIV-2 [Dersoriers et al., 1988; Letvin 
e ta l,  1985].
One of the key features of SIV and HTV is their ability to persist in spite of an 
apparently strong host response to the viras. Infected individuals may remain well for 
years, whde maintaining easily detectable humoral and cellular immune responses, only to 
succumb eventually to the virus. This ability to persist and cause a slow progressing 
disease, seems to be unique to the lentivirus subgroup of retroviruses. Like HTV, SIV has 
a tropism for the CD4 molecule, thus principally infects CD4+ T cells and monocytes, 
resulting in debilitation in their numbers leading to a chronic immunodeficiency. Some 
strains of SIV are capable of inducing fatal immunodeficiency disease, similar to AIDS in 
man, within a time scale that makes it suitable for laboratory investigations. For example, 
one of the most common clinical signs in macaques infected with SIV is diarrhoea, often 
associated with pathogenic bacteria or protozoa. The diarrhoea is often associated with a 
wasting disease similar to HTV in humans.
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SrV infected macaques also develop immunological abnormalities including a 
decrease in CD4+ lymphocyte numbers [Letvin et a l, 1985], decreased responsiveness of 
peripheral blood lymphocytes to mitogenic stimulation, and thymic atrophy.
Immunological abnormalities result in a range of opportunistic infections, many of which 
are seen in humans infected with HIV-1.
Interest in simian immunodeficiency viruses (SIVs) originates primarily from 
three sources. First, a common or related origin of SIV and HIV has been suggested 
because the viruses are similar, both biologically and at the molecular level [Coffin, 1986; 
Daniel et al., 1985; Letvin et al., 1985]. Secondly, the similarities between HTV and SIV 
go beyond structural features. STVmac can be isolated from infected cells using identical 
methods used for isolating HIV, moreover the ability of SIV to infect human and monkey 
lymphocytes depends on the presence of the CD4 molecule on their surface [Kannagi et 
al., 1985]. Thirdly, when SIV was first isolated, not only was its moiphology and culture 
characteristics similar to HIV but also its antigenic properties indicated that it was related to 
HIV-1 [Kanki et al., 1985]. Also, radioimmuneprecipitation analysis revealed SIV- 
proteins of 160,120, 55 and 24 kilodaltons (k), all similar in size to the major gag 
proteins and external envelope glycoprotein of HTV.
The genomes of SIV and HIV-2 have about 75% nucleotide homology but both 
have only 40% of their sequences in common with HTV-1 [Charabrati et al., 1987; Franchini 
et al., 1987]. The overall organisation of their genomes are remarkably similar. The 
sequence of gag and pol genes are highly conserved between primate lentiviruses. The gag 
gene codes for a precursor polypeptide of about 55kD which, in analogy to other 
lentiviruses, is cleaved into polypeptides of about 17,25 and 12 kD. There are only two 
amino acid differences between p27 of STV (strain STVmac) and HIV-2, but 13 differences 
between HTV-1 [Benveniste et al., 1986]. The cleavage site for pol precursor protein that 
yields the protease and the polymerase is œnserved in HTV-1, HIV-2 and STVmac [DiMarzo 
etal., 1986].
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c . / .  S/V, Protective Immunity and Vaccination.
There have been a number of studies on the induction of protective immunity to 
SrV [see review by Stott, 1994], and a general out-line is presented below;
(a) vaccination with attenuated viruses can protect against infection with the wild- 
type viruses. The basis of this protection is unknown, but recent results using SIV/HIV 
chimeric viruses suggest that cell-mediated immune resptmses, rather than neutralising 
antibody, are responsible for the protection seen.
(b) immunisation with whole killed cell virus vaccine can protect, but here the 
protection appeal's to be mediated via anti-host cell responses, rather than via anti-virus 
responses. This may be because lentiviruses incorporate host cell proteins into their 
envelope, e.g. class I and class II MHC molecules. Indeed, protection can be mediated by 
generating an anti-class II MHC response.
(c) no recombinant vaccine, either purified protein in a variety of adjuvants or 
expression vectors such as vaccinia virus, has been able to induce protective immunity to 
SIV. This is despite the finding that many recombinant vaccines that incorporate the 
envelope glycoprotein of SIV induce good neutralising antibodies to the virus. However, 
such vaccines, while failing to protect against infection, may reduce the initial virus load in 
infected cells.
The positive message for these results is that protective immunity can be induced 
by vaccination. Unfortunately, for safety considerations it may not be acceptable to use an 
attenuated HIV vaccine. Consequently, the challenge is to develop a novel and acceptable 
method of vaccination which can induce protective immunity against lentiviruses.
One thing also to bear in mind when considering the design of anti-STV/HIV 
vaccine is that the natural route of infection by the virus is through mucosal surfaces. To 
date, the vaccine challenge studies with STV have rarely used this method of infection and it 
may be necessary to induce mucosal immune responses to protect against natural infection 
with HTV.
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D. Project Objectives.
Solid matrix-antibody-antigen complexes, as described in Section B.4.2.3.4, are 
showing promise as potential muitivalent immunogens. Yet several problems exist in the 
wide-spread use of SMAA complexes as human vaccines. For example, a suitable 
biodegradable solid matrix that is readily acceptable for use in man, needs to be developed. 
At present, alum is being employed as the solid matrix [Randall et al., 1993; 1994], but 
several problems with the use of alum have been described previously. However, the 
advancement in SMAA complex technology has opened the door for new strategies that 
could over-ride the need for the solid matrix. For example, it might be possible to generate 
highly immunogenic complexes by joining a tag-linked adjuvant to one arm of an anti-tag 
antibody, and tag-Hnked antigen to the other arm. This project has been concerned with such 
a strategy. LTB has been used as the adjuvant and antigen-antibody-LTB complexes have 
been constructed. The use of LTB as the adjuvant in the project, gave the added bonus that it 
increased the chances of such complexes acting as mucosal immunogens.
In this project, a small epitope tag (termed Pk) was attached to LTB and SIV 
antigens, that were also tagged with the Pk epitope, were linked to LTB via an antibody 
(anti-Pk) bridge. The systemic and mucosal responses to such complexes were evaluated.
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MATERIALS AND METHODS.
1. Recombinant DNA techniques.
1.1. Plasmids, bacterial strains and culture conditions.
The bacterial strains employed in this project were E.coli strain HB101 (Bolivar et 
al., 1977) and Vibrio sp.60 (Ichige et al., 1988). Liquid cultures of E.coli were grown in 
either in Luiia broth (L-broth) [lOg/1 bactotiyptone (Difco), 5 g/1 yeast extract (Difco), lOmM 
NaCl, pH 7.5] or 2X TYE broth (16g/l bacto-tryptone, lOg/1 yeast extract, 20mM NaCl, pH
7.5) supplemented with 100p.g/ml ampicillin (Sigma). Vibrio sp. 60 is a non-patliogenic 
marine Vibrio, recently described by Ichige et a l, [1988]. Liquid cultures of Vibrio sp. 60 
were grown in L-broth supplemented with an additional 2% NaCl and 100[tg/ml ampicillin.
The vector pMMB66, a derivative of the broad host range plasmid, RSFlOlO, was 
used to clone the gene encoding the B subunit of E.coli heat-labile enterotoxin subunit B, 
which has a 21 amino acid signal sequence followed by 103 amino acid mature sequence 
[Sandkvist et a l, 1987]. Upstream of the B subunit gene is a tac promotor. The 3'-end of the 
gene was modified as described in Sandkvist e ta l, [1987], to give plasmid pMMB138, 
which resulted in a B subunit with a short carboxyl-terminal extension and a HindlQ site near 
the end of the gene. Into this site an oligonucleotide (see fig. 5) was inserted, to give plasmid 
pTRHlOlR. Plasmid pTRHlOlR was a kind gift from Dr. T.R. Hirst, University of Kent.
1.2. Synthesis of synthetic oligonucleotides.
Synthetic oligonucleotides were made using an Applied Biosystems 381A DNA 
synthesiser (kindly performed by I. Arraitt). The oligonuucleotides were resuspended in 
2(X^ of sterile water and precipitated with 1/lOth volume of 3M sodium acetate, l/lOOth 
volume IM magnesium acetate and 3 volumes absolute ethanol. The precipitate was pelleted 
by high speed centrifugation at 4°C for 15 minutes in a bench top microfuge and then
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pTRHlOlR
102 103..glu lys Le(u Leu Glu Asp Pro Leu Val Pro Ala Leu ArgThr G)ln Leu 
.GAA AAG crrr CTA GAG GAT CCA CTA GTG CCG GCC CTG CGG ACC C)AG c i t .
Hindin______ Bam HI    Nael
Xbal Spel
Figure 5. Plasmid pTHRlOlR.
The oligonucleotide (bracketed) was inserted into the Hindin site of pMMB138. The residue 
numbers 102,103 104 etc, refer to those found in the protein EtxB138 expressed from 
pMMB138 [Sandkvist et al., 1987]. The underlined areas represent the sequences recognised 
by the named endonuclease restriction enzymes.
positive stranded oligonucleotide:
5’ AGCTGGGAAAGCCGATCCCAAACCCTTTGCTGGGATTGGACTCCACCTAGA 3' 
negative stranded oligonucleotide:
5’ CTAGTCTAGGTGGAGTCCAATCCCAGCAAAGGGTTTGGGATCGGCnTCC 3'
Figure 6. Sequence of the positive and negative oligonucleotides.
The figure shows the oligonucleotide linkers that were inserted between the 
HindHI and Spel endonuclease restriction sites of plasmid pTRHlOlR.
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resuspended in 200|il of sterile water. The DNA concentration of the oligonucleotides was 
determined by measuring the UV absorbance at 260nm (an absorbance of 1.0 at 260nm is 
taken to be the equivalent to 40pg/ml).
The sequences of the positive and negative oligonucleotides are given Fig. 6. The 
oligonucleotides were annealed by mixing 50jJ,l of the positive stranded olignucleotide with 
50jil of the negative stranded oligonucleotide, boiling for 2 minutes at 100°C, then leaving the 
oligonucleotides to anneal at room temperature for 30 minutes. Once annealed, the 
oligonucleotides were 5-phosphorylated using T4 polynucleotide kinase (New England 
BioLabs) by mixing lOOjil of the annealed oligonucleotides with l lp io f  lOX ligation buffer 
(bacteriophage T4 ligation buffer) and 2jil T4 polynucleotide kinase. The reaction was 
performed at 37°C for 30 minutes. The 5'-phosphorylated double-stranded oligonucleotides 
were then ethanol precipitated and resuspended in 50pl of distilled water.
1,3, Construction o f recombinant plasmid pTRH-Pk,
The basic cloning procedures involved in the construction of plasmid pTRH-Pk are 
modifications of standard protocols from Maniatis et al, 1982.
1,3.1. Preparation of plasmid DNA.
A lOjil sample of E.coli containing plasmid pTRHlOlR was used to inoculate a 10 
ml volume of 2 x TYE broth supplemented with lOOjig/ml ampicillin (TYE/AMP) and the 
culture was incubated for 18 hours at 37°C, on an orbital shaker. 1(X) ml of TYE/AMP was 
inoculated with a 1 ml sample of the overnight culture and following incubation at 37°C for 16 
hours, the bacteria were harvested by centrifugation at 12,000g, at room temperature for 10 
nrtinutes. The desired plasmid was then isolated using a modification of the alkali lysis 
protocol described by Bimboim and Doly [1979]. The bacterial pellets were washed once by 
resuspending the pellets in 10 ml of solution I (25mM Tris-HCl, pH 8.0, 50mM Glucose, 
lOmM EDTA) then centrifugating the suspension at 12,(X)0g for 10 minutes at room 
temperature. The supernatant was discarded and the bacterial pellets resuspended in 4 ml of 
solution I supplemented with lOmg/ml lysozyme and 30pl of DNase-free RNase (Boehringer
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Mannhein), and during a 30 minute incubation at room temperature, the suspension was 
vortexed vigorously every five minutes. To the suspension, 8 ml of freshly prepared solution 
n  [0.2M NaCl, 1% (w/v) SDS] was added, and after a ten minute incubation at room 
temperature, a further 6 ml of solution K (5M potassium acetate, 11.5% (v/v) glacial acetic 
acid, pH 5.5) was added and the suspension incubated fœ a further 5 minutes at room 
temperature. The suspension was centrifuged at 12,000g for 10 minutes at room temperature. 
The resulting supernatant was carefully removed and filtered through two layers of cheese­
cloth into a clean beaker. The plasmid DNA was precipitated by measuring the volume of the 
filtrate then adding 0.6 volumes of isopropanol, vortexing vigorously, followed by 
centrifugation at 4°C for 10 minutes at 12,000g. The supernatant was discarded and the 
pelleted plasmid DNA dried in vacuo. The dried pellet was resuspended in 5 ml of TE buffer 
(lOmM Tris-HCl, ImM EDTA, pH 8.0), following which, lOpl of DNase-free RNase was 
added, and the suspension incubated at 37°C for 30 minutes. The plasmid DNA was then 
purified by phenol/chloroform extraction. The DNA solution was mixed with an equal volume 
of phendi, vortexed vigorously, and centrifuged at 12,000g for 10 minutes at room 
temperature. The aqueous solution, containing plasmid DNA, was gently removed, placed in a 
fresh tube and the volume measured. To this aqueous solution, an equal volume of 1:1 ratio of 
phenolrchloroform was added, the solution vortexed vigorously and centrifuged as before.
The aqueous solution was again retained, measured and the contaminating phenol renxrved by 
adding 1 volume of chloroform, vortexing vigorously, then centrifugating at 12,000g for 10 
minutes at room temperature. After removal of the aqueous layer to a fresh tube, the plasmid 
DNA was ethanol precipitated. The volume of the aqueous layer was measured and 2.5 
volumes of ethanol added, followed by a 1/lOth volume 3M sodium acetate. The plasmid 
DNA was then pelleted by centrifugation at 12,000g for 10 minutes at 4°C. The precipitated 
plasmid DNA was gently washed with 70% ethanol, excess alcohol removed by inverting the 
tube over a tissue, and then dried in vacuo. Once dried, the plasmid DNA was resuspended in 
200)11 of sterile water, a 20pl sample removed to determine the concentration and purity of the 
plasmid DNA preparation (see below), and the remaining volume stored at -20PC until needed.
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1.3.2. Estimation of the concentration and purity of DNA in the plasmid 
preparation.
The concentration of the DNA in the plasmid preparation was determined by 
measuring the absorbance at 260nm of a 20pl sample plasmid DNA (diluted 1:100 in TE 
buffer) using a spectrometer. By using the formula that 1 unit of absorbance is equivalent to 
50pg/ml double stranded DNA, the concentration of the plasmid could be estimated.
Purity of the plasmid DNA preparation was estimated by measuring the absorbance at 
260 nm and 280 nm, and determining the mtio between the two readings. Values of 1.8 
(260nm:280nm) were taken to represent highly purified DNA.
1.3.3. Cleavage of plasmid DNA
Restriction endonucleases Hind III and Spe I (both from New England BioLabs) 
used in the cleavage of the plasmid DNA were supplied with their appropriate lOX buffer. The 
concentrations of enzymes employed in the digestion were chosen following manufacturer's 
recommendations.
A 20jol sample (approximately 2pg) of purified DNA was mixed with lOpl (12 
Units) Spe 1,5p.l (20 Units) Hind IB, 2(^110 X buffer, 2pl acetylated-bovine serum albumin 
(BSA), the volume made up to 200jil with distilled water and the digestion was allowed to 
proceed for 18 hours at 37°C. Following examination of the enzyme digested plasmid by 
horizontal agarose gel electrophoresis (below) to establish that the cleavage had been 
successful, the ends of the cleaved plasmid were dephosphorylated by the addition of 0.5pl 
(12U) of alkaline phosphatase (Boehringer Mannheim) to the DNA solution, followed by a 
one hour incubation at 37°C. The alkaline phosphatase was inactivated by adding EGTA to a 
final concentration of 20mM and incubating the solution at 65°C for 10 minutes.
1.3.4, Horizontal agarose gel electrophoresis.
The digested plasmid DNA was exantined by agarose-gel electrophoresis, in an 
agarose horizontal minigel apparatus (Pharmacia), to determine whether the cleavage had been 
successful. A 2pl sample of digested DNA was separated on a 10 x 10 x 0.5cm agarose gel
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containing 1% agarose (Sigma) reconstituted in TBE buffer (90mM Tris-borate, 2mM EDTA 
pH 8.0). The cleaved plasmid was mixed 1:5 (v/v) with 6X loading buffer [0.25% (w/v) 
bromophenol blue, 30% (v/v) glycerol], added to the gel and horizontally electrophoresed at 
100 volts until the dye front migrated three-quarters of the way through the gel. As a size 
marker, i^age lambda DNA, cleaved with restriction enzyme Hind EH (Boehringer 
Mannheim), was similarly electrophoresed. The gel was then stained with Ipg/ml ethidium 
bromide in TBE buffer and the DNA bands visualized on an ultra violet transilluminator.
1.3.5. Purification of cleaved plasmid by electroelution.
After ascertaining that the plasmid had been successfully cleaved, the cut plasmid 
was electroeluted by the following procedure. Plasmid DNA was cut as before and the DNA 
bands were separated by electrophoresis through a 1% horizontal agarose-gel. Once the dye 
front migrated three-quarters of the way through the gel, the gel was removed from the rig and 
placed on a UV transilluminator to visualize the location of the cut plasmid. A 1mm wide 
trough was carefully excised just in front of the migrating DNA band and the gel returned to 
the rig. TBE buffer was gently poured into the electrode tanks making sure it did not overflow 
the surface of the gel, and using a micropipette, the excised trough was filled with TBE 
buffer. The gel was electrophoresed for 30 seconds at 1(X) volts, after which, the power was 
disconnected. The fluid in the excised trough was extracted with a micropipette and placed in a 
clean eppendorf vial, the trough was then re-filled with fresh TBE buffer. This electroelution 
process was repeated 7-9 times, the progress of which was monitored on the UV illuminator, 
to determine no DNA remained within the gel. The DNA-containing buffer ahquots were 
pooled, the DNA ethanol precipitated and dried, as described above. For vector fragments, the 
DNA was incubated with alkaline phosphatase (Boehringer Mannheim) for 1 hour at 37°C 
prior to phenol/chloroform extraction in cffder to prevent recirculization during subsequent 
ligation reactions. Dried DNA was resuspended in 20|il of water and a 2|xl sample used to 
estimate the level of DNA recovery by 1% horizontal agarose-gel electrophoresis.
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1.3.6. DNA ligation.
Approximately 400ng of vector DNA and 40-400ng of the double stranded 
oligonucleotide insert were combined in a total of 20pl of ligation buffer (50mM Tris-HCl pH 
7.8, lOmM MgCl2, lOmM dithiothreitol, ImM ATP, 25mg/ml BSA) containing 200U T4 
DNA ligase (New England BioLabs) and incubated at 16°C for 1 hour. The ligation mixture 
was used directly for the transformation of competent E.coli.
1.4, Preparation and transformation o f competent bacteria.
E. coli strain JMlOl was made competent using the modified rubidium chloride 
(RbCl) method of Kushner (1978). Briefly, a 60 ml volume of 2 x TYE broth was inoculated 
with E.coli strain JMlOl and the bacteria incubated at 37°C until the OD^oo reached 
approximately 0.5. The bacteria were then cooled by incubating the culture flask on ice for 10 
minutes, and then harvested by centrifugation at 12,000g for 10 minutes at 4°C. The bacterial 
pellet was resuspended in a 20 ml volume of ice-cold MOPS I solution (IM MOPS pH 7.0, 
KXknM rubidium chloride), centrifuged as above, and then resuspended in a 20 ml volume of 
ice-cold MOPS II solution (IM MOPS pH 6.5,700mM CaCl2> lOOmM rubidium chloride). 
After centrifugation at 12,000g for 10 minutes at 4°C, the pelleted bacteria were resuspended 
in a 2 ml volume of MOPS II solution. Competent bacteria were either used directly for DNA 
transformation or stored at 4°C for one week.
Transformation of the bacteria was achieved by combining one-half of the 20pl 
ligation reaction with 100-200|il of competent bacteria and incubating on ice for 30 minutes, 
with occasional end-over-end shaking. The bacteria were then heat-shocked at 42°C for 2.5 
minutes to promote DNA uptake, returned to ice for 5 minutes, and then transferred into a 
1ml volume of 2 x TYE broth. The bacteria were incubated for one hour at 37°C without 
antibiotics, under constant agitation, following which ampicillin-resistant recombinants were 
selected after growth on Luria-agar (L-agar) plates (below) supplemented with 100 fig/ml 
ampicillin, for 24 hours at 37°C.
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1.5. Preparation o f  L-agar plates.
100ml of L-agar (lOg/1 Tryptone, 5g/l yeast extract, lOg/1 NaCl, NaOH, pH 7.5, 2% 
agar) was placed in a water bath at 100°C. When all the agar had melted, the solution was left 
to cool to approximately 50°C and then supplemented with lOOjig/ml ampicillin. The agar 
solution was immediately poured into petri-dishes (Sterilin) and allowed to set. Once set, the 
plates were dried at 42°C and sterilized by ultraviolet radiation. The prepared plates were then 
stored at 4°C in sealed polyethylene bags, until use.
1.6. Screening fo r  pTRH-Pk recombinants.
Single colonies growing on antibiotic supplemented L-agar plates were selected and 
used to inoculate separate 10 ml cultures of Luria-broth containing 100 pg/ml ampicillin. The 
bacteria were then cultured for 18 hours at 37°C on an orbital shaker. A lOOpl sample of the 
overnight culture was used to inoculate a 2 ml volume of antibiotic-supplemented L-broth 
solution and the bacteria grown at 37°C until the ODgoo reached 0.4. At this point, EPTG was 
added to each culture to give a final concentration of 0.5mM and the incubation allowed to 
continue for 4 hours at 37°C. The bacteria were harvested and a 1 ml sample removed, 
centrifuged at high speed in a bench-top microfuge and the bacterial pellets resuspended in a 
1ml volume of ice-cold 0.25M sucrose, O.IM sodium phosphate buffer, pH 7.6, to which 
was added 20|Xg/ml lysozyme and 5mM EDTA. The solution was incubated on ice for 10 
minutes, sonicated at full power for 4 seconds using a Soniprep 150 sonicator, then 
centrifuged at high speed in a bench top centrifuge for 5 minutes at room temperature and the 
supernatant retained.
Bacterial clones producing LTB-Pk were determined by dot-blot assay. A lOpl 
sample from each of the cell lysates was added, in duplicate, to the wells of a terasaki plate 
(Sterilin) and the plates were then electrophoreseed with a 5 cm x 7.5 cm nitrocellulose filter 
(Gelman Sciences). A second terasaki plate was placed on top of the nitrocellulose filter, 
making sure the wells of each plate were aligned, and after clipping the plates tightly together, 
the plates were inverted to bring the lysates into close contact with the nitrocellulose filter. The 
plates were incubated at room temperature for one hour, following which the nitrocellulose
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filter was removed, and rinsed three times in phosphate buffered saline (PBS) containing 1% 
semi-skimmed milk. The nitrocellulose was then incubated for one hour in 20 ml of PBS 
supplemented with 20% semi-skimmed mdk, following which the nitrocellulose filter was 
rinsed three times in successive 20 ml volumes of PBS containing 1% semi-skimmed milk. 
The blots were probed for the presence of the Pk determinant by incubating the nitrocellulose 
filters with a 20 ml volume of PBS supplemented with 1% semi-skimmed milk and 1: 20 
dilution of anti-Pk MAb SV5-P-k (see below). After a one hour incubation at room 
temperature, the nitrocellulose filter was rinsed as before, then incubated with a 20 ml volume 
of PBS containing 1% semi-skimmed milk and a 1: 1000 dilution of ^ ^Iodine-labelled Protein 
A (Amersham), for a further hour at room temperature. Excess radio-label was discarded and 
the nitrocellulose filter washed extensively in PBS, blotted dry and then exposed to Fuji X-ray 
film for 18 hours at -20°C. Positive-LTB-Pk expressing clones were visualized following 
development of the film in a Kodak developer.
Alternatively, colonies expressing LTB-Pk following EPTG induction were screened 
by analysing the cellular lysates for LTB-Pk by Western blot assay.
i.7 . Storage o f  colonies.
Bacterial colonies that were shown to express LTB-Pk were used to inoculate 
separate 10ml cultures of ampicillin-supplemented L-broth. The bacteria were cultured 
overnight at 37°C on an orbital shaker, and the following day, 0.85ml of bacterial culture was 
transferred to a sterile vial containing 0.15ml of sterile glycerol. The bacteria were then stored 
at -70°C.
2. ANTIBODIES.
Monoclonal antibody SV5-P-k (MAb SV5-P-k) recognizes an epitope on the simian 
virus 5 (SV5) phospho (P) and V proteins [Randall et al., 1987] and it's specificity was 
determined in our laboratory [Southern et al., 1991]. MAb SV5-P-k was purified either from 
tissue culture medium, or ascitic fluid stocks by affinity chromatography techniques (see 
below). Horseradish peroxidase (HRP)-conjugated anti-mouse immunoglobulin (Ig) was
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obtained from the Scottish Antibody Production Unit (SABU). HRP-conjugated Protein A 
which specifically interacts with the Fc region of murine IgG2a, IgG2y, and IgGg but not IgGj 
antibodies, was obtained from Amersham International. Goat anti-mouse IgG, IgM and IgA 
antibodies and alkaline-phophatase-conjugated anti-goat antibody were obtained from Sigma. 
FluOTescein isothiocyanate (FITC)-labelled anti-murine CD4, CD8 and Ig antibodies were 
supplied by Sera-Lab.
2.1, Purification o f MAb SV5-P-k by affinity chromatography techniques.
MAb SV5-P-k was purified from ascitic fluid or tissue culture medium by affinity 
chromatography techniques using a Protein A (Pr.A)-sepharose support (Sigma). A 1ml 
sample of Pr.A-sepharose beads were loaded into a column and washed with 20ml of 
phosphate buffered saline (PBS). The resin was incubated with MAb SV5-P-k-containing 
fluid for one hour at room temperature, then material that failed to bind to the column was 
removed by washing the column in 100 column volumes of PBS. Bound MAb SV5-P-k was 
eluted by the addition of a buffer composed of 0.2M glycine, O.IM NaCl, pH 2.8. 1ml 
fractions were collected throughout the elution process, and fractions contained purified MAb 
SV5-P-k were pooled and dialysed against 4 litres of PBS for 18 hours, changing the buffer 
once. The purified antibody was filter sterilized through a 0.22pm nylon filter (Gelman 
Sciences) and stored in 1 ml aliquots at 4°C until use.
3. SDS-PAGE and Western blotting.
3.1, Preparation o f polyacrylamide gels.
All the polyacrylamide gels employed in this project, contained 15% acrylamide. A 
15% SDS-polyacrylamide separation gel was constructed by mixing together 2.675 ml of 
solution A (28% Acrylamide/ 0.735% DATD), 0.625 ml of solution B (3M Tris-HCl, pH
8.5), 1.25 ml of freshly prepared solution C (0.14% ammonium persulphate), 0.425 ml 
distilled H2O, 25pl 20% SDS and 2.5pl N,N,N’,N’-tetra-methylethylenediamine (TEMED; 
Bio-Rad). Immediately after the addition of the TEMED, the gel solution was poured between 
the glass gel cassettes of a Bio-rad Mini Protein System gel rig, leaving a 2 cm gap at the top
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of the cassette. The separation gel was carefully overlaid with 200pl of distilled water, to 
create an even interface, and the gel was left to polymerise at room temperature for 30 
minutes. A stacking gel was prepared by mixing together 1.6 ml of solution C, 400pl of 
solution A, 300pl of solution D (IM Tris-HCl, pH 7.0, SDS) and Ipl TEMED. The H2O was 
gently removed by inverting the gel cassette over a paper tissue, the stacking gel poured on top 
of the separation gel and a comb inserted to create wells. The gel was then left to polymerise at 
room temperature for one-two hours.
3.2 Preparation o f samples for SDS-PAGE and electrophoresis.
15pl samples of protein (unless otherwise stated in the Results) were mixed with 5pl 
of 4x disruption buffer (25% P-mercaptoethanol, 10% SDS, 25% solution B, 12.5% 
glycerol) and boiled for 5 minutes at 100°C (unless otherwise stated). The disrupted protein 
samples were then loaded into the wells of the prepared SDS-polyacrylamide gel using a 
micropipette and electrophoresed in electrode buffer (0.19M Glycine, 0.025M Tris-HCl,
0.1% SDS, pH 8.0) at a constant voltage of 150 volts. When the dye front migrated to a 
position 0.5cm from the bottom of the gel, the current was disconnected and the gel removed 
from the gel rig. Thereafter, the denatured polypeptide chains were either stained with 
Coomassie blue stain or electroblotted onto nitrocellulose filters and analysed by Western 
blotting.
3.3. Coomassie blue staining.
Individual polypeptide chains were visualized by incubating the SDS-polyacrylamide 
gel for 20 minutes in approximately 30 ml of Coomassie blue stain solution (0.2% Coomassie 
brilliant blue R250 (BDH), 20% methanol and 10% acetic acid). On completion of the 
incubation period, the excess stain was poured off and the gel destained with repeated 
washing in destaining solution (10% acetic acid, 10% methanol). During both the staining and 
destaining steps, the gel was gently agitated on a rotatest shaker, to permit uniform 
staining/destaining. The gel was then either dried onto 3MM Whatman filter paper using a 
Bio-rad 583 vacuum gel drier for 2 hours at 80°C, or stored in sealed plastic bags.
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3.4. Western blotting and autoradiography.
Polypqjtide chains separated on 15% polyacrylamide gels were electroblotted onto 
nitrocellulose using a LKB semi dry electroblotter. Both the bottom (anode) and top (cathode) 
graphite plates were washed in distilled H2O prior to electroblotting.
Four sheets of 3MM Whatman filter paper, cut to the same size as the gel, were soaked in 
Western Blotting (WB) buffer (20% methanol, 20mM Tris) and placed on the bottom graphite 
plate. A sheet of nitrocellulose, similar in size to the gel, that had been moistened in WB 
buffer, was placed on top of the filter papers and electrophoreseed with the polyacrylamide 
gel. Four mœe sheets of filter paper were soaked in WB buffer and layered over the gel to 
corr^lete the sandwich. The top graphite plate was put in place and the electrodes attached. 
The gel was blotted for one hour using a current of 1mA per cm^ of the sandwich, after 
which, the current was switched off and the nitrocellulose sheet removed. The nitrocellulose 
sheet was placed in a petri-dish (Sterilin) containing 20 ml of blocking buffer (5% semi­
skimmed milk, 20mM Tris-HCl, pH 7.6, 140mM NaCl, 0.1% Tween 20) and blocked for 15 
minutes at room temperature on a rotatest shaker. The nitrocellulose sheet was then rinsed 
three times in successive 30ml volumes of PBS, followed by a further 10 minute incubation in 
blocking buffer at room temperature. After rinsing in PBS as before, the nitrocellulose sheet 
was incubated in 20ml of blocking buffer containing a 1:1000 dilution of MAb SV5-P-k, for 
30 minutes at room temperature. The nitrocellulose sheet was then rinsed in PBS and after 
washing twice with blocking buffer, incubated for 30 minutes in 20ml of blocking buffer 
containing a 1:2000 dilution of horseradish peroxidase (HRP)-conjugated Protein A 
(Amersham), at room temperature. On completion of the incubation period, the nitrocellulose 
sheet was rinsed in PBS, then twice in the blocking buffer. After a final rinse in PBS to 
remove excess blocking solution, the nitrocellulose sheet was dried briefly between two 3MM 
Whatman filters, and transferred into a fresh petri dish containing 5 ml of enhanced 
chemhuminescence (ECL) Western blotting reagents (Amersham) that had been mixed 
according to the manufacturers recommendations. The nitrocellulose sheet was incubated in 
ECL reagents for 1-2 minutes, placed inside a plastic bag, then exposed to Fuji X-ray film
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adjacent to an intensifying screen fœ 0.5-3 minutes. The film was then developed using an 
automatic developer (Kodak).
4. GMl-enzyme-linked immunoasorbent (GMl-ELISA) assay.
The assay out lined below is an adaption of the procedure described by Svennerholm 
and Holmgren [1978]. Flat bottomed, 96-well microtitre plates (Coming) were coated with 
lOOpl per well of 1.5pg/ml monosialioganglioside-GMl (GMl; Sigma) dissolved in PBS, 
fcr 18 hours at 4°C. The plates were washed twice in PBS and the remaining protein-binding 
sites blocked in 200pl of PBS containing 1% (wA') BSA (Sigma) at 37°C for one hour. After 
blocking, the plates were washed three times in PBS. Test samples were serially diluted in 
PBS supplemented with 0.1% (w/v) BSA (PBS/BSA) and added to the wells in a volume of 
lOOjil and the plates were incubated at rocxn temperature for one hour. The plates were then 
washed three times in PBS, and a lOOpl sample of anti-Pk MAb SV5-P-k (tissue culture fluid) 
diluted 1:20 in PBS/BSA, was added to each well. After incubation for one hour at room 
temperature, the plates were washed three times in PBS containing 0.05% Tween 20 
(PBS/Tween), and then lOOp.1 of horse-radish peroxidase (HRP)-conjugated Protein A, 
diluted 1:1000 in PBS/BSA, was added to each well for one hour at room temperature. The 
plates were washed three times in PBS/Fween. A lOOpl volume of a-phenylene-di-amine 
(1 mg/ml) (Sigma) in 0. IM citrate buffer pH 4.5 (2. Ig citric acid, 2.84g Na2HP04  made up to 
400ml with distilled water), (activated by the addition of 0.4pJ/ml 30% (v/v) hydrogen 
peroxide) was added to each well to detect bound conjugated antibody . The plates were then 
incubated at room temperature for 15-30 minutes following which the adsorbance at 450nm 
was measured using a Dynatech MR5000 microtitre plate reader.
5. Immune-precipitation assays.
A 30pl sample of a heat-killed suspension of Staphylococcus aureus (St. aureus) 
Cowan A strain (10% w/v) was placed in a 500)11 eppendtxf and centrifuged at high speed in a 
microfuge for 5 minutes at room temperature. The supernatant was gently aspirated using a 
pipette tip attached to a vacuum, and the pellet resuspended in 30jil of ice-cold immune
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precipitation buffer (0.65M NaCl, 20mM Tris-HCl pH 7.8, ImM EDTA, 0.5% (v/v) NP-40, 
and 0.1% (w/v) azide). After centrifugation as before, the supernatant was again removed by 
aspiration and the St. aureus pellet resuspended in 30|il of PBS containing approximately 
2mg/ml purified anti-Pk MAb SV5-P-k. The suspension was incubated on ice for 30 minutes 
to allow maximum adsorption of the MAb to the bacterium, then centrifuged at low speed in a 
microfuge, for 3 minutes at room temperature. The supernatant containing unbound antibody 
was gently removed by aspiration, taking care not to disturb the St. aureus-MAb pellet To be 
sure no firee MAb remained, the pellet was resuspended in 30iU of ice-cold immune- 
precipitation buffer, centrifuged as before and the supernatant gently removed. This washing 
step was repeated three times. The pellet was resuspended in a 15|il volume (unless otherwise 
stated in the Results) of the test solution and the suspension incubated on ice for one hour. 
After low speed centrifugation in a microfuge, the supernatant containing unprecipitated 
proteins was gently transferred to a fresh eppendorf vial using a micropipette, a 5|il volume of 
4X disruption buffer added and the sample stored at -20°C until analysed. The precipitate was 
then resuspended in 30|xl of ice-cold immune-precipitation buffer, centrifuged as before, and 
the supernatant discarded. This washing step was repeated four times to ascertain no 
unprecipitated proteins remained. Finally, the pellet was resuspended in 30|il of IX disruption 
buffer and stored at -20°C until analysed.
6. Concentration of LTB-Pk
6.1. Concentration of LTB-Pk by ammonium sulphate precipitation.
Small scale ammonium sulphate precipitations were performed at room temperature. 
A one litre culture of Vibrio sp.60 harbouring the plasmid pTRH-Pk was maximally induced 
with 0.05mM IPTG for 6 hours at 30°C, and the culture supernatant separated from the 
bacteria by centrifugation at 12,000g for 20 minutes at 20°C. To a 200ml volume of the 
supernatant (containing approximately 6mg/l of crude LTB-Pk), 62.6g of solid ammonium 
sulphate was added very slowly with constant stirring, to give a final salt saturation level of 
50%. Protein precipitation was allowed to continue for one hour, after which the solution was 
centrifuged at 2,500g at 4°C. The supernatant was discarded and the pellet containing
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precipitated protein, was resuspended in 20ml of sterile PBS. The suspension was centrifuged 
at 2,500g for 20 minutes at 4°C, to pellet insoluble material. The supernatant was gently 
removed using a pasteur pipette and transferred to a dialysis membrane. Excess salt was 
removed by extensively dialysing the solution over a four day period, against 4 litres of PBS, 
changing the buffer twice daily. On completion of the dialysis period, the protein solution was 
centrifuged at 2,500g for 20 minutes at 4®C to pellet any insoluble material. The supernatant 
was recovered, sterilized by filtration through a 0.22pm sterile filter and stored at 4°C in 1ml 
aliquots until use.
6.2. Concentration o f LTB-Pk by uUrafiUration and in situ dialysis.
Large volumes of culture medium 4 litres) containing crude LTB-Pk were
concentrated by ultrafiltration using a GF 15 kidney dialysis membrane (Gambro®) with a 
porosity of lOK. Prior to use, the membrane was washed extensively in 1 litre of distilled 
water to remove the ethanol preservative. A 4 litre volume of culture medium containing 
approximately 6mg/l of LTB-Pk, was passed through two 3MM Whatman filters, and then 
applied to the membrane. The solution was constantly recycled through the membrane and 
concentrated by applying a pressure of 5-10 lbs/in^ [see Fig. 7(a)]. This strategy helped to 
remove small molecules and water from the recirculating material. The solution was 
concentrated to 150-200ml, then dialysed in situ against either 20mM Tris-HCl, lOmM 
EDTA, pH 7.5 or 25mM Na^PO^, lOmM EDTA, pH 7.0 (depending on whether LTB-Pk 
was to be purified by hydrophobic or ion-exchange chromatography techniques, respectively), 
by recirculating the dialysis buffer counter-cunent to LTB-Pk containing solution [see Fig. 
7(b)]. On completion of the dialysis period, the LTB-Pk-containing solution was recovered 
from the membrane and either applied directly to the appropriate chromatography column or 
stored at 4°C, in the presence of 0.01% sodium azide, until use.
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Figure 7. Concentration of LTB-Pk from Vibrio sp. 60 cultures by ultrafiltration.The figure shows the GF15 kidney dialysis membrane used for the concentration and in situ dialysis of LTB-Pk.
Panel (a): the Vibrio sp.60 culture supernatant containing LTB-Pk is 
pumped through the dailysis unit under a pressure of 5-lOlbs/in^.The arrows indicate the direction of the flow of the medium through the membrane. This stage helped concentrate the culture medium.
Panel (b): the concentrated material was then passed through the membrane system counter-current to the appropriate dialysis buffer (see arrows for the movement of the culture medium versus the dialysis buffer). This latter step, resulted in in situ dialysis of the culture medium.
(pictures courtesy of Dr. C. Botting)
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7. Purification of LTB-Pk
7 J , Purification o f LTB-Pk by Hydrophobic interaction chromatography 
using a phenyl superose matrix on an Fast Protein Liquid Chromatography 
(FPLC) System,
The procedure outlined below is a modification of the procedure described by Amin 
and Hirst [1994]. A 20 ml volume of culture medium containing LTB-Pk that had been 
concentrated by ultrafiltration and dialysed against 20mM Tris-HCl, lOmM EDTA, pH 7.5 
(Section 7.2) was mixed with ammonium sulphate to a final salt saturation of 30%. The 
solution was slowly stirred for 1 hour at room temperature, then clarified by centrifugation at 
17,400g for 20 minutes at room temperature. The resulting supernatant was retained, 5ml of 
winch was filtered through a 0.22pm nylon filter (Gelman Sciences) and the filtrate was 
loaded directly onto a 1 ml FPLC Phenyl superose HR5/5 column (Pharmacia), that had been 
equilibrated with 20mM Tris-HCl, lOmM EDTA containing IM (NH4)2S04 , pH 7.5. Once 
the sample was loaded onto the column, a decreasing salt gradient of IM ammonium sulphate 
in 20mM Tris-HCl, lOmM EDTA, pH 7.5 was applied. 1ml fractions were collected 
throughout the purification, and the adsorbance measured at 280nm. The fractions 
representing the column void were pooled and dialysed overnight against 4 litres of PBS 
containing lOmM EDTA at 4®C. Similarly, the fractions representative of eluted protein, were 
pooled and dialysed. Both samples were filter sterilized by passage through a 0.22pm sterile 
nylon filter and stored at 4°C until use.
7.2. Purification o f LTB-Pk by hydrophobic chromatography using a Bio-rex 
Macroprep® t-butyl support.
The protocol for the purification of proteins by the Macroprep.® t-butyl column 
(Bio-rad) was based on the manufacturer's recommendations. A 5ml hydrophobic t-butyl 
matrix was placed in a 10ml disposable column and washed in 500ml of 20mM Tris-HCl, pH
7.5, lOmM EDTA, IM (NH4)2S04. A 40ml sample of LTB-Pk prepared as described in 
Section 7.1, by mixing the sample with ammonium sulphate to a saturation level of 30%, then 
clarifying the solution by centrifugation. The prepared sample was then filtered as above and
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applied directly to the equilibrated column. When all the sample had been applied, the column 
was washed in 20 column volumes of 20mM Tris-HCl, pH 7.5, lOmM EDTA, IM 
ammonium sulphate to remove material that failed to bind to the hydrophobic matrix. Once the 
column had been washed the following decreasing salt solutions were applied to the column: 
Volume (ml) Salt Molaritv.
200 0.75M ammonium sulphate
200 0.50M ammonium sulphate
200 0.25M ammonium sulphate
5ml fractions were collected throughout tlie purification, and Ipl of each fraction 
spotted onto nitrocellulose paper. Proteinaceous material was then detected by incubating the 
nitrocellulose in approximately 10ml of Naphthlene black stain (0.2% Naphthlene black, 20% 
methanol, 10% acetic acid) for 15 seconds, followed by destaining in a buffer composed of 
10% acetic acid, 10% methanol until the background was sufficiently destained. Fractions 
containing maximal levels of protein (as deteraiined by the amount of stain adsorbed by the 
protein spots) from the column void, were pooled and dialysed against PBS, lOmM EDTA for 
18 hours at 4°C. The fractions containing eluted protein wei^ similarly treated. After dialysis, 
the solutions were filter sterilzed and stored at 4°C until use.
7.3. Purification o f LTB-Pk by ion-exchange chromatography using a Bio-rad 
70 support.
A 25ml Bio-rex® 70 cation-exchange column was prepared by equilibrating the 
column with 25mM Na2P04 , lOmM EDTA, pH 7.0, at room temperature. A 150 ml sample 
of LTB-Pk (at a concentration of approximately 6mg/l) that had been concentrated by 
ultrafiltration and dialysed against 25mM Na2P04 , lOmM EDTA, pH 7.0, was applied to the 
prepai*ed column, and when all the sample had been loaded, the column was washed in 10 
column volumes of 25mM Na2P04 , lOmM EDTA, pH 7.0, to remove any unbound material. 
Bound protein was eluted by applying a buffer composed of 25mM Na2P04 , lOmM EDTA, 
0.5M NaCl, pH 7.5. Throughout the purification 5ml fractions were collected, l|il samples of 
each fraction spotted onto nitrocellulose and proteinaceous material vizualized as described in
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Section 7.2. The fractions containing the highest levels of protein in the column void, were 
pooled and dialysed against PBS, lOmM EDTA. Likewise, the fractions containing eluted 
protein were pooled and dialysed. Both samples were filter sterilized and stored at 4°C until 
use.
So Expression And Purification Of Recombinant SIV Proteins.
SA. Plasmids.
The properties of the plasmids pQE917Pk and pQ927Pk are described in detail 
elsewhere [Hanke et al., 1994]. The recombinant SIV pl7 and p27 proteins encoded by these 
plasmids, respectively, have a short histidine tag at the N-termini and the Pk tag at the C- 
termini. The expression of the recombinant proteins is under control of the lac promotor.
8.2. Expression o f  His-SIV-Pk proteins in E.coli.
Antibiotic supplemented L-agar plates were prepared as described in Section 1.5. 
E.coli transfected with either plasmid pQE917Pk or pQ927Pk were plated out onto the L-agar 
plates and incubated at 37®C for 24 hours. Single colonies were selected and used to inoculate 
a 10 ml volume of supplemented L-broth. The cultures were incubated at 37°C for 18 hours on 
a rotary shaker, following which, a 1ml sample of the overnight culture was used to inœulate 
a 1 litre volume of supplemented L-broth. The bacterial cultures were incubated as before until 
the O.D.600 reached 0.4-0.6, synthesis of the recombinant SIV proteins were induced by the 
addition of 0.05mM IPTG (final concentration) to the bacterial cultures and the induction 
allowed to proceed at 26°C for 2-3 hours (in the case of His-pl7-Pk) or 3 hours (in the case of 
His-p27-Pk). On completion of the induction period, the bacteria were harvested by 
centrifugation at 12,000g for 25 minutes at 4°C. The resulting supernatant was discarded and 
the bacterial pellets resuspended in 30ml of ice-cold TN buffer (20mM Tris-HCl pH 8.0,
0.3M NaCl). lOmg/ml of fresh lysozyme was added to the suspension, and following 
vigorous vortexing, the mixture was incubated on ice for 10 minutes. A 300jiil volume of 
Triton X-100 was added to the lysozyme solution, and the mixture sonicated for two 15 
second bursts using a Branson Sonifer B-12 at full power. The bacterial lysates were
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centrifuged at 3000g for 15 minutes at 4®C, the supernatant retained and either applied directly 
to a Nickel 2+ -nitrilotriacetic acid (Ni2+-NTA) resin or stored at -20®C.
8 J . Purification o f recombinant SIV  proteins by Np-^-NTA affinity  
chromatography.
The protocol for the purification of His-STV-Pk proteins is an adaptation of the 
protocol of Smith et al., 1988. A 1 ml sample of N12+-NTA resin was ti'ansferred into a 50ml 
universal tube and 30ml of 20mM Tris-HCl, pH 8.5,0.3M NaCl added. The mixture was 
centrifuged at 460g for 10 minutes at 4°C in a centrifuge and the supernatant removed. The 
pelleted resin was resuspended in 30ml of 20mM Tris-HCl, pH 8.5,0.3M NaCl and the 
washing step repeated. After the removal of the supernatant, the resin was resuspended in a 
30ml volume of the prepared bacterial lysate (Section 8.2) and incubated at 4°C for one hour 
on an orbital shaker. The mixture was transferred into a 5ml column and the flow through 
collected. Proteins that failed to bind the nickel resin were then removed by washing the resin 
in 50 column volumes of 20mM Tris-HCl, pH 8.5,0.3M NaCl. Purified His-SIV-Pk 
proteins were eluted by the addition of a 30ml volume of 250mM imidazole, 20mM Tris-HCl, 
0.3M NaCl, pH 7.4 to the column. 1 ml fractions were collected throughout the elution step, 
and the fractions containing the highest level of protein [determined by Naphthlene black 
staining (Section 7.2)] were pooled and then dialysed overnight against 4 litres of PBS, 
changing the buffer once. The dialysed proteins were sterilized by filtration through a 0.22pm 
nylon filter, and stored at 4°C until use.
8.4. Expression o f GST-Pk.
Plasmid pGEXcPk codes for the Pk tag attached to the C-temiinus of glutathione S- 
transferase (GST-Pk) [Hanke et al., 1992]. Expression of GST-Pk was achieved using the 
criteria described for the expression of the SIV recombinant proteins. GST-Pk was harvested 
fiom the bacterial lysates of lysozyme treated cells (see above) and stored at -70°C until use.
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9« Immunogeiîtcity studies.
9.1, Mice and immunizations.
Balb/c (H-2K‘^ ) mice, were used for all immunogenicity studies.
For parental immunization, mice were aged 6-8 weeks and were injected intraperitoneally with 
the vaccine formulations in a final volume of 200pl PBS,
For vaccines that were administered in association with alum, the alum precipitate 
was formed and the antigens allowed to absorb. Typically, 900pl of PBS was mixed with 
30pl of IM NaHCOs and 60pl of 10% (w/v) Al2(S04 ).K2S04 .2H20  added to the solution 
dropwise, gently agitating the mixture during the application of the Al2(S0 4 >.K2S04.2H2 0 . 
The precipitate was then centrifuged at 2,500g for 5 minutes, and then resuspended in 900pl 
of PBS containing the appropriate concentration of antigen. The antigen was allowed to 
adsorb to the alum for one hour at 4°C, then the solution was used directly for immunisation, 
using 200pl per mouse.
Balb/c mice aged 10-12 weeks were used for intranasal vaccination. All vaccine 
formulations were prepared in a final volume of 50pl PBS (unless otherwise stated). The mice 
were gently anaesthetised by exposure to diethyl ether, and the vaccines slowly administered, 
dropwise, using a micropipette, to the outer mandrils of the nasal cavity.
9.2. Measurement o f immune sera by the enhanced chemilumescence (ECL)- 
based immune assay.
This assay is an adaptation of the protocol originally described by Randall and 
colleagues [1994]. 7 x 5  cm^ sheets of nitrocellulose (Gelman Sciences) were placed in petri 
dishes and a 10 ml solution of carbonate buffer pH 9.6 (1.59g/l Na2C03 ,2.93g/l NaHCOg) 
containing the purified target antigens at the concentrations shown below. Following a two 
hour incubation at 37®C, on a orbital shaker, the carbonate buffer was removed and the filters 
washed extensively in PBS. The remaining protein binding sites on the nitrocellulose sheets 
were blocked by incubating the sheets in a 20 ml volume of blocking solution (5% semi­
skimmed milk, 20mM Tris-HCl, pH 7.6 ,140mM NaCl, 0.1% Tween-20) for 15 minutes at 
room temperature on an orbital shalcer. The filters were washed in PBS, then blocked for a
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further 10 minutes at room temperature in blocking buffer. The excess blocking solution was 
removed and the filters washed in PBS, as before. The test sera was serially diluted in 
blocking buffer (see Results for dilutions) and added to the wells of terasaki plates (Sterilin) in 
12jil volumes. The terasaki plates were overlaid with the antigen-coated sheets and a 3MM 
Whatman filter, cut to the same size as the nitrocellulose sheets, was moistened in PBS and 
then placed on top of the nitrocellulose. A second terasaki plate was carefully placed over the 
sandwich, making sure the wells of both plates were in alignment The plates were tightly 
clipped together and then inverted to bring the sesa into contact with the antigen-coated 
nitrocellulose sheets. Following one hour incubations at room temperature on an orbital 
shaker, the nitrocellulose sheets were removed fiom the plates and placed in a petri dish 
containing 20ml of blocking buffer. The sheets were then washed twice in blocking buffer for 
15 and 10 minute intervals, followed by a single wash in PBS, before being incubated with a 
10 ml volume of blocking buffer containing a 1:2000 dilution of an horseradish peroxidase 
(HRP)-conjugate (either anti-mouse Ig or Protein A), for 30 minutes at room temperature on 
an orbital shaker. On completion of the incubation, the nitrocellulose sheets were washed in 
blocking buffer and PBS as befbiie. The nitrocellulose sheets were transferred into a fresh 
petri dish and incubated for two minutes at room temperture in a 5 ml volume of enhanced 
chemiluminscence (EC!L) reagents (Amersham) that had been mixed according to the 
manufacturer's recommendations. The nitrocellulose sheets were briefly dried, placed in a 
plastic bag and then exposed to X-ray film (Fuji) adjacent to an intensifying screen. After 
various incubation times, the X-ray film was developed in an automatic developer (Kodak).
Target Antigen Concentration
His-p27-Pk 4pg/ml
His-pl7-Pk 4jig/ml
GST-Pk 20jil of cell lysate
ovalbumin Img/ml
'^LTB-Pk 5pg/ml
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* For sheets coated with LTB-Pk, all nitrocellulose filters were first of all incubated in 10ml of 
carbonate buffer containing L5p.g/ml GMl-monosialoganglioside for one hour at 37°C, prior 
to the addition of LTB-Pk. This helped to potentiate the binding of LTB-Pk to the 
nitrocellulose.
9.3. M msurement o f the secretory immune response by ECL4mmune assays.
Mice were injected intraperitoneally with 2% (v/v) pilocarpine, diluted 1:3 in PBS, in 
a final volume of 2(K)pl PBS, to stimulate salivai flow. Approximately lOOpl of saliva was 
collected in a 1.5ml vial, and following high-speed centrifugation in a bench-top centrifuge, 
stCHed at -20°C until required.
Assessment of antigen-specific secretory antibody was performed using an adaption of the 
ECL-based immune assay above. Briefly, the saliva was serially diluted in blocking buffer 
and incubated with antigen-coated nitrocellulose sheets. Antigen-specific secretory antibodies 
were detœted by incubating the nitrocellulose sheets with goat anti-mouse IgA, followed by 
an HRP-conjugated donkey anti-goat antibody and autoradiography.
9.4. Lymphocyte proliferation assays.
9.4.1. Preparation of splenocytes.
The spleens were placed on a sterile nylon mesh in a petri dish (Steiilin) 
containing 10ml of PBS. The splenocytes were liberated by mashing the tissue through the 
nylon mesh using a flat-bottomed plunger from a 10ml sterile syringe (Sterilin) and the cells 
placed in 30ml universal tubes. The universal tubes were allowed to stand for 3 minutes to 
allow cell debris and fatty tissue to pellet, then the supernatant was gently transfeired to fresh 
30ml universal tubes using a pasture pipette. The cells were centrifuged at 4(X)g for 10 mins at 
20°C, and then resuspended in 10ml of 0.85% ammonium chloride solution to lyse the red 
blood cells. AftŒ a 5 minute incubation at room temperature, the ammonium chloride/cell 
suspension was under-layed with 10ml of foetal calf serum (FCS) and centrifuged at 400g, 
20°C for 10 minutes. The supernatant was discarded and the cells were resuspended in 20ml 
of PBS and centrifuged as before. This last step was repeated four times. The splenocytes
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were then resuspended in 10ml of PBS and the suspension vigorously pipetted, to break up 
any clumps of cells. A 20pl sample of the cell suspension was mixed with 20pl of Trypan 
blue (0.2% Trypan blue: 4.25% NaCl, 4:1), the mixture placed on a haemocytometer and live 
cells (cells that did not stain blue) enumerated. The cells were diluted in T cell medium to a 
final concentration W  cell/ml and used directly in stimulatory assays.
9.4,2. Lymphocyte stimulation and measurement of DNA synthesis.
Purified His-pl7-Pk or His-p27-Pk were diluted to a concentration of 4jjig/ml in T- 
cell medium [RPMI-1640 (Gibco) supplemented with 2mM L-glutamine, 100 U penicillin, 
lOOjXg streptomycin, 5 x lO-^M P-mercpatoethanol] and 2(X)pl added to the top row of an 
appropriately labelled round-bottomed, 96-well microtitre plate, then serial diluted 1:2 in Tcell 
medium to give a final volume of lOOpl in each well. Purified LTB-Pk was diluted in T cell 
medium to a concentration of Ipg/ml, then diluted in the wells of a round bottomed 96-well 
microtitre plate as described for the His-SIV-Pk antigens.
lOOpl of the cell suspension prepared in Section 9.4.1, was added, in triplicate, to 
each well of the antigen containing microtitre plates. The plates were incubated for 5 days in a 
humidified incubator at 37°C, 5% CO2 and during the last 18 hours of the stimulation, 0.5pCi 
[3H]-thymidine was added to each well. The cells were harvested onto glass microfibre filters 
using an Bacon cell harvester and the amount of pH]-thymidine incorporated into the DNA of 
the proliferating cells was determined by scintillation counting.
9.5. Cytokine-ELISA Assays,
9.5.1. Preparation of culture supernatants.
1Q2 cells, prepared from murine spleens were resuspended in 500pl of T cell medium 
(Section 9.4.1) and added to the wells of 24-well microtitre plates (Sterilin). The cells were 
stimulated with the antigens (see Results) for 5 days at 37°C/5%C02 in a humidified 
incubator. l(X)|Lil samples of the culture supernatant were removed on day five of the 
stimulation and stored at -20°C until assayed for cytokines.
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9.5.2. Detection of ÏL-2, IL-5 and IFN-y.
Cytokine production was quantified using sandwich ELISA techniques. Enhanced 
protein binding 96-well ELISA plates (Dynalab Immulon 4) were coated overnight at 4°C with 
50pl of monoclonal anti-cytokine antibody (Pharmingen) at pre determined optimal 
concentrations (see below) in O.IM carbonate buffer, pH 9.6. The plates were then washed 
twice with PBS containing 0.05% Tween 20 (PBS/Tween), after which non-specific protein 
binding sites were blocked by incubation with 2(X)pl of PBS containing 10% FCS for 1 hour 
at 3TC, Following blocking, the plates were washed thiee times in PBS/Tween and samples 
and standards (recombinant murine cytokines), diluted in T-cell medium, were added to 
individual wells in a volume of 50pl and incubated at 37°C for 3 hours. The plates were 
washed 4 times in PBS/Tween and 50pl/well of biotinylated anti-murine cytokine antibody, 
diluted in PBS/10% FCS was added at the concentrations shown in Table. After incubation at 
room temperature for one hour, the plates were washed four times in PBS/Tween and 
lOOpl/well exiravidin-peroxidase in PBS/10% FCS was added to each well at 2jig/ml. 
Following a final incubation for one hour at room temperature, the plates were washed six 
times in PBS/Tween, before lOOji.1 of TMB peroxidase substrate was added to each well. The 
adsorbance was measured at 630nm using an Dynatech MR5(XX) automatic microplate reader 
and cytokine concentrations in test supernatants were determined with reference to a standard 
curve constructed using serial dilutions of the standard cytokines.
Cytokine specific antibody Capture concentration Detection concentration
anti-IL-2 2pg/ml l(Xg/ml
anti-IL-5 4|ig/ml 4jiig/ml
anti-IFN-y 2pg/ml lp.g/ml
9,6. FAC scan analysis.
Mixed lymphocyte populations, prior to, or after a five day stimulation with the 
appropriate antigen (see Results) were placed in 30ml universal tubes and centrifuged at 400g 
for 10 minutes at 20°C. The pelleted cells were resuspended in 10ml of PBS and the number
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of cells present enumerated as described in Section 9,4.1. Aliquots of 10  ^cells were removed 
and placed in 1.5ml eppendorf vials, centrifuged at high speed in a microfuge and then 
resuspended in lOOpl of PBS containing a 1:100 dilution of the appropriate FTTC-labelled 
antibody (anti-mouse CD4, anti-mouse CD8 or anti-mouse Ig; see Results). The suspensions 
were incubated on ice for one hour, then centrifuged at 400g for 5 minutes in a microfuge. 
The pelleted cells were resuspended in 500pJ of PBS and centrifuged as before. This washing 
step was repeated three times to ensure no uncomplexed FTTC-labelled antibody remained. 
After the final wash, the cells were resuspended in 500pl of PBS and transfered into Becton 
Dickson FACSscan tubes (Falcon 2500). 10,(X)0 events were collected using the Becton 
Dickson Consort 30 program and the percentage of fluorescent cells in 10,000 events 
(collected using the Consort 30 program) was measured using the LYSYS program.
9.7. Enzyme-linked Immunospot (ELISPOT) assay fo r  the detection o f  
antibody secreting cells.
The ELISPOT assay was developed for the detection of antibody secreting cells is an 
adaptation of the protocol described by Czerkinsky et al., 1983.
9.7.1. Preparation of lung cells
Mice were killed by anaesthesia and their lungs removed under aseptic conditions 
and placed in a 30ml universal (Sterilin) containing 10ml of sterile PBS. All other procedures 
were performed in a sterile cabinet The lungs were placed into a 25mm2 petri dish containing 
10ml of PBS and the lungs were gently washed to remove excess blood. The tissue was then 
removed to another 25mm2 petri dish containing 10ml PBS and cut into small 2mm sections 
using a scalpel and forceps. The outer epithelial layer of the lungs were removed by placing 
the dissected lung pieces into a 10ml universal tube (Sterilin) and adding a solution of PBS 
containing lOmM MgClg, 0.5U/ml collagenase A (Boehringer Mannhein) and 0.025% 
DNasel (Boeliringer Mannhein) (1ml of solution per lung). After a 45 minute incubation at 
37°C under gentle agitation, the digested tissue was then placed on a nylon mesh in a 25mm2 
petri dish containing 10ml of PBS and the cells released by mashing the tissue through the 
mesh using a plunger from a 10ml syringe. The cells were placed into 30ml universal tubes,
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the cell debris pelleted by standing the universal tubes upright for 3 minutes and the 
supernatant was gently removed to fresh 10ml universal tubes. The cells present in the 
supernatant were centrifuged at 2G°C for 10 mins at 470g and then resuspended in red cell 
lysis buffer (0.15M NH4CI, O.OIM KHCO3,0.lmM EDTA, pH 7.4), using 2ml of buffer 
per lung. After 10 minute incubations at room temperature, the cells were centrifuged at 470g 
for 10 mins and the supernatant discarded. The cells were resuspended in 10ml of PBS and 
centrifuged as before. This step was repeated twice more. The cells were then resuspended in 
1ml of PBS per lung and the number of live cells enumerated following trypan blue staining 
(Section 9.4.1).
9.7.2.Preparal;ion of spleen cells.
Spleen cells were prepared as described in Section 9.4.1.
9.7,3 Detection of an ti body “Specific spo t form ing cells (S.F.C.)
Purified His-p27-Pk was diluted to a concentration of 4pg/ml in carbonate buffer and 
added to the wells of a 96-well, flat-bottomed microtitre plate in lOOpl volumes. After a 2 hour 
incubation at 37°C, the plates were washed three times in PBS. Excess liquid was removed by 
shaking the plates and the remaining binding sites blocked by adding 200pl volumes of 1%
BS A in PBS to each well. Following a three hour incubation at 37°C, the blocking solution 
was decanted and the plates were washed three times in PBS.
The cells were diluted to an appropriate density (10  ^to 10  ^cells/ml) in Iscove's medium 
(Gibco), supplemented with lOOU/ml penicillin, lOOpg/ml streptomycin and added to tlie 
plates in lOOpf volumes. The plates were incubated overnight at 37°C, 5% CO2 in a 
humidified incubator, following which the cells were discarded and any remaining bound cells 
lysed by incubation in PBS containing 0.5% Tween-20. A 1:1(X)0 dilution of anti-mouse IgM, 
IgG or IgA antibody [diluted in PBS containing 0.1% BSA (PBS/BSA)] was added to each 
well in lOOp.1 volumes and the plates were incubated at room temperature for 3 hours. The 
plates were washed three times in PBS containing 0.05% Tween-20, then a 1:1000 dilution 
(in PBS/BSA) of an alkaline-phosphatase conjugated antibody was added to each well in
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lOOpl volumes. The plates were incubated at 37°C for three hours, and after washing the 
plates three times in PBS/Tween followed by twice in distilled water, antibody-antigen 
complexes were visualized by the addition of 100[il of alkaline phosphatase-substrate [lOOmg 
BCIP (5-brorao-4-chloro-3-indoyl phosphate) dissolved in 100ml AMP buffer (9.58ml 2- 
amino-2-methyl-l-propanol (Sigma), 15mg MgCl2,0.lmg sodium azide, made up to 100ml 
in distilled water)]. The plates were incubated at 37°C until blue spots became visible, and 
when the spots were fully developed, the plates were gently washed in distilled water and the 
number of spot forming cells enumerated by examining the plates under a dissection 
microscope.
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R E SU L T S
SECTION A. Expression and Characterisation of LTB-Pk.
A .L  Introduction
Section A of the results describes the addition of a 14 amino acid tag, termed Pk, to 
the carboxy terminus of the B subunit of the heat-labile enterotoxin (LTB) from 
Escherichia coll (E,coli ) and the expression of tlie novel fusion protein, LTB-Pk, in both 
E.coli and the non-pathogenic marine Vibrio, Vibrio sp.60. The influence that the Pk 
epitope exeits on the physical properties attributed to authentic LTB are investigated.
Ao2, Construction o f expression vector pTRH-Pk
The plasmid pTRHlOlR is a controlled expression vector, into which the coding 
sequence for the LTB gene, containing a short oligonucleotide sequence addition at its 3'- 
end, was cloned downstream from the isopropyl-p,D-thiogalactopyranoside (IPTG)- 
inducible tac promoter. This extended sequence contained five unique endonuclease 
restriction sites for cloning additional sequences onto the 3'-end of the gene. Cleavage of 
pTRHlOlR at the HindlH and Spel restriction sites facilitated the insertion of a double­
stranded oligonucleotide sequence encoding a 14-amino acid tag, termed Pk. (The amino 
acid sequence of the Pk tag is shown in Fig. 8) The resulting novel plasmid pTRH-Pk, 
encoding recombinant LTB-Pk, was transfected into either E.coli or Vibrio spÆ  (this 
latter transfection was kindly performed by Dr. T.R. Hirst, University of Kent, 
Canterbury).
A 3 . Comparison o f the expression and cellular localisation o f LTB-Pk in 
E.coli and Vibrio sp.60
E.coli and Vibrio sp. 60 have both been shown to be capable of expressing native 
LTB molecules, the latter host having the additional advantage that the LTB molecules are 
secreted into the external milieu [Leece et al., 1988]. To determine whether the
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recombinant protein LTB-Pk could be similarly expressed, E.coli and Vibrio jp.60 
harbouring plasmid pTRH-Pk, were cultured in ampicillin supplemented L-broth at 37°C 
and 30°C (respectively) and when the O-D^oo reached 0.4, LTB-Pk was induced by the 
addition of 0.5mM IPTG (final concentration) to the bacterial cultures.
Aftor a 4 hour induction, 1ml samples from each culture were removed, the bacteria 
separated from the culture media by centrifugation and the culture media retained. The 
bacterial pellets were then resuspended in 1ml of 20mM Tris, 0.3M NaCl, pH 8.0 and the 
intracellular proteins released by lysozyme treatment. As a control, bacteria containing 
plasmid pTRH-Pk, but not exposed to IPTG, were similarly treated. Equivalent volumes 
from the protein containing medium and cell lysate for each culture, were electrophoresed 
through a 15% (w/v) SDS-polyacrylamide gel and the resulting polypeptide chains 
electroblotted onto a nitrocellulose filter. The presence of LTB-Pk was visualised by 
probing the blots with the anti-Pk monoclonal antibody (MAb), MAb S V5-P-k and 
detecting bound antibody by enhanced chemiluminiscence (ECL) Western blotting assay, 
utilising horseradish peroxidase (HRP)-conjugated Protein A and autoradiography 
(Fig.9).
A signal was present on the autoradiograph, representing the interaction of MAb 
S V5-P-k with the Pk epitope of the recombinant protein in both E.coli and Vibrio sp. 60 
after exposure to IPTG, demonstrating that LTB-Pk can be expressed in both organisms. 
However, following a four hour induction with IPTG, the cellular location of LTB-Pk 
differed for the respective bacteria. In the case of E.coli, LTB-Pk was detected in the 
cellular lysate (lane 3) but not in the culture medium (lane 2), suggesting that LTB-Pk 
remained cell associated in this organism. In contrast to E.coli, only a small proportion of 
LTB-Pk was present in the cell lysate from Vibrio sp. 60 cultures (lane 6), as shown by 
the weak band on the autoradiograph, the vast majority of the fusion protein being 
secreted into the culture medium (lane 5).
When the cell lysate from E.coli control cultures (lane 1) and the culture medium 
from Vibrio sp. 60 control cultures (lane 4) were similarly analysed, no LTB-Pk was 
detectable, demonstrating that LTB-Pk expression is under control of the tac promoter.
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leu giy lys pro ilfi p m asn pm leu
CTG GGA AAG CCG ATC CCA AAC CCT TTG
C COT TTC GGC TAG GGT TTG GGA AAC
leu gly leu a sp ser thr AMB
CTG GGA TTG GAC TTC ACC TAG A
GAG COT AAC CTG AAG TGG ATC TGA TC
Figure 8. DNA linker coding for the Pk tag
The figure shows the sequences of the positive and negative strand oligonucleotides, which were designed to give after annealing Hindlll-compatible and Spel cohesive ends. The Pk tag linker codes for amino acids 95-108 derived from SV5 P and V proteins (shown in bold letters). Underlined region corresponds to the sequences recognized by MAb SV5-P-k.
E.coli Vibrio sp. 60
1
Figure 9 . Expression and cellular localization of LTB-Pk.
Plasmid pTRH-Pk was transferred into E.coli and Vibrio sp. 60, and the bacteria were cultured in the absence (lanes 1&4) or presence (lanes 2-3& 5-6) of 0.5mM IPTG for 4 hours. The bacteria were then harvested by centrifugation and the intracellular proteins released by lysozyme treatment. The expression of LTB-Pk in the culture medium (lanes 2&5) and the cellular lysate (lanes 3&6) for the respective bacteria, was detected with MAb SV5-P-k in an ECL-Western blotting assay utilizing HRP-conjugated Protein A and autoradiography.
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A.4. Oligomerisation o f altered B subunits.
At room temperature, native LTB exists as stable pentamers in the ionic detergent 
sodium dodecyl sulphate (SDS), but dissociates into its constitutive monomers upon 
boiling [Hardy et ai, 1988]. To determine whether LTB-Pk also existed as a heat-labile 
oligomer, the mobility of heat-treated and untreated LTB-Pk was investigated.
Equal samples of culture media from IPTG induced Vibrio sp. 60 cultures, were 
mixed with an appropriate volume of 4X dismption solution and then either heated at 
lOO^ C for five minutes or left at room temperature. The prepared samples were added to 
duplicate gels, one of which was stained with Coomassie blue [Fig. 10 (a)], the other. 
Western blotted onto nitrocellulose and the presence of LTB-Pk detected with the anti-Pk 
MAb in an ECL-Westem blotting assay [Fig. 10 (b)].
Two major protein species were detectable by Coomassie blue stain in the sample 
from Vibrio 5p,60 culture medium that had been boiled prior to the addition to the gel 
[Fig. 10(a), lane 2]. Of the two proteins seen, the protein with faster mobility, migrated 
with an apparent molecular weight of approximately 14kD (lane 1) and was recognised by 
MAb SV5-P-k in the corresponding autoradiograph [Fig. 10(b), lane 1]. However, in 
samples that had not been exposed to heat treatment prior to SDS-PAGE, a single protein 
migrated with an apparent molecular weight of approximately 45kD, was detectable in 
both the Coomassie stained-gel [Fig. 10 (a), lane 2] and the Western blot [Fig. 10(b), lane 
2,]. Similar Western blot analysis of LTB-Pk expressed in E.coli, presented identical 
results to tliat of Vibrio sp.60 expressed LTB-Pk (data not shown).
These findings clearly show that LTB-Pk is a heat-labile oligomer, thereby 
demonstrating that the presence of the Pk epitope at the C-terminus of LTB does not 
prevent subunit-subunit association of the LTB-Pk monomers. In addition, Coomassie 
staining of the proteins detectable m the culture supernatant of IPTG-induced Vibrio 
sp.60, suggests that LTB-Pk and a second protein of unknown function, predominate.
A.5, Binding of LTB-Pk to the glycolipid, GMl-ganglioslde.
Native LTB has been shown to bind to gangliosides and certain sugars, 
presumably through the affinity of the enterotoxin subunit for galactose residues 
[Finkelstein and Clements, 1979]. It is this property that is thought to target LTB onto 
cells bearing these molecules, promoting the uptake and potentially the immunogenicity, 
of LTB-fused epitopes. To further characterise LTB-Pk, the ganglioside-binding 
properties of the recombinant protein were analysed in a GMl-ganglioside-based ELISA 
(GMl-ELISA) assay.
A 96-well microtitre plate was coated with either GMl-ganglioside or a control 
antigen, ovalbumin, and then incubated with LTB-Pk-containing medium. The binding of 
the fusion protein to either antigen was detected by incubation with MAb SV5-P-k 
followed by HRP-conjugated Protein A and HRP substrate and measuring the adsorbance 
at 450nm. As secondary controls, the antigens were incubated MAb SV5-P-k or PBS 
alone, prior to the addition of HRP-conjugated Protein A, to ascertain the degree of non­
specific binding of the MAb and HRP-conjugate, respectively, to either the GMl 
ganglioside or ovalbumin.
As shown in Fig. 11, only low levels of adsorbance were detectable at 450nm in the 
control wells of GMl alone (lane 1) or GMl incubated with MAb S V5-P-k (lane 2) 
demonstrating that neither the HRP-conjugated Protein A nor the anti-tag MAb alone, 
were capable of binding to GMl ganglioside. However, a prior incubation between GMl 
and LTB-Pk-containing medium, before the addition of the antibody and Piotein A, 
resulted in a sharp increase in adsorbance (lane 3) demonstrating that LTB-Pk bound to 
the glycolipid. Confirmation of the specificity of the interaction between the glycolipid and 
LTB-Pk was provided when LTB-Pk was assayed against a control antigen, ovalbumin 
(lane 6), where the level of adsorbance was below background levels (lanes 4 & 5).
Thus, the addition of the Pk-epitope to LTB does not prevent interaction of the 
enterotoxin subunit with its glycolipid substrate.
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(a)
1 2
(b)
1 2
66.2
45.0 oligomericLTB-Pk
31.0
14.4 monomericLTB-Pk
Figure 10. Oligomerization of LTB-Pk.
A sample of the culture medium from Vibrio jp.60 induced cultures containing plasmid pTRH-Pk was mixed with an appropriate volume of 4X disruption buffer, then either boiled for 5 mins (lanes 1) or left at room temperature (lanes 2) prior to 15% (w/v) SDS-PAGE. The presence of LTB-Pk was visualized by Coomassie blue staining (Panel (a)) or Western blotting (Panel (b)>. Molecular marker weights are shown on the right-hand-side of Panel (a).
O.D. at 
450nm
0.8 -
0.6-
0.4-
0.2 -
1 2 3 4 5 6
Figure 11. Affinity of LTB-Pk for GMl-ganglioside.96-well microtitre plates were coated with either 1.5|ig/ml GMl ganglioside (lanes 1-3) or 1 mg/ml ovalbumin (lanes 4-6) then incubated with PBS alone (lanes 1&4), MAb SV5-Pk (lanes 2&5) or LTB-Pk-containing culture medium (lanes 3&6). On completion of the incubation, MAb SV5-P-k was addù to all wells, followed by an HRP-conjugated Protein A antibody and the adsorbance at 450nm was measured after the addition of substrate. The results are presented as the mean ± standard deviation for duplicate cultures.
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A .6. Optimising the expression o f  LTB-Pk.
One of the considerations in developing an expression system is to establish the 
ideal comiitions that lead to optimum production of the desired protein, this being 
particularly important if the protein is to be used in substantial amounts. To determine the 
ideal conditions for the expression of LTB-Pk in E.coli and Vibrio 5/7.60, the influence of 
the (a) temperature and (b) IPTG concentration on the synthesis of LTB-Pk in the 
respective bacteria, was investigated.
Identical 200ml cultures of E.coli and Vibrio sp. 60, were cultured until the O.D,6oo 
reached approximately 0.4 and then the fusion piotein was induced for 4 hours at either 
37“C or 30"C, with a final concentration of IPTG ranging from lmM-0.05mM. On 
completion of the induction period, a 1ml sample was removed from each culture and the 
level of LTB-Pk expression was determined by Western blotting.
Comparison of the signal intensities on the autoradiograph after probing the blots 
with the anti-Pk MAb, suggested that a reduction in temperature favoured increased yields 
of LTB-Pk for both bacterial species, the overall expression of LTB-Pk seeminged higher 
in Vibrio sp. 60 than in E.coli (Fig. 12). Interestingly, two bands were detectable on the 
autoradiograph in E.coli cultures induced at 30°C, the band with a slightly higher 
molecular weight possibly representing precursca* molecules of LTB-Pk, where the N- 
terminal signal sequence, which targets precursor LTB molecules to the cytoplasmic 
membrane prior to secretion [Palva et al., 1981], was not efficiently cleaved from LTB- 
Pk. In contrast to E.coli, in Vibrio sp. 60, LTB-Pk was consistently detectable as a 
single band on autoradiography at either 30°C or 37°C.
The influence of the IPTG concentration on the synthesis of LTB-Pk in the bacteria 
was particularly noticeable at 30°C. In Vibrio sp. 60, there is an apparently uniform level 
of LTB-Pk productivity throughout the IPTG range added to the cultures, but, in E.coli, 
maximum yields of LTB-Pk were obtained only at higher IPTG concentrations of 1- 
0,5mM. However, this was not the case when LTB-Pk was induced at 37°C in E.coli 
where there seemed to be little difference in the level of LTB-Pk synthesis following
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Vibrio sp.60 E.coli
1 0.5 0.1 0.05 1 0.5 0.1 0.05 (mM IPTG)
30®C
Vibrio sp.60 E.coli
1 0.5 0.1 0.05 1 0.5 0.1 0.05 (mM IPTG)
37®C
Figure 12. Effect of IPTG concentration and temperature on the expression of LTB-Pk in Vibrio sp.60 and E.coli.Cultures oWibrio sp.60 or E.coli harbouring the plasmid pTRH-Pk were induced for 4 hours at either 30°C or 37°C, with a final concentration of IPTG ranging from 0.05mM-1.0mM. On completion of the incubation period, the bacteria were harvested by centrifugation and 15|xl samples were removed. The samples were boiled for 5 minutes, then electrophoresed through a 15% (w/v) SDS-polyacrylamide gel. The level of expression of LTB-Pk in the culture medium (fœ Vibrio sp.60) or the cell lysate (for E.coli) was determined by Western blotting, using MAb SV5-P-k as the detection antibody.
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addition of ImM IPTG or 0.05mM IPTG. Similarly, differing IPTG concentrations had 
little effect on the overall expression of LTB-Pk in Vibrio sp.60 at 37®C. These results 
suggest that Vibrio sp.60 is a more suitable expression vector than E.coli for the 
expression of LTB-Pk.
On the basis of these findings, the expression of LTB-Pk in Vibrio sp. 60 was 
further analysed to determine at what time after induction maximum accumulation of the 
fusion protein occurred in the culture medium. A 100ml culture of Vibrio sp.60 was 
grown until the O.D.600 reached 0.4, then the fusion protein was induced at 30°C by the 
addition of O.OSmM IPTG to the bacterial culture. At the times indicated in Fig. 13, a 1ml 
sample of the culture was removed, the bacteria pelleted by centrifugation, and the culture 
medium retained. 15fil samples of the culture medium were electrophoresed tlirough a 
SDS-polyacrylamide gel, the polypeptides transferred onto nitrocellulose and the level of 
LTB-Pk expression in relation to the induction time was determined by Western blotting. 
(Fig.l3).
It was evident from the resulting autoradiograph, that LTB-Pk was detectable in 
the culture medium as rapidly as 30mins after the addition of IPTG to the culture, and the 
amount of LTB-Pk accumulating in the culture medium rose rapidly over tlie next two 
hours. Thereafter, although the slight increasing intensity in the autoradiograph signals 
implied that LTB-Pk was stiU being synthesised and secreted into the culture medium over 
an 18 hour induction period, the actual rate of LTB-Pk synthesis was more constrained. 
Significantly, LTB-Pk was detectable at all times with MAb SV5-P-k as a single protein 
band on the autoradiograph, suggesting that the fusion protein was not degraded, even 
after a prolonged 18 hour induction.
The amount of LTB-Pk present in the culture supernatant at various times after 
induction with IPTG, was quantitated in a GMl-ELISA assay, using purified LTB-Pk as 
the standard in the assay.
As shown in Table 1, the concentration of LTB-Pk detectable in the culture 
medium increased in correlation with the length of the induction period, the maximum
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Length of 
Incubation
0.5 1 2 3 4 5 6 18 (Hrs)
Figure 13. Influence of induction times on the expression of LTB-Pk
harbouring plasmid pTRH-Pk was induced with O.OSmM IPTG at
„ II . j  u indented above, a 1ml sample was removed, the bacteriapelleted by centngugation and the supernatant retained. Equal volumes from 
%1 Z  was subjected to SDS-PAGE through a 15% SDS-polyacrylamide gel, the polypeptides electroblotted onto nitrocellulose paper and the blot g - o ^  with MAb SV5-P-k. Bound antibody was detected with HRP-conjugated Protein A, ECL and autoradiography.
Time after 
Induction
2 hours
3 hours
4 hours
5 hours
6 hours
18 hours
Concentration of LTB Pk 
1.1 mg/1
1.3 mg/1 
3.1 mg/1
4.9 mg/1
8 mg/1
12 mg/1
Table Î. Concentration of LTB-Pk In relation to time.The concentration of LTB-Pk secreted from induced Vibrio sp. 60 was quantitated by GMl-ELISA assays.
Doubling dilutions (starting at a concentration of 1:10) of the LTB-Pk containing culture s u p ^ a t^ t  was performed along GMl-coated wells, and bound protein was detect^ \wth MAb SV5-P-k, followed by HRP-conjugated Protein A. Puntied LTB-Pk (3mg/ml) was employed as the standard in the quantitation.
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level of recombinant protein obtained following an 18 hour induction with IPTG was 
approximately 12mg/litre.
A.7. Stability o f  LTB-Pk following expression in Vibrio sp.60.
The Western blot and GMl-ELISA assays (Section A.6) provided evidence that 
LTB-Pk can be expressed in Vibrio sp.60 to high levels. However, these assays relied on 
the interaction of the Pk determinant of LTB-Pk with the anti-Pk MAb SV5-P-k and thus, 
are insufficient at determining whether the culture medium contained a mixture of LTB-Pk 
and LTB (degraded LTB-Pk ) molecules.
To investigate the stability LTB-Pk following expression in Vibrio sp.60, 
immune precipitation reactions were performed. Staphylococcus aureus (St.aureus) was 
saturated with MAb SV5-P-k, then 21p.l volumes of the culture supernatant obtained after 
the 6 and 18 hour inductions were mixed with the St. aureus-MAh complex. The proteins 
that precipitated onto the bacteria in the presence of MAb SV5-P-k and the proteins present 
in the unprecipitated supernatant were analysed by Coomassie blue staining, following 
SDS-PAGE (Fig. 14). As a control, St. aureus was mixed with a 21 pi sample of the 
culture supernatant obtained after an 18 hour induction with IPTG, to establish whether 
LTB-Pk was capable of binding to the bacteria in the absence of MAb SV5-P-k.
Analysis of the precipitate from the reaction between St. aureus and LTB-Pk, 
revealed that the fusion protein was unable to bind to the bacteria in the absence of MAb 
S V5-P-k (lane 5) and therefore, LTB-Pk remained in the non-precipitated fraction (lane 
6). However when LTB-Pk, present in the samples removed after 6 and 18 
hour inductions, was incubated with MAb SV5-P-k-saturated St. aureus, LTB-Pk was 
detectable in the precipitate (lanes 3 & 1, respectively). Further, examination of the non­
precipitated fraction yielded no evidence of degraded LTB-Pk products (lanes 4 & 2, 
respectively).
Hence, in terms of protein stability, these results provide evidence that LTB-Pk 
can be expressed in Vibrio sp.60 for prolonged periods (up to 18 hours), without any 
obvious concomitant degradation.
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IgL
LTB-Pk
Figure 14. Stability of LTB-Pk following expression in Vibrio sp.60.
Vibrio sp.60 harbouring plasmid pTRH-Pk was cultured at 30°C and synthesis of LTB-Pk induced by the addition of O.OSmM IPTG to the bacterial culture. 21 pi samples of the culture medium were removed after 6 (lanes 3 &4) and 18 (lanes 1,2 & 5,6) hour inductions, and mixed with MAb SVS-P-k-saturated St aureus (lanes 1 & 3)or St. aureus alone (lane 5). Both the immune-precipitated complexes and non-precipitated supernatants were electrophorised through a 15% (w/v) SDS-polyacrylamide gel, and the protein bands stained with Coomassie blue.
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SECTION B. Concentration and Purification of LTB-Pk.
B A . Introduction
In Part A of the results, it was demonstrated that a 14 amino acid tag, termed Pk, 
could be attached to the C-terminus of LTB, and the novel LTB-Pk fusion protein could 
be subsequently expressed and secreted in Vibrio sp. 60. In addition, LTB-Pk displayed 
physiological propeilies akin to native LTB molecules. In Part B, the results concentrate 
on the purification strategies that have been employed to generate either a partially or 
highly purified sample of LTB-Pk and the stability of the fusion protein LTB-Pk after 
such manipulations.
B.2. Concentration o f LTB-Pk,
Although the secretion of LTB-Pk from Vibrio ap.60 bypasses the need for cellular 
lysis as an initial step in purification procedures, it does present the problem that LTB-Pk 
has to be purified from volumes of culture media greater than 1 litre, depending on the 
amount of protein desired. Such large volumes are difficult to work with, and highlight 
the need for a procedure that will concentrate LTB-Pk into a volume that is easier to handle 
in subsequent purification protocols. One of the oldest protein concentration methods 
known for recovering and purifying proteins, is precipitation by neutral salts e.g. 
ammonium sulphate [see 'Protein Purification Applications' 1990], and the early 
concentration protocol, described in the next section, was based on the precipitation of 
LTB-Pk from Vibrio sp. 60 cultui'e medium using ammonium sulphate at 50% saturation.
However it soon became apparent that, although ammonium sulphate ((NH4)2S04] 
precipitation was obviously quite successful in concentrating LTB-Pk from culture 
supernatants, to employ such a technique for large scale preparations of 1 litre or more, 
would be both extremely time-consuming and involve vast quantities of (NH4)2S04 . It 
had been demonstrated in our laboratory that monoclonal antibodies could be concentrated 
from bulk tissue culture preparations by ultrafiltration, using a GFE 15 fibre dialysing
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membrane with a pore size of lOK (Dr. R.E. Randall, pemonal communication), and this 
presented the interesting option of employing the memtsane for concentrating LTB-Pk.
In the following sections, both the ammonium sulphate precipitation and 
ultrafiltration protocols and the efficacy of each procedure at concentrating LTB-Pk from 
Vibrio sp.60 culture supernatants, is described.
B.2.I. Concentration and partial purification of LTB-Pk by ammonium 
sulphate precipitation
To detamine whether ammonium sulphate precipitation could be employed for 
concenti'ating LTB-Pk, a 200ml culture of Vibrio sp.60 was grown at 30*^ 0 until the 
O.D.600 reached 0.4 and then LTB-Pk synthesis was induced by the addition of O.OSmM 
IPTG to the bacterial culture. After a 6 hour induction, the bacteria were pelleted by 
centrifugation and the 200ml culture supernatant retained. A 20 ml sample of the 
supernatant was mixed with (NH4)2S04 (to a saturation level of 50%), and the 
precipitated proteins were collected by centrifugation. Following resuspension in 5ml of 
PBS, excess salt was removed by dialysing the precipitated proteins extensively against 
the saline buffer.
15pl volumes from both the original crude preparation of LTB-Pk and the 
precipitated protein were electrophoresed through a SDS-polyaciylamide gel, and the 
protein bands stained with Coomassie blue, the result of which is shown in Fig. 15.
Examination of the Coomassie stained gel revealed very few protein contaminants 
were detectable in the culture medium prior to precipitation, the two major proteins being 
LTB-Pk and a second protein of unknown function, which was present in higher 
quantities than LTB-Pk (lane 1). When the proteins present in the sample from the 
(NH4)2S04 precipitated fraction was examined, although both LTB-Pk and this second 
protein could be precipitated, the efficiency of their pi’ecipitation using a salt saturation 
level of 50%, varied remarkably. Whereas LTB-Pk could be readily precipitated and 
concentrated approximately 3-fold, it was apparent that the second protein precipitated 
weakly and thus, was not efficiently concentrated (lane 2). In addition, there was little
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protein ofunknownfunction
LT B-Pk
Figure 15. Ammonium sulphate precipitation of LTB-Pk from Vibrio sp.60 cultures.
Coomassie blue stained gel comparing the concentration and purity of LTB-Pk from IPTG induced Vibrio sp. 60 culture supernatant before (lane 1) and after (lane 2) precipitation with ammonium sulphate at a final saturation level of 50%. The precipitated protein was resuspended in, and dialysed against PBS, to remove excess salt, prior to analysis. The final volume of concentrated material was less than the starting medium.
1 2
Figure 16. Cleavage of the Pk-tag from LTB-Pk following ammonium sulphate precipitation.
An equal sample of unprecipitated (lane 1) and precipitated (lane 2) LTB-Pk was electroblotted onto nitrocellulose paper and the presence of the Pk-tag determined in Western blot assays, by probing the blot with MAb SV5-P-k. Bound antibody was detected with HRP-conjugated Protein A, ECL and autoradiography.
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evidence that any other proteins were precipitated/concentrated under the conditions 
described These findings suggest that not only can (NH4)2S04 precipitation efficiently 
concentrate LTB-Pk, the procedure can also help to partially purify the fusion protein from 
the major protein contaminants in Vibrio sp.60 cultures.
However, closer examination of the Coomassie blue stained gel, revealed that 
pi^pitated LTB-Pk migrated to a position slightly lower than that of unprecipitated LTB- 
Pk, suggesting that the Pk epitope may have been cleaved from the enterotoxin subunit 
following precipitation. To determine if this was the case, 15[iJ samples of unprecipitated 
and precipitated LTB-Pk were analysed for the presence of the Pk-epitope by Western 
blotting utilising MAb SV5-P-k as the detection antibody (Fig. 16).
Examination of the resulting autoradiograph, revealed that LTB-Pk was detectable as a 
single band in tlie unprecipitated fraction (lane 1), but was hardly detectable in the sample 
from the precipitated fraction (lane 2). This finding confirms that the Pk epitope was 
cleaved fixim LTB following exposure of the culture medium to (NH4)2S04.
B.2.2. EOT A snacfivatioii of protease activity; protection of the 
Pk-fuslon
Sensitive LTB-fusions can be degraded by metallo-like proteases secreted from 
Vibrio sp.60 (Dr. T.R. Hirst, personal communication). If such protease activity was 
responsible for the cleavage of the Pk epitope, then the addition of ethylenediaminetetra- 
acetic acid di-sodium salt (EDTA), a well-known inactivator of metallo-like proteases, 
might preserve the fusion. To determine whether EDTA could prevent cleavage of the Pk 
tag from LTB-Pk, the precipitation reaction described above was repeated, and after 
resuspending the precipitate in PBS, tlie solution was divided into two equal aliquots. The 
first aliquot was dialysed against PBS over a 2-72 hour period, the second, against PBS 
supplemented with lOmM EDTA and the stability of the LTB-Pk fusion at each time 
interval, was verified by the Western blotting (Fig. 17). As a control, LTB-Pk from 
unprecipitated cultures was included in the assay.
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LTB-Pk was readily detectable in the control sample from the unprecipitated 
cultmos (lanel). However, althought LTB-Pk was present in precipitated cultures that had 
been dialysed against PBS for 2 hours (lane 2), by 24 hours of dialysis, very little intact 
protein was detectable (lane 3), confirming that the Pk-epitope is cleaved from LTB-Pk 
following exposure of the culture medium to (1^ 4)2804. In contrast to this finding, 
when the precipitated protein was dialysed in the presence of lOmM EDTA, the intact 
fusion protein was clearly detectable by MAb SV5-P-k at all times over the 72 hour 
dialysis period (lanes 6-9).
To confirm the efficacy of EDTA in preventing the cleavage of the Pk-epitope 
from LTB, a 15|Jd sample of precipitated LTB-Pk that had been dialysed in the presence of 
EDTA, was incubated with either St.aureus-sBtamt&d with MAb-S V5-P-k, or St.aureus 
alone. The proteins present in both the precipitated and non-precipitated fractions were 
subsequently electtophoresed tlirough a SDS-polyacrylamide gel.
Coomassie blue staining of the SDS-polyacrylamide gel (Fig. 18) revealed the 
(NH4)2S04 concentrated sample of LTB-Pk, that had been dialysed in the presence of 
EDTA, efficiently precipitated onto St. aureus when the bacteria were saturated with MAb 
SV5-P-k (lane 1), there being no detectable LTB-Pk degradation products in the 
unprecipitated supernatant (lane 2). Confirmation that this iramune-precipitation of LTB- 
Pk was through the affinity of the intact fusion protein for the Pk-specific MAb, was 
provided when it was demonstrated that LTB-Pk did not precipitate onto the bacteria in the 
absence of the MAb SV5-P-k (lane 3) and thus, was detectable in the unprecipitated 
fraction (lane 4).
These results clearly demonstrate that EDTA is highly efficient at stabilising the 
LTB-Pk fusion after (NH4)2S04 precipitation, possibly through its ability to inactivate a 
metallo-activated protease secreted from Vibrio sp. 60.
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LTB-Pk was piwipitated from IPTG-induced Vibrio sp.60 culture medium with
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Figure 18. Immune-precipitation of LTB-Pk.
LTB-Pk that had been dialysed in the presence of incubated with MAb SV5-P-k-saturated St. aureus (lanes 1&2) or St.aureus alone (lanes 3&4) and the polypeptides present in both the immune-pi^ipitated complex (lanes 1 &3) and the unprecipitated retenate (lanes 2&4) were separated by electrophoresis through a 15% SDS-polyacrylamide gel, which was stained with Coomassie blue.
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3.2.3. CoiîceiîSratîoïî of LTB-Pk fey iiltraiHtration.
The procedure for concentrating LTB-Pk by ultrafiltration using the GFE 15 fibre 
dialysing membrane was adapted from the protocol used to concentrate monoclonal 
antibodies from bulk tissue culture solutions.
A four litre culture of Vibrio 5/7.60 was induced with 0.05mM IPTG for 6 hours 
at 30“C, and the bacteria were separated from the culture medium by centrifugation. The 
resulting 4 litre supernatant was then applied to the GF15 dialysis membrane and the 
solution constantly recirculated through the dialysis unit under a pressure of 5-10 lbs/in^ 
[Fig. 7(a)]. Such a strategy helped remove molecules that were smaller than the lOK pores 
of the membrane, as well as water molecules, resulting in a 150ml retentate which was 
dialysed in situ [Fig. 7(b)] against an appropriate buffer, Wfore being recovered from the 
dialysis unit.
Figure 20 [Panels (a-c) lanes 1] show examples of the proteins that are 
concentrated following ultrafiltration and gives the clearest evidence yet that few protein 
contaminants are present in culture medium from which LTB-Pk has to be purified. In 
addition, estimation of the concentration of LTB-Pk in the ultrafiltrate in comparison to the 
original culture medium, suggested that approximately 85-90% of LTB-Pk was recovered 
from the membrane. Furthermore, since no extraneous salt agent was added at any time 
during the ultrafiltration process, it seemed unlikely that the Pk epitope would be cleaved 
from LTB and this was vindicated when it was demonstrated that LTB-Pk, concentrated 
by ultrafiltration, could be efficiently precipitated on St. aureus through the interaction of 
the anti-Pk MAb and the Pk epitope (data not shown).
These results provide evidence that, not only is ultrafiltration using a GFE 15 
fibre dialysis membrane an excellent strategy for concentrating LTB-Pk proteins from 
large bulk Vibrio sp. 60 cultures, but also, in terms of stability of the LTB-Pk fusion, it is 
better than ammonium sulphate precipitation.
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B J , Purification o f  LTB-Pk
Initial attempts to purify concentrated LTB-Pk by affinity chromatography 
using sepharose-based beads was unsuccessful. This was primarily due to the high 
affinity that the LTB has for sugar-based matrices [Finkelstein and Clements, 1979], such 
as sephadex, which required strong dénaturation conditions to elute bound LTB-Pk,
While the search for an alternative column support was underway, a report was published 
[Amin and Hirst, 1994], that demonstrated LTB could be purified from Vibrio sp.60 
culture supernatants by hydrophobic interaction chromatography, using a phenyl superose 
support operated on a Fast Protein Liquid Chromatography (FPLC) system. This 
presented the possibility tliat hydrophobic interaction chromatography could be adapted 
for purifying LTB-Pk. Two hydrophobic supports were investigated; the phenyl superose 
matrix originally employed by Amin and Hirst to purify LTB, and a Macro-prep® t-butyl 
matrix (acrylamide-based beads), which offered a cheaper alternative to phenyl superose, 
and did not necessitate the need for specialised equipment The use of ion-exchange 
chromatography, using acrylamide-based beads, was also examined.
B.3.1. Purification of LTB-Pk using a phenyl superose support and 
FPLC .
The procedure outlined below is a modification of the method described by Amin 
and Hirst [1994].
A 4 litre volume of Vibrio 5/7.60 that had been induced with IPTG for 6 hours 
was centrifuged to pellet the bacteria, and the supernatant concentrated by the ulti afiltration 
method described above. The protein-rich filtrate was dialysed in situ against 20 volumes 
of 20mM Tris-HCl, lOmM EDTA, pH 7.5 and the resulting 150 ml dialysate recovered 
from the membrane. A 20ml volume of the retentate was mixed with solid ammonium 
sulphate to a concentration of 30% saturation, then clarified by centrifugation at 17,400g. 
The supernatant was retained, 5ml of which was filtered through a 0.22pm filter and 
applied to a 1ml phenyl superose column, that had previously been equilibrated with 
20mM Tris-HCl pH 7.5, lOmM EDTA containing IM (NH4)2S04 , on an FPLC system.
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Once the sample was loaded the column was washed in the above buffer to remove 
unbound proteins, and purified material was eluted by a decreasing salt gradient. 
Throughout the purification procedure, 1ml fi-actions were collected and the presence of 
proteinaceous material monitored by measuring the adsorbance at 280nm. An example of 
the phenyl superose purification profile is shown in Fig. 19.
At two stages during the purification process, high levels of materials that 
adsorbed strongly at 280 nm were detectable; 1) during early washing steps, representing 
protein that failed to bind the column (fractions 1-15) and 2) during the elution step, at an 
ammonium sulphate molarity of approximately 0.65M (fractions 25-28). To furtlier 
investigate the proteins present in these fractions, fractions 1-15 were pooled, as were 
fractions 25-28, and 15|ii samples were removed, electrophoresed through a SDS- 
polyacrylamide gel and the proteins visualised by Coomassie blue staining [Fig.20, Panel 
(a)].
Coomassie blue staining of the polypeptide chains, revealed that of the original 
proteins present in the unpurified material (lane 1), the vast majority of the contaminating 
proteins failed to bind to the column and were removed duiing the washing steps, (lane
2). In contrast to this finding, it was evident that the LTB-Pk efficiently bound to the 
phenyl superose, and was eluted at a salt molarity of approximately 0.65 (lane 3). 
Estimation of the concentration of LTB-Pk applied to the phenyl superose, in comparison 
to the quantity of LTB-Pk eluted from the column, suggested a recovery rate of 
approximately 67%. However it was noteable that, traces of the major contaminating 
protein could still be detected in LTB-Pk that had been purified in this manner.
B 3.3. Purification off LTB-Pk by hydrophobic chromatography using a 
M acro-prep.® t-butyl support.
The second hydrophobic column to be investigated was a Macro-prep.® t-butyl 
support. The criteria for purifying LTB-Pk on this mildly hydrophobic matrix, was an 
adaptation of the procedure for the purification of LTB-Pk on phenyl superose.
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A 40 ml sample of the protein-rich dialysate containing concentrated LTB-Pk was 
applied under high salt conditions, to a 5ml t-butyl column that had been equilibrated with 
20mM Tris-HCl, pH 7.5, lOmM EDTA containing IM (1SIH4)2S04 at room temperature. 
Once all the protein solution had been added, the column was washed in 10 column 
volumes of 20mM Tris-HCl, pH 7.5, lOmM EDTA containing IM (NH4)2S04 to remove 
unbound proteins. A decreasing ammonium sulphate concentration step gradient was 
generated by washing the column in 200ml of 20mM Tris-HCl, pH 7.5, lOmM EDTA 
containing IM, 0.75M, 0.5M, and 0.25M (NH4)2S04 sequentially. Throughout the 
purification process 5ml fractions were collected and a Ipl sample from each fraction was 
allowed to adsorb onto niuocellulose paper. The presence of protein in each fraction was 
visualised by staining the nitrocellulose with 0.2M Naphthalene black (data not shown). 
By examining the amount of stain adsorbed by the protein spots, it was evident that 
proteins that failed to bind to the t-butyl matrix were detectable in fractions collected 
during the early stages of the purification procedure (data not shown). In subsequently 
collected fractions, the protein levels detectable fell, until the buffer containing 0.75M 
ammonium sulphate was applied to the column (data not shown). Thereafter, the level of 
protein eluting from the column fell in correlation with a decrease in the ammonium 
sulphate concentration.
Fractions collected early in the purification, that contained the highest levels of 
protein, were pooled, as were the fractions that were assumed to contain high levels of 
eluted protein. 15jil volumes from both samples were subjected to SDS-PAGE and the 
resulting polypeptide chains stained with Coomassie blue.
The results presented in Fig.20, Panel (b), demonstrate that purification of LTB- 
Pk using the t-butyl hydrophobic support gave a similar result to that of the phenyl 
superose column, where the majority of contaminating proteins present in the unpurified 
sample (lane 1) were removed during the washing steps (lane 2). Furthemiore, LTB-Pk 
efficiently bound to the t-butyl support (lane 2) but was eluted following the application of 
a decreasing salt gradient to the column (lane 3). Estimation of the recovery rate of LTB-
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Figure 20. Purification of LTB-Pk.An example of the efficacy of Phenyl superose (Panel (a)), Macroprep® t- butyl (Panel (b)) or Bio-rex-70 (Panel (c)) affinity columns in purifying LTB-Pk from Vibrio sp.60 culture medium. IPTG-induced Vibrio sp. 60 culture medium was concentrated by ultrafiltration, and a sample of the concentrated solution applied to the appropriate column. The proteins present in 15|il samples from the concentrated starting material (lane 1), were compared to the proteins present in a similar volume from the column wash (lane 2) and the column eluate (lane 3) by 15% (w/v) SDS-PAGE and Coomassie blue staining.
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Pk from the column revealed that, of the starting material that was applied to the column, 
62% of LTB-Pk eluted.
However, once again, it was evident that LTB-Pk was not completely purified, 
since there was evidence of minor traces of contaminating proteins in the eluted material 
(lane 3)
3,3.3. Purification of LTB-Pk by ion-ezchange chromatography
using a Bio-Rex® cation-exchange support.
The third method used for purifying LTB-Pk utilised a sulphur-based cation- 
exchange column based on acrylamide-bead support. Preliminary experiments established 
that in a buffer composed of 0.25mM Na2PO^, pH 7.0, purified LTB molecules (a kind 
gift from Dr. T.R. Hirst) were sufficiently ionised to enable the protein to bind to the 
negatively charged support, but could be eluted following the addition of 25mM Na2pO^, 
0.5M NaCl, pH 7.5 to the column. It was decided to assess the ion-exchange protocol for 
its ability to purify LTB-Pk fr om Vibrio sp. 60 culture medium.
A 4 litre culture of Vibrio sp. 60 was grown at 30°C and when the O.D.6qo 
reached 0,4, LTB-Pk was induced for 6 hours by the addition of 0.05mM IPTG to the 
bacterial culture. The bacteria were pelleted by centrifugation, and the 4 litre supernatant 
was concentrated by ultrafiltration, as previously described. When the supernatant was 
concentrated to a 150ml volume, the solution was dialysed in situ against 25mM Na2P04, 
lOmM EDTA, pH 7.0, clarified by centrifugation at 17,4O0g and the supernatant applied 
directly to a 25ml Bio-rex® 70 cation-exchange column that had been equilibrated with 
25mM Na2P04, lOmM EDTA, pH 7.0. The column was washed with 10 volumes of 
25mM Na2P04, lOmM EDTA, pH 7.0 to remove any unbound proteins and bound 
protein was then eluted by the application of a buffer composed of 25mM Na2P04, lOmM 
EDTA, 0.5M NaCl, pH 7.5 to the column. Samples were taken throughout the 
purification process and assayed for the presence of protein material using the 
Naphthalene black-based procedure described above. The fractions containing protein that 
failed to bind the column, were pooled, as were the fractions that contained piotein that
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eluted from the column and 15 pi samples were removed for analysis by SDS-PAGE and 
Coomassie blue staining [Fig. 20, Panel (c)].
It was evident that of the major proteins present in the original concentrated 
material (lane 1) LTB-Pk bound to the ion-exchange column at pH 7.0, [whereas the 
major protein contaminants did not (lane 2)], but was eluted after the addition of 25mM 
Na2P04 , lOmM EDTA, 0.5M NaCl, pH 7.5 buffer to the column (lane 3). Of more 
significance, LTB-Pk was the only protein detectable in the eluted material, all the other 
contaminating proteins being removed during the washing steps of the purification process 
(lane 2). Thus, in terms of protein purity, ion-exchange chromatography is more efficient 
at purifying LTB-Pk from concentrated culture medium, than hydrophobic 
chromatography. Furthermore, estimation of the yield of purified LTB-Pk from the cation- 
exchange matrix, suggested approximately 84% of LTB-Pk eluted.
B.4. Functional properties o f LTB<>Pk purified by ion-exchange 
chromatography and the stability o f the Pk-epitope.
Examination of the proteins eluted from the three columns investigated in the 
previous sections, demonstrated that, ion-exchange chromatography was the best and 
most convenient method for purifying LTB-Pk, To confirm that purified LTB-Pk retained 
the physiological properties of unpurified LTB-Pk, the ability of purified LTB-Pk to 
oligomerize and bind to GMl-ganglioside were investigated in vitro.
Firstly, the oligomerization properties of purified LTB-Pk were determined by 
analysing the migration pattern of heat-treated and untreated samples of the fusion protein, 
following SDS-PAGE. As a comparison, purified LTB molecules were also included in 
the assay. C(x>massie blue staining of the resulting polypeptide bands revealed that, in 
boiled samples purified LTB and LTB-Pk migrated as monomers (Fig.21, lanes 1 & 2, 
respectively), LTB-Pk migrating to a position slightly higher than LTB. When purified 
LTB and LTB-Pk were applied to the SDS-polyacrylamide gel without prior heat- 
treatment, both proteins migrated as stable oligomers (Fig. lanes 3 & 4, respectively). 
Secondly, the affinity of purified LTB-Pk for GMl-ganglioside was
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21. Oligomerization of LTB-FTc following purification by ion-exchange chromatography
S ^ p le s  of purified LTB (lanes 1 & 3) and purified LTB-Pk (lanes 2 & 4) were mixed 
^  ^  volume of 4X disruption buffer and either boiled for 5 minutes
^  r  temperature (lanes 3 & 4) prior to SDS-PAGE on an 15%^ /v )  SDS-polyacryl^dc gel. The resulting polypeptide chains were visualized by Coomassie blue staining. ^
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Figure 23. Immune-precipitation of purified LTB-Pk.
The stability of the LTB-Pk fusion after purification of LTB-Pk by 
ion-exchange chromatography was examined in immune-precipitation assays. Samples of purified LTB or LTB-Pk were were incubated with either St. aureus ^one (l^e s  1-4) or MAb SV5-P-k-saturated St. aureus (lanes 5 & 8) and both the piwipitates (lanes 1,3,5 & 7) and the unprecipiated supernatants (lanes 2 4,6 & 8) were analysed by 18% SDS-PAGE and Coomassie blu staining for the presence of purified LTB (lanes 1,2,5 & 6) and LTB-Pk (lane 3, 4, 7 & 8)
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Figure 22. Binding of purified LTB-Pk to GMl-ganglioside.
The figure shows the retention of the CM 1-binding property of LTB-Pk after purification by ion-exchange chromatography. 96-wcll microtitre plates were coated with either (1.5p,g/ml) CM 1 (lanes 1-3) or (1 mg/ml) ovalbumin (lanes 4-6) and then incubated with PBS alone (lanes 1&4), MAb SV5-P-k (lanes 2&5) or purified LTB-Pk (lanes 3&6). The anti-Pk MAb was added to all wells and bound protein was detected with HRP-conjugated Protein A. Following addition of the HRP-substrate, the adsorbance at 450nm was measured.The results are presented as the mean ± standard deviation for duplicate cultures.
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vindicated in a GMl-ELISA assay (Fig.22) where it was evident that LTB-Pk bound to 
the ganglioside in a highly specific manner (column 3). Thus, the purification of LTB-Pk 
by ion-exchange chromatography does not destroy the physiological properties of LTB- 
Pk.
In addition to the analysis of the physiological properties of purified LTB-Pk, the 
stability of the Pk-fusion following purification was determined in immune-precipitation 
reactions, where both purified LTB and LTB-Pk were assessed for tlieir ability to bind to 
MAb-S V5-P-k-saturated St. aureus, or to St. aureus alone.
As shown in Fig. 23, puiified LTB was unable to bind to either St.aureu^ alone 
(lane 1) or anti-Pk MAb-saturated St.aureus (lane 5) and was therefore, detectable in the 
unprecipitated fractions (lanes 2 and 6). Likewise, purified LTB-Pk did not bind to St. 
aureus alone (lane 3) and was also detectable in the unprecipitated fraction (lane 4). In 
contrast to this finding, when purified LTB-Pk was mixed with MAb S V5-P-k-saturated 
St.aureus, all the purified protein was present in the precipitate (lane 7), with no evidence 
of degraded LTB-Pk pioducts in the unprecipitated fraction (lane 8). Thus, purification of 
LTB-Pk by ion-exchange chromatography does not result in the destruction of the Pk- 
epitope.
SECTION Co Expression and Purification of HIS“SIV“Fk 
Proteins and Construction of SIV-MAb-LTB 
complexes.
C .i. Imtroduction.
In section C of the results, the recombinant SIV proteins used in the 
immunisations procedures, are introduced and their unique tag-linked purification by 
nickel affinity chromatography is described. In the later stages of the section, the 
construction of the novel SIV-MAb-LTB immunogen, and the targeting of such 
complexes onto GMl-ganglioside, is presented in detail.
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C.2. Construction and expression o f recombinant His-SIV-Fk proteins.
The addition of the 14 amino acid Pk tag to the C-teraiini of a variety of Simian 
Immunodeficiency Vims proteins has been described in detail by Hanke and colleagues 
[Hanke et a/.,1994], Such SIY-Pk proteins were expressed as fusion proteins with a 12 
amino add long peptide containing six histidines (His) at the N-terminal of the 
recombinant proteins, in the E.coli pQE-9-derived vector [Randall et al,, 1993]. In this 
expression system, the novel His-SIV-Pk gene is under control of the lac promoter, tiius, 
the recombinant proteins can be induced by IPTG. The choice of recombinant SIV gag 
gene products, His-pl7-Pk and His-p27-Pk, for the vacdnation strategies described later, 
was motivated by the moderate to high level of expression of these recombinant proteins 
in E.coli (lOmg/litre and 200-7()0|i.g/litre, respectively), and that both antigens have been 
shown to be immunogenic when incorporated into solid matrix antibody-antigen 
complexes [Randall et al, 1994].
C.2. Purification o f His-SIV-Pk proteins by Nickel Affinity  
Chromatography.
The protocol developed for the purification of His-SIV-Pk antigens was based on 
the observation that histidine residues have a high affinity for metal cations, and can, 
therefore, be purified by chelating immobilised metal ions such as nickel [Smith et al., 
1988].
1 litre cultures of E.coli containing plasmids pQE917Pk, encoding His-pl7-Pk, 
or p()927Pk, encoding His-p27-Pk, were induced at 26°C with O.OSmM IPTG when the 
O.D.600 reached approximately 0.4-0.6. After 2-3 hour inductions, the bacteria were 
harvested by centrifugation, resuspended in 30ml of 20mM Tris-HCl, 0.3M NaCl, pH 
8.0 and the intracellular proteins released by lysozyrae treatment, followed by vigorous 
sonication. The protein rich lysate was centiifuged, and the resulting supernatant 
incubated with a 1ml sample of Ni^+-NTA resin for 1 hour at 4°C. The beads were loaded 
into a column and unbound proteins were removed by washing the column in 20mM Tris- 
HCl, 0.3M NaCl, pH 8.0. Bound His-SIV-Pk proteins were eluted by the application of
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Figure 24. Purification of the His-SIV-Pk antigens.E.coli containing plasmids that encode the recombinant His-pl7-Pk (Panel (a)) and His-p27-Pk (Panel (b)) proteins were induced for 3 hours with O.OSmM IPTG at 26°C. The His-SrV-Pk antigens were purified by Nickel affinity chromatograpy and the purity of the eluted protein was examined by 15 % (w/v/) SDS-PAGE and Coomassie blue staining.Lanes l;total cell lysate, lanes 2; insoluble cell fractions, lanes 3; soluble cell fractions, lanes 4; protein that did not bind to the nickel columns and lanes 5; protein that was eluted from the nickel columns with imidazole (see text).
250mM Imidazole, 20mM Tris-HCl, 0.3M NaCl, pH 7.4 to the column and the purity of 
the eluted His-pl7-Pk and His-p27-Hc, were examined by SDS-polyacrylamide gel 
analysis [Fig. 24, Panels (a) & (b), respectively].
Coomassie blue staining of the polyacrylamide gels revealed that the His-SIV-Pk proteins 
are present in the soluble fraction upon lysis (lanes 3) and are not restricted to insoluble 
inclusion bodies (lanes 2) in E.coli., a finding that supports the observations of Dr. T. 
Hanke [research thesis, 1993]. The vast majority of the contaminating material was 
removed during the washing stages (lanes 4) yielding a highly purified His-SIV-Pk 
protein upon elution (lanes 5).
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C,3. Construction o f the Simian Immunodeficiency Virus-Antibody-LTB  
(SIV-M Ab-LTB) Complex,
The method that was developed to produce SIV-MAb-LTB complexes can be 
divided into three major steps; 1) incubation of purified His-SIV-Pk with a five-fold 
excess of purified MAb SV5-P-k, such that, on average a single antibody molecule will 
only have one molecule of antigen attached 2) purification of SIV-MAb complexes from 
uncomplexed antibody, by nickel affinity chromatography, and 3) linkage of the SIV- 
MAb complexes to LTB-Pk via the free antigen binding site on the antibody molecule. A 
diagrammatic representation of the procedure is shown in Fig. 25.
(1) Construction of SIV-MAb complexes
The formation of immune-complexes that contained an His-SIV-Pk antigen 
occupying only one of the antigen-binding sites of MAb SV5-P-k, tliereby leaving the 
second site free for complexing with LTB-Pk, was the most critical step in the 
construction of SIV-MAb-LTB complexes. It is generally accepted that in a solution in 
which the concentration of an antibody molecule is in excess to its specific antigen, the 
vast majority of antibody molecules will have only one of their antigen-binding sites 
occupied by the antigen. On this basis, it was thought that mixing His-SIV-Pk proteins 
and MAb SV5-P-k at a molar ratio of 1:5 (SIViMAb) would result in sub-saturation of the 
anti-Pk MAb. Thus, as a first step in the construction of SIV-MAb-LTB complexes, the 
concentration of purified His-SIV-Pk in relation to the concentration of purified MAb 
SV5-P-k was estimated by SDS-PAGE and Coomassie blue staining (data not shown).
(2) Purification of SIV-:MAb_comDlexes,
The second step in the construction of SIV-MAb-LTB complexes involved the removal of 
uncomplexed antibody. After incubating His-SIV-Pk and MAb SV5-P-k at a molar ratio 
of 1:5 for 50 minutes at 4°C, the solution was mixed with a 1ml volume of Ni^+-NTA 
resin for 45 minutes at 4°C. After loading the resin into a column, uncomplexed MAb 
SV5-P-k that did not bind to the NF+-NTA resin, was removed by washing the column in 
20 volumes of 20mM Tris-HCl, 0.3M NaCl, pH 8.0. Purified SIV-MAb complexes were 
then eluted by the addition of 0.25M Imidazole, 20mM Tris-HCl, 0.3M NaCl, pH 7.4 to
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Step One.
Pk linked SIV proteins containing 
a six histidine tag at the N-terminus 
is mixed with Pk specific MAb SV5-P-k, 
at a SlV;MAb ratio of 1 ;5.
This ensure incomplete sarurabon of the 
MAb.
Step Two
The affinity of the histidine tag  for 
chelating ions enables SIV-MAb 
complexes to  be purified by nickel 
affinity chromatography, and faciliates 
the removal of excess MAb.
Step ThreeQuantitation of the amount of SIV 
antigen irKorporated into the 
immune-complex by SDS-PAGE, 
determines of the corxzentration of 
LTB-Pk that w8l suffice to  fill the  
remaining antigen-binding site  on the 
MAb.
e  SIV Ag
•  H isüdine tag 
^  PV tag
MAbSV5-P-k
LTB
Figure 25. Construction of SIV-MAb-LTB complexes.A diagrammatic representation of the three step procedure involved in the construction of SIV-MAb-LTB complexes.
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the column. To estimate if these eluted SIV-MAb complexes had an His-SIV-Pk protein 
occupying only one antigen-binding site of MAb S V5-P-k, the concentration of the His- 
SIV-Pk protein in relation to the concentration of the light chain of MAb SV5-P-k, was 
analysed by SDS-PAGE and Coomassie blue staining. An example of such an analysis is 
shown in Figure 26. It is evident from the Coomassie stained gel, that the concentration of 
His-p27-Pk is approximately half the concentration of the light chain of the anti-Pk MAb, 
suggesting that the antigen-binding sites of MAb SV5-P-k are incompletely saturated.
(3) Linkage of LTB-Pk to purified SIV-MAb complexes.
The last step in the construction of SIV-MAb-LTB complexes involved the 
linkage of purified SIV-MAb complexes to LTB-Pk. Since only one antigen-binding site 
of MAb SV5-P-k was presumed to be unoccupied, it was thought that mixing SIV-MAb 
complexes with LTB-Pk at a molar ratio of 1:1, would suffice to saturate the remaining 
antigen-binding site of MAb SV5-P-k. These resulting SIV-MAb-LTB complexes would 
thereby contain an identical amount of His-SIV-Pk and LTB-Pk proteins. Thus, the 
concentration of LTB-Pk in relation to the concentration of His-SIV-Pk in SIV-MAb 
complexes was estimated by SDS-PAGE and Coomassie blue staining. By comparing the 
strengths of the Coomassie stained bands, the amount of LTB-Pk that gave a signal 
identical to that of the His-SIV-Pk protein, determined the amount of LTB-Pk that was to 
be mixed with the immune complex.
To establish whether mixing SIV-MAb complexes with LTB-Pk at a molar ratio 
of 1:1 resulted in all the available LTB-Pk being incor|x>rated into the complex, an 
immune precipitation assay was performed. SIV-MAb-LTB complexes were mixed with 
St. aureus md after a 30min incubation, the precipitates were pelleted by centrifugation. 
Both the precipitated pellet, and the unprecipitated supernatant were analysed by SDS- 
PAGE and Coomassie staining. Such analysis demonstrated that LTB-Pk efficiently 
bound to the SIV-MAb complex and was present in the precipitated fraction, there being 
no detectable free LTB-Pk molecules present in the unprecipitated supernatant (data not 
shown).
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H«-p27-Pk
IgL
Figure 26. Sub-saturation of MAb SVS-P-k.
The figure shows an example of SIV-MAb complexes that have been constructed by incubating recombinant p27 and MAb S V5-P-k at a ratio of 1:5, and then purified nickel affinity chromatography. A 15|il sample of the purified complexes was subjected to SDS-PAGE and the protein bands stained with Coomassie blue.
O.D.
450nm
0.81
0.6 “
0 .4-
0.2 -
Figure 27. Binding of SIV-MAb-LTB complexes to GMl.The figure shows the targeting to GMl-binding by SIV-MAb-LTB complexes.96-well microtitre plates were coated with either (1.5pg/ml) GMl (lanes 1-3) or (1 mg/ml) ovalbumin (lanes 4-6) and then incubated with SIV-MAb complexes (lanes 1&4), MAb-LTB complexes (lanes 2&5) or SIV-MAb-LTB complexes (lanes 3&6). Bound complexes were detected with HRP-conjugated Protein A. Following addition of the HRP-substrate, the adsorbance at 450nm was measured.The results are presented as the mean ± standard deviation for duplicate cultures.
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Thus, mixing SIV-MAb complexes with LTB-Pk at a molar ratio of 1:1, results in all 
the available LTB-Pk molecules being incorporated into the immune-complexes.
C,4. Binding o f  the SIV-MAb-LTB complex to GM l- 
ganglioside.
To further analyse SIV-MAb-LTB complexes, the ability of such complexes to 
bind to GMl-ganglioside was investigated in a GMl-ELISA assay.
A 96-well microtitre plate was coated with 1.5fig/ml GMl-ganglioside or 
ovalbumin and tlien a 1:10 dilution of SIV-MAb-LTB complexes was added to the wells. 
As positive and negative controls, MAb-LTB and SIV-MAb complexes (respectively) 
were included in the assay. After a 1 hour incubation, bound complexes were detected 
with HRP-conjugated Protein A, substrate added and the adsorbance at 450nm measured 
(Fig. 27).
T h ^  was no evidence that SIV-MAb complexes were capable of binding to GMl 
(lane 1) as shown by the weak adsorbance at 450nm. In contrast, both MAb-LTB (lane 2) 
and SIV-MAb-LTB (lane 3) bound to GMl with high affinity, demonstrating that the 
incorporation of LTB-Pk into the MAb-SIV complex can bind the immune complex onto 
GMl-ganglioside in vitro.
SECTION D. Systemic Immunogenicity of LTB-Pk.
D ,l. Introduction,
The mechanism(s) responsible for the adjuvant nature of LTB is, at present, 
unloiown. However, the physiological properties of LTB i.e. its existence as a pentamer 
and affinity for GMl-ganglioside are thought to play a critical role. In addition, it is 
theorised that the high immunogenicity of LTB itself, may contribute to its adjuvancity 
[Dertzbaugh et ai, 1990]. In Section D, the immunogenicity of LTB-Pk following 
parental administration and the attempts to classify the antibody response to the 
recombinant enterotoxin subunit, are desciibed.
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It is important to note, that, at the time of these preliminary immunogenicity 
studies, an efficient purification protocol for LTB-Pk was unavailable. Thus, the vaccines 
contained LTB-Pk that had been precipitated from IPTG induced Vibrio sp.60 culture 
supernatants with ammonium sulphate, and then dialysed against PBS containing lOmM 
EDTA.
D,2, Systemic Immunogenicity o f  LTB-Pk,
Peptide epitopes have been linlced to LTB in attempts to raise an immune 
response to the peptide [e.g. Schodel et al., 1991]. It was of interest to monitor the 
immunogenicity of LTB-Pk, both in teims of the antibody response to LTB and to the Pk 
epitope. In addition, the immunogenicity of MAb-LTB complexes were also investigated, 
since it was of interest to establish whether the linkage of MAb SV5-P-k to LTB-Pk 
influenced the immunogenicity of the fusion protein, a factor that could have implications 
on the use of SIV-MAb-LTB complexes as immunogens.
Groups of four 6-8 week old Balb/c mice were immunised with the equivalent of l[ig 
LTB-Pk alone (Group A) or after adsorption of the fusion protein onto the adjuvant, alum 
(Group B). LTB-Pk was mixed with MAb SV5-P-k at a molar ratio of 1:1 and the 
equivalent of l[ig LTB-Pk in MAb-LTB complexes were injected intraperitoneally either 
alone (Group C), or after adsorption onto alum (Group D). Prior to immunisation, a 15fXl 
sample of each vaccine was analysed by SDS-PAGE and Coomassie blue staining, to 
ascertain that each vaccine contained an equivalent amount of LTB-Pk (Fig.28).
All mice were immunised three times with their respective vaccines, two weeks 
separating the first and second vaccination, and three weeks the second and third. Ten 
days after the final immunisation, the sera from each mouse was assayed for antibodies 
specific for LTB-Pk, or a control antigen (ovalbumin) using an ECL-based immune assay.
Briefly, the sera from each mouse within a vaccination group was diluted 1:2(X) 
and from this starting dilution, the sera was further serially diluted 1:2 in the wells of 
terasaki plates. MAb SV5-Pk and sera from non-immunised mice were similarly treated 
and used as positive and negative regulatory controls (respectively) m the assay. The
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Figure 28. Comparative analysis of the LTB-Pk-based vaccines.
Analysis of the vaccines used for immunization against LTB-Pk. Each vaccine was resuspended to a final volume of 200pl in PBS and 30|il removed, electrophorised through a 15% SDS-polyacrylamide gel and the polypeptide chains stained with Coomassie blue. Lanel: soluble LTB-Pk; lane 2: LTB-Pk adsorbed onto alum; lane 3: LTB-Pk conjugated to MAb SV5-P-k (MAb-LTB); lane 4: MAb-LTB adsorbed onto alum.
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terasaki plates were overlaid with individual nitrocellulose sheets that had been coated with 
either LTB-Pk or a control antigen (ovalbumin), and the plates were incubated for one 
hour at room temperature. Total antibody levels m the sera of vaccinated and control mice, 
to the respective antigens, were detected by incubating the nitrocellulose sheets with HRP- 
conjugated anti-mouse immunoglobulin (Ig), followed by exposure to ECL buffers and 
autoradiography. An example of the ECL-immune assay is shown in Fig.29 and the 
antibody titres to LTB-Pk for each vaccination group presented in Table 2. column 1.
Sera from non-immunised mice failed to bind to either of the target antigens, 
highlighting the specificity of the immune assay. Following three intraperitoneal 
vaccinations with LTB-Pk alone, all mice in Group A exhibited a high degree of immunity 
to LTB-Pk, with the average titre within the gioup being approximately 25,600. 
Interestingly, tliis immune response to LTB-Pk was not, on average, enhanced by 
administering LTB-Pk in association with alum (Group B). Although immunisation with 
MAb-LTB (Group C) resulted in a slight decrease in the immune response to LTB-Pk, 
this could be overcome by adsorbing the immune complex onto alum, prior to vaccination 
(Group D). These findings suggest that LTB-Pk itself, is a potent systemic immunogen, 
that does not apparently require the presence of additional adjuvants to potentiate the 
response to fusion protein. However, linkage of MAb SV5-P-k to LTB-Pk may slightly 
decrease the potency of LTB-Pk.
Wlien the immune sera was re-assayed for antibodies capable of recognising the 
control antigen, ovalbumin, there was no evidence that any vaccinated mouse contained 
immunity to ovalbumin [Fig.29 Panel (b)].
To further analyse the immune response to LTB-Pk, the serum from each 
vaccinated mouse was assayed for antibodies specific for the Pk-epitope to investigate 
whether the antibodies, detectable to LTB-Pk, were interacting with the Pk-tag. The sera 
was diluted as before, then incubated with nitrocellulose sheets that had been previously 
coated with GlutatIiione-5-transferase-linked Pk (GST-Pk). Bound antibody was once 
again detected in ECL-immune assays that utilised an HRP-conjugated anti-mouse 
immunoglobulin. The antibody titres are shown in Table 2, column 2.
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(a) LTB-Pk (b) control antigen
Group _A__
Group B__
GroupB
GroupC__
Group_D__
MAb SyS-P-K
LTB 5 ads. alum g
MAb SV5-P-K
LTB 7 
ads. alum g
MAb-LTB 11 
12
MAb SV5-P-K
13
MAb-LTB 14 
ads. alum i s
16
control sera
Figure 29. Immunogenicity of LTB-Pk
An example of the ECL-based immune assay used in the detection of antigen-specific antibodies in the sera of immune mice.
Groups of four Balb/c mice were immunized three times with the vaccines shown in Fig.28. Ten days after the last immunization, the sera was assayed for antibodies to LTB-Pk or a control antigen, ovalbumin. The sera was diluted 1:200 and from this starting dilution, serial diluted 1:2 in the wells of a terasaki plate, then incubated with nitrocellulose filters that had been pre-coated with either LTB-Pk or ovalbumin. As a control, sera from non-immunised mice were similarly treated. Bound antibody was detected with an HRP-conjugated anti-mouse immunoglobulin (Ig) antibody, ECL and autoradiography.
Group A: mice immunized with soluble LTB-Pk (LTB); Group B: mice immunized with LTB-Pk adsorobed onto alum (LTB ads. alum); Group C: mice immunized with LTB-Pk linked to MAb SV5-P-k (MAb-LTB) and Group D: mice immunized with MAb-LTB adsorbed onto alum (MAb-LTB ads. alum).
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Except for the mice that were immunised with MAb-LTB alone, all mice 
exhibited some immunity to the Pk-tag. However, the actual antibody titres were 
consistently small, irrespective of the immunising agent, with an average titre of only 400- 
800.
Thus, the Pk-tag is a poor systemic immunogen, a finding that supports the 
observations of Randall and colleagues [1994], and therefore, suggests that the majority 
of the immune response generated to LTB-Pk is directed at LTB.
SECTION E. Systemic Immunogenicity of Partially Purified 
pl7°MAl5“LTB complexes.
E .l. lutroducUoiu
In this section of the results, the prcliminaiy findings on whether the conjugation 
of recombinant SIV antigens to LTB-Pk via MAb SV5-P-k was a successful strategy for 
promoting humoral and cell-mediated immunity to the recombinant SIV antigen, following 
parental administration, are presented.
The Pk-linked SIV antigen chosen for use in the initial immunisation studies was 
the recombinant gag gene product His-pl7-Pk. This recombinant protein had several 
important attributes that increased its attractiveness as a SIV target antigen. For example, it 
could be over-expressed in E.coli to high levels [Hanke et al.., 1994] and was easily 
purified from the cell lysates by nickel affinity chromatography. Also, incorporation of 
His-pl7-Pk into solid matrix-antibody-antigen complexes had previously been shown to 
induce recombinant pi 7-specific humoral and cell-mediated immune responses following 
intraperitoneal immunisation [Hanke eta i, 1994].
E.2» LTB ’^ Pk enhances the immune response to recombinant S IV  antigens
To investigate whether conjugation of Pk-linked SIV proteins to LTB-Pk via 
MAb SV5-P-k, led to an enhancement of the immune response to the recombinant SIV
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protein, SIV-MAb-LTB immune complexes were constructed and their immunogenicity 
were examined in vivo. pl7-MAb complexes were constructed as described in Section
C.3 and the purified pl7-MAb complexes divided into two equal aliquots. One of the 
aliquots was then mixed with the appropriate concentration of ammonium sulphate 
purified LTB-Pk, to create pl7-MAb-LTB complexes with a molar ratio of pl7- 
MAb:LTB-Pk of 1:1. The second aliquot of pl7-MAb was retained and used in a separate 
group of immunisations (below).
Groups of four Balb/c mice aged 6-8 weeks were immunised intraperitoneally 
with the equivalent of Ipg His-pl7-Pk alone (Group A) or after adsorption onto alum 
(Group B), pl7-MAb alone (Group C) or with alum (Group D), pl7-MAb-LTB alone 
(Gmup E) or with alum (Group F) in a final volume of 200pl. Prior to immunisation,
30pl of each vaccine was subjected to 15% (w/v) SDS-PAGE and the protein bands 
visualised by staining the gel with Coomassie blue to confirm that each vaccine 
preparation had an identical concentration of tlie His-pl7-Pk and, in the case of the 
vaccines composed of pl7-MAb-LTB, LTB-Pk (Fig.30).
All mice were immunised three times intraperitoneally, on days 0, 14 and 37.
Ten days after the second and third immunisations, the mice were bled and the sera 
examined for antibodies specific for His-pl7-Pk, and a control antigen, ovalbumin. 
Antigen-specific antibodies were again detected by the ECL-immune assay, described 
previously. An example of the assay is shown in Fig.31, the antibody titres to His-pl7-Pk 
after two and three immunisations with the appropriate vaccines, presented in Table 3, 
columns I & 2, respectively.
With the exception of soluble His-pl7-Pk all the vaccines investigated were 
capable of eliciting anti-His-pl7-Pk specific antibodies, the level of immunity increasing 
with each consecutive immunisation (Table 3, compare columns 1 and 2). None of the 
mice in Group A responded to His-pl7-Pk, demonstrating that, on its own, the purified 
recombinant protein is not immunogenic. However, when His-pl7-Pk was administered 
in the presence of alum (Group B), the adjuvant enhanced the immune response to the 
recombinant protein, though the antigen-specific antibody titres obtained varied
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Figure 30. Comparative analysis of His-pl7-Pk-based vaccine formulations.
All vaccine formulations were made up to a final volume of 200pl with PBS and BOpl removed for analysis. The samples were electrophorised through a 15% (w/v) SDS-polyacrylamide gel and the protein concentrations estimated by staining the gel with Coomassie blue.
Lane 1: soluble His-pl7-Pk; lane 2: His-pl7-Ht adsorbed onto alum; lane 3: His-pl7-Pk conjugated to MAb SV5-P-k (pl7-MAb); lane 4: pl7-MAb adsorbed onto alum; lane 5: pl7-MAb linked to LTB-Pk (pi7-MAb-LTB); lane 6: pl7-MAb-LTB adsorbed onto alum.
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remarkaWy within the vaccination group. Similariy, the immunogenicity of His-pl7-Pk 
could be enhanced by presenting the recombinant protein to the immune system as part of 
an immune ccmiplex either alone (Group C) or after adsorption onto alum (Group D). 
Having said this, it was evident that pl7-MAb complexes were far less immunogenic on 
their own, than when administered with alum, with one mouse in Group C having no 
detectable serum immunity specific for His-pl7-Pk even after three immunisations with 
pl7-MAb.
Examination of the sera fiom mice vaccinated with pl7-MAb-LTB complexes 
(Group E) for antibodies reactive with His-pl7-Pk, revealed immunisation with pl7- 
MAb-LTB complexes alone resulted in an approximately 4-8 fold enhancement in the 
immune response to His-pl7-Pk, in comparison to the immunity induced following 
vaccination with soluble pl7-MAb. Furthermore, the level of immunity detectable was 
relatively consistent throughout the mice of Group E. Adsorption of pl7-MAb-LTB 
complexes (Group F) onto alum resulted in minor enhancement (2-fold) in the 
immunogenicity of pl7-MAb-LTB complexes.
When the immune sera from each mouse was re-assayed for antibodies 
specific for LTB-Pk (using the ECL-based immune assay and purified LTB-Pk as the 
solid-phase target antigen), only the mice in Groups E and F, demonstrated an antibody- 
specific response to the recombinant enterotoxin subunit On average, the level of 
immunity directed at LTB-Pk was 6-8 fold higher than the response to the His-pl7-Pk 
component of the vaccine, this being particularly noticeable when pl7-MAb-LTB 
complexes were administered along with alum (data not shown). This bias of the immune 
system in favouring the induction of immunity to the LTB moiety of LTB-conjugates, has 
been demonstrated by others [Schodel et al., 1990]. Examination of the immune sera for 
andbodies specific for the Pk-epitope, also demonstrated that very little of the immune 
response was directed at this determinant (data not shown) which supports the previous 
findings that the Pk-epitope is a poor systemic immunogen.
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SV5-P-k
pl7
pl7 ads. alum
pl7-MAb 101112
13pl7-MAb 14ads. alum 15
16
17
pi 7-MAb-LTB 1819
20
21pl7-MAb-LTB 7,2ads. alum 23
24
(a) His-pl7-Pk (b) Control antigen
»
a ê e  # » # # #•  •  •
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Figure 31. Induction of systemic immunity to His-pI7-Pk
Groups of four Balb/c mice were immunized three times with soluble His-pl7-k (pl7), His-pl7-Pk adsorbed onto alum (pl7 ads. alum)3üs-p 17-Pk conjugated to MAb SV5-P-k (pl7-MAb), pl7-MAb adsorbed onto alum(pl7-MAb ads. alum), pl7-MAb linked to LTB-Pk (p 17-MAb-LTB) or pl7-MAl>LTB adsorbed onto alum (pi7-MAb-LTB ads. alum). All mice were immunized with the equivalent of l|ig of His-pl7-Pk for each vaccine formulation. Antibodies specific for His-pl7-Pk or a control antigen, ovalbumin, were measured using an ECL-based immune assay.The sera were diluted 1:100 and from this starting dilution, serial diluted 1:2 in the wells of a terasaki plate. The dilutions were then incubated with nitrocellulose filters that had been pre-coated with either purified His-pl7-Pk or ovalbumin. Bound antibody was detected with an HRP-conjugated anti-mouse Ig antibody, ECL and autoradiography.
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Tlius, linkage of His-pl7"Pk to LTB-Pk by way of a Pk-specific antilxidy bridge, 
can help potentiate the immune response to the recombinant SIV protein. Furthermore, the 
potency of pi 7-MAb-LTB complexes in the absence of alum, indicate that the presence of 
LTB-Pk in pl7-MAb-LTB complexes may bypass the need for additional ^juvants.
E,3, Chmrmterisation o f the antibody response to His-piy^Pk and 
L T B -P k .
Different isotypes of antibcxlies exist, each having its own particular 
immunological role in host defence. The murine IgG^  ^isotype is an antibody that is 
thought to play a crucial role in the protection against viral infection [Coutlier et al.. 1987]. 
It was of interest to investigate whether conjugation of His-pl7-Pk to LTB-Pk helped 
modulate the antibody response to the recombinant SIV protein.
Sera from each mouse in a vaccination group were incubated with His-pl7-Pk- 
coated nitrocellulose sheets and bound antilx>dies were classified into Protein A-binding 
[Protein A (Pr.A) preferentially interacts with murine antibodies of the IgG^a, IgG^y and 
IgGg subclasses] and non-Pr. A binding antibcxiies (usually antibodies of the IgGj 
subclass) by detecting bound antibody with HRP-conjugated Pr. A.
None of the mice from vaccination Groups A-D had anti-His-pl7-Pk specific 
antibodies of an isotype that was recognised by HRP-conjugated Pr. A (Table 3, column
3). Thus, in these experiments, and in contrast to the results of Randall et al.. 1994, 
immunisation with His-pl7-Pk or pl7-MAb complexes in the presence or absence of 
alum, did not induce detectable levels of anti-recombinant SIV antibodies of the IgG^a, 
IgG2b or IgGa subclasses. In contrast to this finding, immunisation with pl7-MAb-LTB 
did induce anti-His-pl7-Pk and LTB-Pk-specific antilxdies of an isotype detectable with 
the Pr. A conjugate. Similarly, when the sera from vaccinated mice were assayed for Pr.A 
binding and non-binding antibodies specific for LTB-Pk, the sera from mice vaccinated 
with pi 7-MAb-LTB complexes alone or in the presence of alum, contained very high 
levels of Pr-A binding antibcdies (data not shown).
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These results suggest that conjugation of His-pl7-Pk to LTB-Pk via MAb SV5- 
P-k can enhance the immune response to the recombinant SIV protein, but also, that LTB- 
Pk helps modulate the isotype of the antibody response to His-pl7-Pk.
E A, p l7 ’>MAb'’LTB complexes prime the immune system to SIV.
The previous assays relied on tlie recognition of the recombinant SIV protein, 
His-pl7-Pk, by antigen-specific sera as an assessment of each vaccines potential to induce 
immunity to SIV.
To determine whether vaccination with either His-pl7-Pk, pl7-MAb or pl7- 
MAb-LTB alone or after adsoiption onto alum led to serum antibodies that could recognise 
pl7 from an SIV infected cell, the sera within each vaccination group was pooled and 
reacted in Western blots with viral proteins from SIV-infected cells. Briefly, proteins 
present in the lysate of an SIV infected cell were separated on a 15% (wA^ ) SDS- 
polyaoylamide gel and the denatured proteins electroblotted onto nitrocellulose. The 
nitrocellulose was cut into 0.5cm x 7cm strips, and individual strips were incubated with a 
1:800 dilution of pooled sera from each vaccination group or with control sera from non­
immunised mice. Bound antibodies were detected by autoradiography after incubating of 
the strips with an HRP-conjugated anti-mouse Ig, followed by ECL buffers and 
autoradiography (Fig. 32).
Using this method, no antibodies could be detected in the sera of control mice 
(lane 1) or mice immunised with His-pl7-Pk (lane 2), or pl7-MAb (lane 4), the last 
finding being rather surprising since immunisation with pl7-MAb stimulated an antibody 
response specific for His-pl7-Pk. The sera from mice immunised with His-pl7-Pk in the 
presence of alum (lane 3), reacted only weakly with pl7. In contrast, sera from mice 
immunised either with pl7-MAb complexes adsorbed onto alum (lane 5) or pl7-MAb- 
LTB complexes alone (lane 6) or with alum (lane 7), specifically interacted with both pl7 
and its precusor molecule, p57. It was particularly interesting to note that the immune sera 
from mice vaccinated with pl7-MAb-LTB complexes gave a stronger response to the SIV 
proteins than immunisation with pl7-MAb complexes in the presence or absence of alum,
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Figure 32. Induction of immunity to pl7 from SIV-infected cell lysates.
Viral proteins from a SIV-infected cell lysate were separated through a 15% (w/v) SDS-polyacrylamide gel, then electroblotted onto a nitrocellulose filter and the filter cut into strips. The sera within each vaccination group (see below) was pooled and diluted 1:800, then incubated with the protein-coated nitrocellulose strips. As a control, sera from non-immunized mice was similarly treated. Bound antibodies were detected with an HRP-conjugated anti-mouse Ig antibody, ECL and autoradiography.Lane 1 represents control sera, lanes 2-7 represent sera from mice immunized three times with pl7 (lane 2), p i7 ads. alum (lane 3), pl7-MAb (lane 4), pl7-MAb ads. alum (lane 5), pl7-MAb-LTB (lane 6), or pl7-MAb-LTB ads. alum (lane 7).
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thereby supporting the previous observation that conjugation of pl7-MAb complexes to 
LTB-Pk may bypass the need for additional adjuvants to efficiently prime the immune 
system.
E.S. Induction celUmediated immunity to His-pI7-Pk by immunisation 
with p I7 ’>MAb‘-LTB complexes.
Lymphokines secreted from CD4+ T cells, are known to control in vivo 
immunoglobulin isotype selection [Finkelman et al.y 1990]. Since all naive B cells 
normally secrete IgM during primary antigenic stimulation, the presence of IgG antibodies 
to His-pl7-Pk and LTB-Pk following immunisation with pl7-MAb-LTB complexes, is an 
indication of the involvement of cell-mediated immunity in the generation of the antigen- 
specific B cell response to His-pl7-Pk and LTB-Pk.
To investigate whether immunisation with pl7-MAb-LTB complexes led to 
efficient priming of the cell-mediated immune system and tlie generation of His-pl7-Pk 
and LTB-Pk-specific T cells, the lymphocytes from mice immunised three times 
intraperitoneally, as described above, were examined in lymphocyte proliferation assays 
for their ability to respond to specific stimulation with His-pl7-Pk or LTB-Pk six months 
after the final immunisation. For comparison, the lymphocytes from mice that had been 
immunised with His-pl7-Pk or pl7-MAb, in the presence or absence of alum, were 
similarly analysed. The spleens from two mice in each vaccination group, or from non­
immunised control mice, were removed and single-cell suspensions prepared. lOOpl 
samples of the unfractionated splenocyte suspension at a concentration of approximately 
10  ^cells/ml, were then added to the wells of a 96-well plate, and stimulated in vitro for 5 
days at 3TCI5% CO2 with purified His-pl7-Pk or ammonium sulphate-purified LTB-Pk 
at the concentrations shown in the legends of Figs. 33(a) & (b). As positive and negative 
controls, the cells were also cultured with medium alone or 2pg/ml phytohaemagglutinin 
(PHA, a well-known T cell mitogen), respectively. During the final 18 hours of the 
stimulation, O.SfxCi pH]-thymidine was added to each well in the assay and after 
harvesting the cells onto glass fibre filters, the proportion of pH]-thymidine incorporated
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into the DNA of proliferating cells was determined in a (^-scintillation counting [Fig. 
33(a)]. The assay was performed in triplicate and the data is presented as counts per 
minute (cpm) ±  standard error of mean (SEM).
The immune ceUs from each vaccination group and naive cells showed an 
enhanced response following mitogenic stimulation with PHA (see legend of Fig.33). 
Furthermore, there was no evidence the lymphocytes from immunised or control mice 
proliferated non-specifically when cultured in medium alone (see legend of Fig.33). Upon 
stimulation with His-pl7-Pk, the greatest proliferative response occurred with immune 
cells recovered from mice immunisW intr^eritoneally with either pl7-MAb-LTB or p i7- 
MAb-LTB adsorbed onto alum, there Wing little difference in the antigen-specific 
response between the two vaccination groups.
In contrast to this finding, the immune cells from mice vaccinated with purified 
His-pl7-Pk or pl7-MAb complexes showed an enhanced immune response to the 
recombinant SIV protein, if the purified protein or immune complexes had been adsorbed 
onto alum prior to administration, though the actual response was evidently lower than the 
proliferative response demonstrated by the primed lymphocytes from mice vaccinated with 
pl7-MAb-LTB complexes. In all cases, the response to His-pl7-Pk was highly specific, 
since lymphocytes from naive, non-immunised mice failed to proliferate upon stimulation 
with the recombinant SIV protein.
Enhanced proliferative responses were also evident when primed cells from pl7- 
MAb-LTB immunised mice were challenged in vitro with LTB-Pk [Fig.33 (b)]. Once 
again, adsorption of the complex onto alum only had minor effects on the proliferative 
response to LTB-Pk. None of the mice immunised with purified His-pl7~Pk or pl7-MAb 
with or without alum, nor naive mice, proliferated in response to stimulation with LTB- 
Pk. Thus the proliferative response seen for primed cells from pl7-MAb-LTB vaccinated 
mice was highly specific and not due to the ammonium sulphate precipitated LTB-Pk non- 
specifically stimulating the lymphocytes.
These results suggest that immunisation with pl7-MAb-LTB complexes may 
efficiently prime the cell-mediated immune system to His-pl7-Pk and LTB-Pk. In
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addition, since the assay was performed six months after the final immunisation, the 
evidence presented here implies that parental administration of pl7-MAb-LTB complexes 
may lead to the induction of long-term memory cells specific for both His-pl7-Pk and 
LTB-PL
E,4. FACscan and cytokine analysis o f the proliferating cell type.
Mixed lymphocyte proliferation assays, are normally a reflection on the response of 
T cells (usually €04*^ T cells) to antigen-specific stimulation. In an attempt to establish 
whether the lymphocyte population fiom the unfractionated splenic cultures that responded 
to stimulation with His-pl7-Pk was indeed CD4+ T cells and not B cells, the proliferation 
assay was repeated and the ratio of cells bearing membrane immunoglobulin or murine 
CD4 molecules, before and after stimulation, was examined in immunofluorescence 
assays.
Single-cell suspensions were prepared fiom the spleens of vaccinated mice, then 
added to the wells of a 24-well cultuie plate in 1ml volumes, at a concentration of 
apprexiimtely 10^  cells/ml. The cells were then stimulated in vitro for five days with an 
4{ig/ml purified His-pl7-Pk at 3>TCJ5% CO2. The remaining cells not used in the 
proliferation assay, were retained to examine tlie ratio of B cells to CD4+ T cells in the 
spleens of vaccinated mice prior to antigen-specific stimulation. After a five day culture 
period, the cells were gently harvested for phenotypic analysis. The ratio of B cells to 
CD4+ T cells prior to, and after, antigen-specific stimulation was determined by directly 
staining the unfractionated lymphocyte populations with fluorescein isothiocyanate 
(H rC)-labeUed antibodies specific for murine Igs or CD4 molecules, respectively, and 
calculating the percentage of fluorescent cells in 10,000 events using the LYS YS program 
of a Becton Dickson FACscan. An example of the FACscan result is shown in Fig 34. 
Panels (a) and (b).
In unstimulated spleens, the ratio of B cells to (D4+ T cells in the mixed 
lymphocyte culture, was approximately 45:40, irrespective of the vaccination group 
studied, which is consistent with the normal ratio of lymphocytes populating the spleen
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[see * Practical hnmunology'] [Fig. 34, Panel (a)]. However, after stimulation with His- 
pl7-Pk, the proportion of cells detected with FTTC-labelled anti-mouse Ig antibody to the 
proportion detectable with FTTC-labelled anti-murine CD4 antibody, was approximately 
4:70 [Fig. 34, Panel (b)]. These results suggest that following a five day stimulation with 
His-pl7-Pk, CD4+ T cells predominate.
In a further attempt to characterise the responding cell population in the 
proliferation assay, the culture supernatant at the end of the stimulation period was 
analysed for tlie presence of T cell secreted lymphokines using cytokine-ELISA assays.
Immune cells derived from the spleens of mice vaccinated with pl7-MAb 
complexes in the presence of alum or p 17-MAb-LTB complexes alone or after adsorption 
of the complexes onto alum, were stimulated in vitro for five days with medium alone, 
2pg/ml PHA or 4p.g/ml of His-pl7-Pk (as described above), and at the end of the culture 
period, the supernatant from each culture was examined for IL-2, IL-5 and IFN-y, using 
cytokine-ELIS A assays (kindly provided by Dr. A. Mowat, Glasgow University). The 
reason for only examining the cells from these tliree vaccination groups was due to the fact 
that the anti-cytoîdne antibodies used in the assays were both extremely expensive and in 
limited quantities, tlius it was felt that it would be more pmdent to only analysis the three 
vaccination gioups that had exhibited the highest proliferative response to His-pl7-Pk.
High protein-binding 96-well microtitre plates were pre-coated with anti-IL-2, 
IL-5 and XFN-yantilxKlies for 18 hours at 4®C. 50pl of the culture supernatants recovered 
after a five day stimulation period in vitro, was added to the first wells in a row and then 
double-diluted along the row. To measure cytokine levels in unstimulated and mitogen 
stimulated cultures, the supernatant from lymphocytes stimulated with medium alone or 
PHA were also included in the assay. After a three-hour incubation at 37®C, the presence 
of EL-2, IL-5 and EFN-y was detected with a biotin-conjugated anti-IL-2, EL-5 and BFN-y 
antibcdies, followed by extravidin-peroxidase then TMB substrate, and the adsorbance at 
630nm measured. The cytokine concentrations in the test supernatants were quantitated by 
reference to a standard curve constructed using serial dilutions of the standard cytokines.
The level of EL-2 detected in the culture supernatant after a five day specific
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Lymphocytes stained with
Anti-Ig Anti-CD4
(a)
10®
(b)
10®
Figure 34. FACscan analysis of HiS“pl7-Pk stimulated cells.The figure shows an example of the phenotypic analysis of the immune cells from p 17-MAb-LTB vaccinated mice, prior to [Panel (a)] and after [Panel (b)] a five day 
stimulation in vitro with His-pl7-Pk. The proportion of B cells and CD4+ T cells in an unfractionated population of immune spleen cells was determined by staining the cells with FTTC-labelled anti-murine Ig or CD4 antibodies. Positive fluoresence is shown on the right hand side of each graph.
stimulation period was negligible for each vaccination group studied (Table 4) and was 
well below background levels of DL-2 from unstimulated cultures. Similarly, when the 
amount of IL-5 was quantitated for each culture, although immune cells from all 
vaccinated mice were shown to secrete the cytokine, the actual values obtained were small,
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even in PHA stimulated cultures. This minimal detection of BL-5 in the late stages of 
specific stimulation has t ^ n  observed by others [Wilson etaL, 1991]. Examination of the 
cultures for IFN-y proved illuminating. Although antigen-specific stimulation of immune 
cells fiom mice vaccinated with pl7-MAb complexes in association with alum resulted in 
detectable IFN-y levels in the culture supernatant, the actual cytokine level was less than 
non-specific prWuction of IFN-yfrom unstimulated cultures. In contrast, stimulation of 
lymphocytes fiom mice vaccinated with p 17-MAb-LTB complexes, demonstrated high 
levels of IFN-ypioduction, particularly if the complexes were administered in the 
presence of alum.
These results suggest that the presence of LTB-Pk in the vaccine formulation may lead to 
the priming of cells that are capable of secreting IFN-y.
SECTION Fo Mucosal lîîimunogeîîlcity of Partially Purified 
pl7«MAb»LTB complexes.
F .l. Imtroduciion^
The success of soluble p 17-MAb-LTB complexes in inducing systemic immunity to 
His-pl7-Pk and viral proteins from SIV infected cells, led to the investigation as to whether 
such complexes were also capable of stimulating mucosal and/or systemic immunity to the 
recombinant SIV antigen, following intranasal immunisation. In Section F of the results, the 
findings of these preliminary mucosal immunisation studies are presented.
F.2. LTB-Pk does not potentiate the immune response to His-pl7->Pk 
follomng intranasal immunisation.
To determine whether p 17-MAb-LTB complexes were immunogenic by the mucosal 
route, a series of intranasal immunisation studies were conducted, p 17-MAb-LTB complexes 
were constructed as before, and their efficacy compared with purified His-pl7-Pk, pl7-MAb 
and His-pl7-Pk co administered with (but not coupled to) LTB-Pk (pl7/LTB). This latter
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vaccine was included in the studies to determine the relevant importance of the p 17-MAb-LTB 
linkage, as a means of potentiating the response to His-pl7-Pk.
Groups of four Balb/c mice, aged 10-12 weeks, were gently anaesthetised and the 
vaccines, containing the equivalent of Ipg of His-pl7-Pk (and where appropriate, Ipg LTB- 
Pk), were administered intranasally in a final volume of 50p,l. All mice were vaccinated three 
times at two week intervals and the immunogenicity of each vaccine was determined by 
analysing the sera ten days after the third immunisation for antibodies to His-pl7-Pk, LTB-Pk 
or a contix)! antigen, ovalbumin, using an ECL-based immune assay (Fig.35). The antibody 
titres to the His-pl7-Pk and LTB-Pk are shown in Table 5.
Examination of the sera from non-immune control mice, revealed no detectable serum 
antibodies specific for any of the test antigens. When the sera from mice immunised with His- 
pl7-Pk (Group A), pl7/LTB (Group B), pl7-MAb (Group C) or pl7-MAb-LTB (Group D) 
were assayed for antibodies to His-pl7-Pk, no serum immunity to His-pl7-Pk was 
detectable. Examination of the sera from each vaccinated mouse for immunity to LTB-Pk, 
demonstrated that only the mice in Groups B and D contained serum antibcxlies specific for 
LTB-Pk, there being little difference in the LTB-Pk-specific antibody titres between the two 
groups. In addition, none of the mice exhibited detectable antibody responses to the control 
antigen (data not shown).
To investigate whether the vaccines induced mucosal immunity to His-pl7-Pk and/or 
LTB-Pk, the saliva from each vaccinated mouse was examined for His-pl7-Pk- and LTB-Pk- 
specific IgA antibodies, fourteen days after the third immunisation. As a control, saliva from 
non-immunised mice were also assayed. Analogous to the findings of the serum analysis, no 
antibodies specific for His-pl7-Pk were detectable in the saliva of vaccinated mice (Fig. 36, 
Table 6). However, when the saliva was assayed for immunity to LTB-Pk, the mice that were 
immunised with eitha* pl7/LTB or p 17-MAb-LTB were shown to contain IgA antibodies- 
specific for LTB-Pk.
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Figure 35 and Table 5. Serum antibody responses to His-pl7-Pk and LTB-Pk following intranasal immunization.
Groups of four Balb/c mice were immunized intranasally with His-pl7-Pk alone; co-administered with LTB-Pk (P17/LTB); His-pl7-Pk conjugated to MAb SV5-P-k (pl7-MAb); or pl7-MAb linked to LTB-Pk (pl7-MAb-LTB), three times. Ten days after the third immunization the sera was assayed for total antibody levels to His-pl7-Pk or LTB-Pk, using an ECL-based immune assay. The sera were diluted 1:50 and from this starting dilution, serially diluted 1:2. Bound antibody was detected with an HRP-conjugated anti-mouse immunoglobulin.N.B. only two mice remained after the third immunization with p 17-MAb-LTB, the other two mice died due to an adverse reaction to the anaesthetic.
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Figure 35.
(a) His-pl7-Pk (b) LTB-Pk
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pl7-Ab-LTB 1314
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pl7/LTB
SVS-P-k
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control Ab
pl7-Ab-LTB
# # # #
# #  #
Table 5.
Vaccine Mousenumber
Antibodies to 
His.pl7-Pk LTB.Pk
Group A His.pl7.Pk
1234
^ 0^ 0^ 0^ 0
^ 0^ 0^ 0^ 0
5 ^ 0 25600
Group B pl7/LTB 6 ^ 0 256007 ^ 0 12800g ^ 0 25600
9 ^ 0 ^ 0
Group C pl7.MAb 10 ^ 0 ^ 011 ^ 0 ^ 012 ^ 0 ^ 0
Group D pI7-MAbLTB 1314
^ 0^ 0 1280025600
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Figure 36 and Table 6. Antibodies to His-pl7-Pk and LTB-Pk in the saliva of intranasally vaccinated mice.
Groups of four mice were immunised intranasally three times with the vaccines shown, and fourteen days after the third immunisation the saliva from immunised mice or non-immunised control mice, were collected and assayed for antibodies to His-pl7-Pk, LTB-Pk or a control antigen, ovalbumin, using ECL-based immune assays. The saliva was diluted 1:50 and from this starting dilution, serially diluted 1:2 in the wells of a tersaki plate. The dilutions were then incubated with nitrocellulose filters pre-coated with the appropriate antigen. Bound antibody was detected with a goat anti-mouse IgA antibody, followed by an HRP-conjugated anti-goat Ig, ECL and autoradiography. The antibody titres are tabulated in Table 6. N.B. Only two mice remained following three immunisations with p 17-MAb-LTB, since two died due to an adverse reaction to the anaesthetic.
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Figure 36.
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Table 6.
V accm e Mousenumber
Antibodies to 
His-pl7-Pk LTB-Pk
Group A HiS“pl7»Pk
1234
^ 0  ^ 0  ^ 0  ^ 0  ^ 0  ^ 0  ^ 0  ^ 0
Group B pl7/LTB
56 1 8
9101112
1314
^ 0  400 ^ 0  400 ^ 0  400 ^ 0  400
Group C pl7»MAb
^ 0  ^ 0  ^ 0  ^ 0  ^ 0  <50 ^ 0  ^ 0
Group D p 17-MAb-LTB ^ 0  1600 ^ 0  1600
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F.3. JnstabiUty o f  His-pl7-Pk in saliva.
One possibility for the failure of the vaccines described in Section F.2 to induce 
immunity to His-pl7-Pk following inti’anasal immunisation, was that His-pl7-Pk may 
undergo mpid degradation upon exposure to the protease-rich mucosal environment. This 
hypotliesis was tested by analysing the stability of His-pl7-Pk in saliva, an example of a 
protease-rich mucosal secretion.
Purified His-pl7-Pk at a concentration of 2 or 4pg was mixed with saliva (12% v/v) 
and the solution was incubated at 37°C. At the times indicated in the legend of Figure, a ISpl 
sample was removed and mixed with an appropriate volume of 4X disruption buffer. As a 
control, 2 or 4pg purified His-pl7-Pk was incubated with PBS (12% v/v) at 37°C for the full 
40 minute incubation period. All samples were electrophoresed through a 15% (w/v) SDS- 
polyacrylamide gel, and the stability of His-pl7-Pk determined by staining the gel with 
Coomassie blue and comparing the quantity of His-pl7-Pk present in control cultures, with 
the amount remaining after a 10,20, and 40 minute exposure to saliva (Fig. 37).
A strong band representing His-pl7-Pk was detectable in the control cultures that had 
been incubated for 40 minutes at 37°C with PBS alone (lanes 2 & 6). Thus, at this 
temperature, His-pl7-Pk was not susceptible to breakdown in the absence of protease activity. 
However, upon exposure to salivai proteases, His-pl7-Pk was rapidly degraded (lanes 3-5 & 
7-9), this being more evident at lower His-pl7-Pk concentrations. Therefore it is a strong 
possibility that the failure of the His-pl7-Pk containing vaccines to prime the mucosal and 
systemic immune systems after intranasal immunisation, was due to rapid degradation by 
mucosal proteases of the His-pl7-Pk component in the experimental vaccines.
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Figure 37. Instability of His-pl7-Pk in saliva.
2pg or 4pg of purified His-pl7-Pk in 15pl of PBS (lanes 2-5 and 6-9 respectively), were incubated with either 2pl of saliva (lanes 3-5 and 7-9) or 2pl of PBS Qanes 2 & 6) at 37®C for 10 minutes (lanes 3 & 7), 20 minutes (lanes 4 & 8) or 40 minutes (lanes 2, 5,6 & 9). The polypeptides present in these samples were separated by electrophoresis through a 15% SDS-polyacrylamide gel, then stained with Coomassie blue.Lane 1 shows an example of the proteins detectable in a 2pl sample of saliva.
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SECTION G. Mucosal Immunogenicity of Partially Purified 
p27-MAb-LTB complexes.
G .i. Imtmduciion,
Section G of the results, describes tlie finding that His-p27-Pk is more 
resistant to degradation in saliva, and that p27-MAb-LTB complexes induce systemic and 
mucosal immunity to His-p27-Pk.
G.2, Resistance o f HiS’-p27-Fk to saliva! degradation.
The susceptibility of His-pl7-Pk to degradation by salivai proteases led to the 
search for a suitable recombinant SIV antigen that was more resilient to mucosal degradation. 
His-p27-Pk, like His-pl7-Pk, is a recombinant gag gene product that is expressed in 
moderately high quantities in Exoli (approximately 700pg/litie) and can be purified from cell 
lysates by nickel affinity chromatography. Thus, it was of interest to establish whether His- 
p27-Pk could resist rapid destruction by mucosal proteases and therefore, increase the 
potential of using bivalent immune complexes containing His-p27-Pk on one arm of MAb 
SY5-P-k and LTB-Pk on the other arm, as mucosal immunogens.
l.Spg of purified His-p27-Pk was mixed with saliva (12% v/v) and incubated at 
37°C. 15pl samples of the protein/salival solution were removed after 10,20,40,60 and 120 
minutes incubation and mixed with an appropriate volume of 4X disruption buffer. As a 
control, l.Spg of His-p27-Pk was mixed with PBS (12% v/v) and incubated for 2 hours at 
37°C. Each of the prepared samples were subjected to SDS-PAGE and the polypeptide chains 
electroblotted onto nitrocellulose. The proportion of His-p27-Pk remaining after each time 
interval was estimated by an ECL-Westem blotting assay, using MAb S V5-P-k as the 
detection antibody (Fig. 38). The decision to monitor the stability of His-p27-Pk by Western 
blotting, as opposed to Coomassie blue staining, was due to the fact that the Western blotting 
assay would also deteimine if the Pk-epitope was proteolytically cleaved from His-p27-Pk in 
saliva. Such an outcome would obviously have serious implications on the feasibility of using 
complexes that rely on the linkage of recombinant Pk-bearing proteins to MAb
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SV5“P“k, as mucosal immunogens.
In the absence of salivai proteases (lane 1), His-p27-Pk was detected as a single 
band in the control sample that had been incubated at 37°C In contrast to this finding, 
following incubation of His-p27-Pk with saliva, both intact His-p27-Pk and a second protein, 
presumed to be a degi*aded product of the recombinant protein, were detectable by MAb SVS- 
P-k (lanes 3-6). However, it was evident by comparing the strengths of the His-p27-Pk bands 
after incubation with PBS and saliva, that even after a prolonged two hour incubation with 
saliva, the majority of His-p27-Pk remained undegraded. These findings suggest that His- 
p27-Pk may be relatively resistant to mucosal proteolysis.
To determine whether salivai proteases would impair the structural integrity of 
p27-MAb-LTB complexes, the stability of p27-MAb-LTB complexes (prepared in a similar 
fashion to that described for p 17-MAb-LTB complexes) following incubation with saliva, was 
investigated in immune precipitation assays. The equivalent of 1.5pg of p27-MAb-LTB 
complexes was incubated with saliva (12% v/v) at 37°C for two hours. As a control, 1.5(ig of 
p27-MAb-LTB complexes were mixed with PBS (12% v/v) and similarly incubated. The 
stability of the p27-MAb-LTB complexes following incubation with PBS or saliva, was 
determined by precipitating the complexes onto St. aureus and examining the precipitates for 
the presence of both His-p27-Pk and LTB-Pk, by Western blotting. As controls, His-p27-Pk 
and LTB-Pk were incubated with St.aureus alone, to determine whether the recombinant 
proteins could precipitate onto St.aureus in the absence of MAb SV5-P-k.
As shown in figure 39, neither His-p27-Pk nor LTB-Pk bound to St. aureus in the 
absence of MAb SV5-P-k (lanes 1&2, respectively). However, two bands representing 
the recombinant proteins were present in the precipitate from the control culture, 
demonstrating that p27-MAb-LTB complexes were not degraded following a two hour 
incubation in PBS at 37°C (lane 3). When the stability of p27-MAb-LTB complexes that had 
been incubated witli saliva were examined by Western blotting, it was evident that the whole 
complex remained intact and could be captured by St.aureus (lane 4).
Hence, p27-MAb-LTB complexes were resistant to degiadation by salivai 
proteases under the conditions described.
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Figure 38. Stability of His-p27-Pk in saliva
The stability of His-p27-Pk after exposure to salivai proteases was investigated in a Western blot assay. 1.5pg of His-p27-Pk in 15pl of PBS was incubated with either 2pl of PBS (lane 1) or 2pl of saliva (lanes 2-6) at 37®C for 10 minutes (lane 2), 20 minutes Gane 3), 40 minutes (lane 4), 60 minutes (lane 5) or 120 minutes (lanes 1 & 6). Samples were removed after the appropriate times and the proteins electroblotted onto nitrocellulose. The presence of His-p27-Pk was detected by probing the blot with MAb SV5-P-k followed by HRP-conjugated Protein A, ECL and autoradiography.Lane 7 represents a control sample of 2pl saliva that had been incubated at 37®C for 120 minutes.
1 2 3
His-p27-Pk
 LTB-Pk
Figure 39. Stability of p27-MAb-LTB complexes after exposure to salivai proteases. 
The stability of p27-MAb-LTB complexes was investigated in immune-precipitation assays. 1.5|ig of p27-MAb-LTB complexes in 15pl of PBS were incubated with either 2|il of PBS (lane 3) or 2pl of saliva (lane 4) for 2 hours at 37°C. The complexes were then mixed with St. aureus and the resulting precipitates analysed by Western blot assay for the presence of His-p27-Pk and LTB-Pk. As a control, His-p27-Pk (lane 1) and LTB-Pk (lane 2) were incubated with St.aureus , to determine whether the recombinant antigens were bound by St. aureus in the absence of the anti-Pk MAb.
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G.3, p27‘^ MÂb'’LTB complexes can induce mucosal and systemic immunity 
to the recombinant SIV  protein, follovnng intrmiasal inoculation.
On the basis of the evidence outlined in Section G.2., it was decided to 
investigate whether p27-MAb-LTB complexes were immunogenic following intranasal 
inoculation.
Eight Balb/c mice, aged 10-12 weeks, were gently anaesthetised with di-ethyl 
ether and the equivalent of 1.5pg of His-p27-Pk in p27-MAb-LTB complexes was 
administered into the nasal cavity, in a final volume of 75pl. All mice received two further 
immunisations of Ifig of p27-MAb-LTB in a final volume of 50pl at two week intervals. 
Ten days after the third immunization, the serum was analysed by ECL-based immune 
assays for immunity to His-p27-Pk-, LTB-Pk, GST-Pk or a control antigen, ovalbumin 
(Fig.40). The antibody titres to the respective antigens are shown in Table 7.
All mice i^eceiving intranasal doses of p27-MAb-LTB complexes contained 
circulating antibodies reactive with His-p27-Pk, although the actual antibody titres varied 
between immunised mice [Fig.40, Panel (a) & Table 7, column 1], High levels of serum 
antibodies specific for LTB-Pk were also detectable throughout the vaccination group, but 
in contrast to the variable immunity to His-p27-Pk, the antibody titres to LTB-Pk were 
relatively consistent [Fig. 40 Panel (b) & Table 7, column 2]. Very little of the immunity 
generated to His-p27-Pk and LTB-Pk was directed at the Pk-epitope [Fig. 40 Panel (c) & 
Table 7, column 3], and none of the mice contained antibodies to the control antigen [Fig. 
40 Panel (d)]. The sera from immunised mice were also tested for their ability to react with 
viral proteins in SIV-infected cell lysates, as described in the legend of Fig. 41. As a 
control, sera finom non-immunised mice was also included in the assay.
Examination of the resulting autoradiograph revealed that immune sera (lane 1), 
but not control sera (lane 2), reacted strongly with both p27 and its percursor molecule, 
p57.
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Antibodies in the sera
MouseDumber ms.p27.Pk
to
LTB-Pk GST-Pk
1 14580 ^3542940 602 540 ^3542940 603 1620 ^3542940 <204 1620 >3542940 <205 393660 >3542940 <20
6 4860 >3542940 <207 540 >3542940 <208 43740 >3542940 <20
Table 7, Antibody titres in the sera of mice intranasally immunized with p27-MAb-LTB complexes.
Table shows the total Mtibody titres to His-p27-Pk, LTB-Pk and GST-Pk in the sera of mice Balb/c mice following three intranasal inoculations with the equivalent of l|ig of His-p27-Pk in p27-MAb-LTB complexes. The sera was assayed 10 days after the third immunization (see Rgure 40).
p57 
p27
Figure 41. Induction of systemic immunity to SIV following intranasal immunization with p27-MAb-LTB complexes.The pooled sera from l»th mice immunized with p27-MAb-LTB complexes (lane 1) and non-immunized mice (lane 2) were incubated with nitrocellulose strips that had been pre-coated with viral proteins from an SIV-infected cell lysate. Bound antibodies were detected with an HRP-conjugated anti-mouse Ig, ECL and autoradiography.
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G,4, Analysis o f the mucosal response to HiS'^p27-Pk and LTB-Pk in 
vaccinated mice.
The presence of serum antibodies to p27 and LTB-Pk following intranasal 
administration of p27-MAb-LTB complexes suggests that the immune complexes were 
processed at the local mucosal level in the upper respiratory tract To establish whether the 
mucosal system was also primed to His-p27-Pk and LTB-Pk following intranasal 
vaccination with p27-MAb-LTB complexes, both the upper and lower respiratory tract 
were examined for evidence of an immune response to tlie i^ecombinant antigens.
(1) Measurement of secretory antibody.
To measure the level of specific-humoral immunity to His-p27-Pk and LTB-Pk 
in the upper respiratory tract, saliva was collected from pilocarpine treated mice, 11 days 
after the third intranasal immunisation. Saliva was serially diluted 1:2 from a starting 
dilution of 1:5 in the wells of a terasaM plate and then incubated with either His-p27-Pk 
LTB-Pk, or GST-Pk coated nitrocellulose sheets. As a control, saliva from non­
immunised mice were similarly treated. Antigen-specific antibodies were visualised upon 
autoradiography after incubating the sheets with goat anti-mouse IgA followed by an 
HRP-conjugated anti-goat Ig, exposure to ECL buffers and autoradiography (Fig. 42). 
The antibody titres to His-p27-Pk and LTB-Pk are shown in Table 8.
Following three intranasal immunisations with p27-MAb-LTB, all vaccinated 
mice contained anti-LTB-Pk antibodies in the saliva 11 days after immunisation (Column 
1), the actual titres varying from 20-320. In contrast to this finding, only minor levels of 
His-p27-Pk-specifrc antibcxiies were detectable in die saliva of two of the vaccinated mice 
(column 2). When the saliva was assayed for antibodies specific for the Pk-epitope, or a 
control antigen, no antigen-specific antibodies were detectable (data not shown).
(2) ELISPOT Analysis.
To further analyse the efficacy of intranasal administration of p27-MAb-LTB 
complexes to induce mucosal immunity to His-p27-Pk, the lungs from vaccinated mice 
were investigated for immunity to the recombinant antigens using an enzyme-linked 
immunospot (ELISPOT) assay. Such assays are particularly suitable for investigating
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Figure 42 and Table & Antibodies in the saliva of p27-MAb-LTB intranasally vaccinated mice specific for His-p27-Pk or LTB-Pk.
Eight Balbl/c mice were immunised intranasally at two week intervals with the equivalent of l^ig of His-p27-Pk in p27-MAb-LTB complexes. Eleven days after the third immunisation, the saliva was collected and assessed for His-p27-Pk and LTB-Pk-specific IgA antibodies as described in the legend of Fig. 40. The antibody titres are ^ven in Table 8.Please note that in this instance, the saliva was diluted 1:5 and from this starting dilution, serially diluted 1:2.
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Figure 42.
(a) His-p27-Pk (b) LTB-Pk
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Table 8.
Antibodies in Saliva 
to
His-p27-Pk LTB-PkMousenumber
1 <5 160
2 <5 80
3 <5 160
4 20 80
5 <5 320
6 20 160
7 <5 80
8 <5 20
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humoral immunity in tissues that are normally difficult to analyse e.g. Peyer's patches of 
tlie gut [Czeridnsky et al., 1983], and since they measuie specific antibody secretion at 
tlie single cell level, they are ultimately more sensitive than conventional ELISA's that 
measure specific antibodies in external secretions. Furthermore, with selective use of 
isotypically different detection antibodies in the assays, it is possible to monitor the 
isotype pattern of the antigen-specific antibody secreting cells.
Fourteen days after the third immunisation two mice were killed and their lungs 
extract^ To measure the difference in the level of anti-recombinant p27 antibodies 
secreting cells between peripheial and mucosal tissues following intranasal immunisation 
with p27 -MAb-LTB complexes, tlie spleens were also removed for analysis. For the 
lungs, tlie outer epithelial layer was removed by treatment with collagenase A and DNase 
I, and the cells liberated by straining the digested tissue through nylon mesh. Spleen cells 
were prepared as described in Methods. As controls, the lungs and spleens from non­
immunised, agW-matched Balb/c mice were similarly treated.
The cells were resuspended in ISCOVE's medium containing 10% FCS to give 
a concentration of approximately 10^  cells/ml. KXlpl of the cell suspension was added to 
the top wells of His-p27-Pk-coated 96-well microplates and four serial 1:4 dilutions in 
ISCOVE's medium were performed. The plates were incubated at 37°C, 5% CO2 in a 
humidified incubator for 18 hours to allow antibody secretion to occur. After the removal 
of cells, a 1:1(X)0 dilution of sheep anti-mouse IgM, IgG or IgA antibodies were added to 
the appropriate wells of replicate plates, followed by a 1:1000 dilution of an alkaline 
phosphatase goat anti-sheep streptavidin-conjugated antibody. Secreted and bound 
antibody was visualised as discrete spots, by the addition of alkaline phosphatase 
substrate to each well, and when the spots were fully developed, tlie wells were washed 
gently in distilled water to remove excess substrate. The number of antibody secreting 
cells (ASCs) of the particular isotype were determined by enumerating the number of 
spots present under a dissecting microscope (Table. 9).
His-p27-Pk-specific antibodies of all the major isotypes could be detected in the 
lungs of mice vaccinated three times intranasally with p27-MAb-LTB. Intriguingly, the
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predominant anti-His-p27-Pk antibody response was of the IgG isotype, tliough IgA 
antibodies specific for the recombinant SIV protein were also present in high numbers. In 
comparison, although the spleen of vaccinated mice also contained B cells actively 
secreting antibodies to His-p27-Pk, very few cells secreted antibodies of the IgA isotype, 
instead IgG secreting cells predominated.
Thus, intranasal administration of p27-MAb-LTB complexes can induce 
immunity to His-p27-Pk in the lungs of vaccinated mice.
G.5. Cell-mediated immune response.
Recent reports have suggested tliat, in contrast to popular belief, the mucosal 
immune system does exhibit memory [Vajdy and Lycke et al,, 1993]. To further 
investigate the efficacy of p27-MAb-LTB complexes as immunogens, the ability of the 
complexes to induce memory to His-p27-Pk and LTB-Pk was investigated.
Firstly, the spleens from intranasally vaccinated mice were recovered three 
months after the third intranasal vaccination and analysed for their ability to respond to 
specific antigenic challenge with purified His-p27-Pk and LTB-Pk in lymphocyte 
proliferation assays. As a control, tlie cells from non-immunised, aged-matched mice were 
similarly analysed. 10^  cells/ml were either added to the wells of a 96-well microtitre plate 
(lOOpJ per well), or to the wells of a 24-well micintitre plate (1ml per well). All cells were 
then stimulated in vitro witli medium alone, 2|Xg/ml PHA, purified His-p27-Pk or purified 
LTB-Pk (see Fig. legend for the concentrations of the recombinant antigens). The plates 
were incubated at 37°C, 5%C02 for five days in a humidified incubator and O.SpCi of 
[3H]-thymidine was added to each well of the 96-well microtitre plate for the last 18 hours 
of the stimulation. The cells in the 96-well plate were then harvested and the amount of 
-thymidine incorporated into the DNA of proliferating cells quantitated by a 
scintillation counting (Fig. 43). The cells in the 24-well culture plate, were gently 
haivested after a five day stimulation period with 2pg/ml PHA, 4pg/ml purified His-p27- 
Pk or O.Spg/ml LTB-Pk and retained for phenotypic analysis, as described in previously.
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Although all cells responded to mitogenic stimulation with PHA (see legend of 
Fig.43), neither immune cells or control cells responded with non-specific proliferation 
when cultured in medium alone (see legend of Fig.43). There was also no evidence that 
naive cells from non-immunised mice responded to stimulation with either His-p27-Pk or 
LTB-Pk- In contrast, a significant enhancement in the proliferative responses to the 
recombinant proteins was seen when immune cells from mice vaccinated intranasally three 
months previously with p27-MAb-LTB complexes, with maximum proliferation occurring 
after stimulation with 4pg/ml purified His-p27-Pk and 0.5pg/ml LTB-Pk,
To determine whether that the cells responding to His-p27-Pk and LTB-Pk 
were antigen-specific memory T cells, the immune cells in the 24-well plate that had been 
stimulated with 4pg/ml His-p27-Pk or 0.5{0.g/ml LTB-Pk were harvested and divided into 
three equal aliquots of 10  ^cells. One of the aliquots was then incubated with a 1:100 
dilution of FTTC-labelled anti-mouse Ig, the second aliquot with FTTC-labeUed anti­
murine CD4 and the third aliquot with FTTC-labelled anti-murine CD8. As a comparison, 
the cells that had been stimulated with PHA were similar labelled.
For immune lymphocytes stimulated with the PHA, only the CD8+ T cells and 
CD4+T cells were identified as responding to the T cell mitogen (Fig.44). Following a 
five day stimulation with 4}xg/ml of purified His-p27-Pk, both CD4+T cells and CD8+ T 
cells were detectable in the stimulated cultures. In contrast, only CD4+ T cells were 
detectable after stimulation with LTB-Pk, suggesting that intranasal administration of 
LTB-Pk specifically primes the CD4+ T cell subset For none of the antigen or mitogen 
stimulated cultures were B cells detectable in the assay after a five day stimulation period.
Secondly, two mice were given a fourth intranasal boost with 1.5pg of His- 
p27-Pk in p27-MAb-LTB complexes, three months after the third immunisation, and the 
sera was assayed for immunity to His-p27-Pk, LTB-Pk, GST-Pk or a control antigen. In 
botli instances, the mice were seen to respond with antiWdy titres to His-p27-Pk and 
LTB-Pk similar in magnitude to that seen following three intranasal immunisations (data 
not shown). This response was highly specific since no antibodies were detectable to 
either the Pk-epitope or the control antigen.
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ANTI Ig
L Y M PH O C Y TE S ST A IN E D  W ITH  
ANTI CD4
-iV—Tf-
A NTI CDS
T p  I E
PHA
stimulated
His-p27-Pk
stimulated
LTB-Pk
stimulated
Figure 44. FACscan analysis of recombinant PHA, p27 and LTB-Pk stimulated Immune cells.Immune cells from mice that had been intranasally immunised three times with p27- MAb-LTB complexes were stimulated in vitro with either PHA, His-p27-Pk or LTB- 
Pk for 5 days. The cells were recovered and the proportion of B cells, C D 4 ^  cells 
and CD8+ T cells present after stimulation with the respective antigens, was measured by FACscan using FTTC-labelled anti-murine Ig, CD4 or CD8 antilxxlies as the detection antibodies.
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Thus, these results suggest that intranasal administration of p27-MAb-LTB complexes can 
lead to anti-recombinant p27 and LTB-Pk memory B and T cells.
SECTION H, Systemic Immunogesilcity of Highly Purified p27- 
MAb»LTB Complexes.
H .Î. Introduction.
The development of an efficient purification protocol for LTB-Pk meant, towards 
the end of this work, that immunogenicity studies using highly purified SIV-MAb-LTB 
complexes could be performed. In this last section of the results, the initial findings on 
the ability of such purified complexes to induce humoral immunity to His-p27-Pk 
following parental immunisation are presented.
H.2. Purified p27‘>MAb-’LTB can prime the systemic immune system to 
S IV .
To determine the efficacy of purified SIV-MAb-LTB complexes as systemic 
immunogens, p27-MAb-LTB complexes were constructed as described previously but 
incorporating LTB-Pk that had been purified by ion-exchange chromatography. Groups of 
four Balb/c mice were immunised intraperitoneally with the equivalent of Ipg purified 
His-p27-Pk (Group A), purified His-p27-Pk co administered with Ipg purified LTB-Pk 
(Group B), p27-MAb (Group C) or p27-MAb-LTB (Group D). Each mouse was 
immunised three times on days 0,14 and 37 and 10 days after the second and third 
immunisations the sera was analysed for the total level of antilxxlies to His-p27-Pk, LTB- 
Pk, GST-Pk or a control antigen, ovalbumin, using the ECL-based immune assay. As 
before, prior to immunisation, a 30pl sample of each vaccine was removed and after 
electrophoresis through a 15% SDS-polyacrylamide gel, similiar concentrations of His- 
p27-Pk in each vaccine were verified by staining the gel with Coomassie blue (data not 
shown). Figure 45 shows the ECL-based result of antibody levels to His-p27-Pk and the
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control antigen after two and three immunisations, respectively. The full antibody titres to 
His-p27-Pk, LTB-Pk, and GST-Pk are presented in Table 10.
Examination of the sera for anti-His-p27-Pk antibodies revealed a significant 
difference in the immune response to the recombinant SIV protein between the different 
groups of mice. In contrast to the findings with puiified His-pl7-Pk in Section E.2, 
purified His-p27-Pk was immunogenic when administered alone, with maximum levels of 
immunity obtainable after three inoculations, though there was some evidence that 
complexing the recombinant protein to MAb S V5-P-k resulted in a decrease in the 
immunogenicity of His-p27-Pk (Table 10, columns 1 &2).
Intriguingly, immunisation with p27-MAb-LTB complexes resulted in an 
average 8-10-fold enhancement in the immune response to the recombinant SIV protein, 
compared to vaccination with puiified His-p27-Pk co administered with LTB-Pk. 
However, after three immunisations there was no significant difference in the antibody 
titres obtained fi*om immunising with p27/LTB, and p27-MAb-LTB. These results 
indicate that, although the overall level of humoral immunity to His-p27-Pk is similar in 
mice immunised with His-p27-Pk co administered with LTB-Pk and mice immunised 
with p27-MAb-LTB complexes, p27-MAb-LTB complexes are more efficient at priming 
the immune system since fewer vaccinations are needed for the complex to induce 
appreciable antibody titres to the recombinant SIV protein. Sera from immunised mice 
also reacted with p27 (and its precursor p57) present in the total lysate of SIV infected 
cells, the strength of the signals obtained suggesting that p27-MAb-LTB complexes were 
more efficient at stimulating anti-p27 immunity (Fig. 46).
Examination of the sera response to LTB-Pk revealed only the LTB-Pk vaccine 
constructs induced antibodies to the recombinant enterotoxin subunit (data not shown), 
and there was little difference in the antibody titres obtained following immunisation with 
p27/LTB and p27-MAb-LTB. When the sera was re-assayed against GST-Pk to determine 
the proportion of antibodies that were interacting with the Pk epitope, only vaccination 
with p27/LTB seemed to induce a response to the tag antigen (Table 10, column 4).
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Figures 45 (a) and (b). Antibody response to His-p27-Pk after Immunisation with purified p27-MAb-LTB complexes.Groups of four mice were immunised with the Ipg of punfied His-p27-Pk alone (p27), co-administered with Ipg purified LTB-Pk (p27/LTB), His-p27-Pk conjugated to MAb S V5-P-k (p27-MAb) or p27-MAb linked to LTB-Pk (p27-MAb-LTB). All mice were immunised three times and the sera assayed ten days after the second [Fig.45 (a)] and third (Fig.45 (b)] immunisations.For sera taken after the second immunisation, the sera was diluted 1:20 and from this starting dilution, serially diluted 1:2. For sera assayed after the third immunisation, the starting dilution was 1:100, then the sera was once again serially diluted 1:2. All sera were assayed against His-p27-Pk and a control antigen, ovalbumin using the ECL-based immune assay. Bound antibody was detected with an HRP-conjugated anti mouse Ig, ECL and autoradiography.
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Figure 46. Detection of antibodies to SIV p27 and p57
The sera within each vaccination group (see below) or control sera from non-immunized mice, were pooled, diluted 1:400 and then reacted with nitrocellulose strips that had benn pre-coated with viral proteins from an SIY-infected cell lysate. Bound antibodies were detected with an HRP-conjugated anti-mouse Ig antibody, ECL and autoradiography.Lane 1 represents control sera, lanes 2-5 represent sera from mice imunized three times with purified: p27 (lane 2); p27/LTB (lane 3); p27-MAb (lane 4) or p27-MAb-LTB (lane 5).
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DISCU SSIO N
1, Expression o f LTB-Pk,
A number of plasmid vectoi-s have been constructed that permit the insertion of 
DNA sequences at the C-terminus of the LTB gene [Sandkvist et al.  ^ 1987]. One such vector 
is pTRHlOlR, which encodes full length LTB with a short amino acid extension, containing 
five unique lestiiction sites, at the carboxyl terminus. A double stranded oligonucleotide 
sequence, encoding a 14-amino acid tag (Pk) was successfully inserted between the Hind HI 
and Spe I mstiiction sites, and the novel plasmid pTRH-Pk encoding LTB-Pk, was mobilised 
into botli Escherichia coll, and Vibrio 5p.60. Studies on the expression of LTB-Pk in either 
organism demonstrated that the recombinant enterotoxin subunit was under control of the 
inducible tac promoter, a hybrid trp~lac promoter [Bagadassarian et a/., 1983] and as such, 
LTB-Pk could only be expressed following induction with IPTG. One striking observation 
resulting from these expression studies was that LTB-Pk resided in two different cellular 
locations, depending on the host bacterium. In E.colU LTB-Pk was detectable by Western 
blot assays in the cellular lysates but not the extracellular fluid, suggesting LTB-Pk remained 
cell-associated in this organism. However, in Vibrio jp.60, although minor levels of LTB-Pk 
were present in the cellular fraction, the vast majority of LTB-Pk was secreted into the 
external milieu. Previous studies on the cellular location of LTB following expression in 
E.coli and Vibrio species has demonsti*ated a similar pathway of secretion to that of LTB-Pk, 
suggesting that the addition of the Pk-tag does not interfere with the normal translocation of 
LTB subunits. Further, since LTB-Pk was detected in Western blotting assays using anti-Pk 
MAb SV5-P-k as the detection antibody, this implies that; (1) the Pk-epitope is not removed 
prior to, or during export of LTB-Pk and, (2) the Pk-sequence is not structurally modified 
following expression in E.coli or Vibrio sp.&) since the epitope retains its antigenicity when 
coupled to the C-terminus of LTB.
Studies into the efficacy of E.coli and Vibrio sp.60 as expression systems for 
LTB-Pk, investigated the ideal conditions that promote maximal yields of LTB-Pk . In 
E.coli, maximal levels of LTB-Pk production occurred when the culture conditions were
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changed from 37°C to 30®C. However, the high level expression of LTB-Pk at this reduced 
temperature only occurred following induction with IPTG concentrations of l-0.5mM and 
there was an indication that LTB-Pk was inefficiently processed under these conditions; the 
detection of a second protein in the assay that had a slightly higher molecular weight than the 
LTB-Pk monomers, suggested that the N-lerminal signal sequence present on precursor 
molecules of LTB (and thus LTB-Pk) [Dallas and Falkow, 1980], was not efficiently cleaved 
to yield the mature protein. Enhanced expression of LTB-Pk in Vibrio sp. 60 could also he 
achieved by decreasing the temperature during induction, yet in contrast to E.coli, the level of 
LTB-Pk synthesis was consistent throughout an IPTG dose range of l-0.05mM. In addition, 
there was no evidence that LTB-Pk was susceptible to degradation following expression in 
Vibrio sp.60. These findings clearly demonstrate that Vibrio sp.60 is a more efficient 
expression system for LTB-Pk than E.coli, both in terms of stability of LTB-Pk and 
economy-wise, since reduced amounts of IPTG are necessary for maximal synthesis. Further 
support for the suitability of Vibrio sp.60 as an expression system for LTB-Pk, was provided 
by tlie evidence demonstrating that LTB-Pk was expressed at high levels in the Vibrio sp.60. 
Quantitative GMl-ELISA assays estimated that the amount of LTB-Pk detectable in the 
culture medium from IPTG-induced Vibrio sp.60 reached levels of 6 mg/litre after a 6 hour 
induction, increasing to 12 mg/Utre if the induction period was permitted to continue 
overnight. Vibrio species have previously fc^n investigated as expression systems for LTB- 
fusions [Amin and Hirst, 1994; Schodel etal., 1991]. However in those studies, there was a 
limitation to the length of time the induction could be performed, due to on-going proteolysis 
of the fused epitope. Such a finding was not demonstrable for LTB-Pk. This was first 
suggested when the level of LTB-Pk with anti-Pk reactivity in the extracellular medium was 
shown to markedly increase in correlation with increasing induction times and subsequently 
confinned in immune-precipitation assays, where all inducible protein was found to bind to 
Staphylococcus aureus in the presence, but not absence, of MAb S V5-P-k.
These results suggest that not only is Vibrio sp.60 a convenient expression 
system for LTB-Pk, but also the high level of expression and remarkable stability of LTB-Pk
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increases the recombinant enterotoxin subunit’s attractiveness as a component of novel 
vaccines.
2. ChamcÈerisution o f LTB-Pk.
Characterisation studies on LTB-Pk demonstrated that if LTB-Pk molecules were 
not exposed to heat-treatment prior to SDS-PAGE, LTB-Pk migrated with an apparent 
molecular weight of 45kD. However, when LTB-Pk was boiled prior to SDS-PAGE, the 
recombinant enterotoxin had a greater electrophoretic mobility, migrating with an apparent 
molecular weight of approximately 13.5 kD. These differential migration patterns showed that 
LTB-Pk is an heat-labile oligomer, similar to native LTB [Hardy et aL, 1988] and 
demonstrate that the presence of tlie Pk-addition does not interfere with subunit-subunit 
association. This observation was confirmed when heat-treated and untreated LTB-Pk were 
analysed by Western blot, where it was shown that MAb SV5-P-k could detect monomeric 
and oligomeric structures, respectively.
Fuither characterisation studies examined whetlier the presence of the Pk epitope 
influenced the ganglioside binding properties of LTB-Pk, the natural substrate for native LTB 
[Finkelstein and Clements, 1979]. Such studies demonstrated that LTB-Pk could efficiently 
bind to the glycolipid, GMl-ganglioside. These findings not only show that the Pk tag did 
not prevent binding of LTB to its glycolipid substrate, but also indicated that following 
binding, the interaction of the Pk-specific antiserum with the Pk-epitope of LTB-Pk was not 
inhibited. Thus the orientation of LTB-Pk once bound to GMl-ganglioside is such that the 
Pk-epitope is readily available for subsequent association with MAb S V5-P-k, and increases 
the chances that MAb SV5-P-k containing immune-complexes can be targeted to GMl- 
ganglioside through the affinity of LTB-Pk for the glycolipid. This was subsequently shown 
in GMl-ELISA assays, where SIV-MAb-LTB complexes could bind to the glycolipid, but 
SrV-MAb complexes could not.
It is interesting that these characterisation studies have demonstrated that a 14- 
amino acid sequence addition does not apparently interfere with the physiological properties 
of native LTB. Sandkvist and colleagues [1987] have shown that alterations to the carboxy
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terminus of LTB can severely inhibit both the pentamerisation and glycolipid-binding 
properties of LTB. The exact sequence requirements involved in this inhibition are unknown.
3. Concentration o f LTB-Pk,
Purification of recombinant antigens for subsequent use in vaccine formulations is 
highly ircqjorlant since, contaminating material may increase the toxicity of the vaccine as weU 
as induce adverse immunological reactions, e.g. hypersensitivity responses. The secretion of 
LTB-Pk from Vibrio sp.6Q is clearly an attractive attribute, since it means that there are fewer 
contaminants from which LTB-Pk has to be purified. This latter point is supported by SDS- 
PAGE analysis of Vibrio sp.60 culture supernatants, where LTB-Pk and another protein, of 
unknown function, are the major protein species detectable. However, the secretion of LTB- 
Pk entails that the protein has to be purified from large volumes of medium, thus necessitating 
that a preliminary concentration step be employed prior to the purification procedures. Early 
attempts to concentrate LTB-Pk from culture supernatants employed the traditional approach 
of ammonium sulphate precipitation. The minimum concentration of ammonium sulphate 
necessary to efficiently precipitate LTB-Pk was determined empirically, by observing the 
proportion of LTB-Pk precipitated from culture supernatants following the addition of 
ammonium sulphate to a saturation level of 80%, 60%, 50% or 40% (data not shown). From 
such observations, 50% salt saturation levels were selected and subsequently employed to 
concentrate LTB-Pk from small scale volumes (<200 ml) of culture medium. Although this 
strategy was quite successful at concentrating LTB-Pk, the exposure of the culture medium to 
ammonium sulphate resulted in cleavage of the Pk epitope. This was first suggested when 
unprecipitated and precipitated samples of LTB-Pk were analysed by SDS-PAGE, where it 
was shown that precipitated LTB-Pk had a greater electrophoretic motility than unprecipitated 
LTB-Pk. Confirmation that this difference in the migi ation of LTB-Pk was due to cleavage of 
the Pk-epitope was demonstrated by the failure of MAb SV5-P-k to detect precipitated LTB- 
Pk in Western blot assays. Preliminary attempts to preserve the LTB-Pk fusion by the 
addition of the metal-ion chelator, EDTA, were based on the observation that Vibrio sp.60 
secretes a metallo-like protease [Dr. T.R. Hirst, personal communication], and thus the
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presence of EDTA could potentially inhibit the protease activity. The fidelity of this strategy 
was vindicated when samples of precipitated LTB-Pk tliat had been dialysed against PBS- 
EDTA buffers, were assessed for the presence of full-length LTB-Pk in both Western blot 
and immune-precipitation assays. The earlier observations that LTB-Pk could be expressed, 
intact, in Vibrio sp.60 suggested that the Pk sequence did not contain a binding site for any 
Vibrio sp.60 secreted protease. Tims, the susceptibility of LTB-Pk to protease activity 
following exposure of the culture medium to ammonium sulphate was interesting. It is 
possible that the protease responsible for the cleavage of the Pk-epitope is a zymogen and 
becomes activated in the presence of ammonium sulphate. Alternatively, it is possible that 
ammonium sulphate caused a conformational change or partial unfolding of the LTB-Pk, to 
reveal the protease binding site, resulting in subsequent cleavage. In either case, the cleavage 
of the Pk-epitope highlights the problems of using ammonium sulphate to concentrate LTB- 
Pk, since it involves the inclusion of an additional chemical substance that may influence the 
efficacy of the final product. In addition, ammonium sulphate precipitation is not a feasible 
strategy for concentrating LTB-Pk fiom large volumes (over 1 litre) of culture medium, since 
it requires extensive quantities of the salt, and is extremely time consuming.
An alternative and more attractive procedure for concentrating LTB-Pk from culture 
medium was ultrafiltration using a GF15 dialysis membrane with a selective porosity of lOK. 
The principal advantages over ammonium sulphate precipitation being (1) there was no need 
to add an extraneous substance that subsequently had to be removed (2) the absence of 
ammonium sulphate could potentially preserve the LTB-Pk fusion bypassing the need for 
EDTA and (3) there was little limitation in the volume of culture medium that could be 
concentrated. Such procedures could be used to extensively concentrate LTB-Pk from culture 
volumes in excess of 4 litres, the removal of water and small molecules (<10K) was 
facilitated by recirculating the culture medium through the membrane under pressures of 5-10 
IbsAn .^ One interesting observation resulting from the SDS-PAGE analysis of ultrafiltrated 
LTB-Pk, was that, apart from LTB-Pk, there was only one other protein that could be 
concentrated to appreciable levels at the same time as LTB-Pk. This suggests that few 
proteins are constituitively secreted from Vibrio sp.60 and thus, supports the notion that
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selective secretion of LTB-Pk from Vibrio sp.60 could permit easier purification of LTB-Pk, 
since less protein contaminants have to be removed. Concentration of LTB by ultrafiltration 
using a cross-flow system and employing polyethersulphone membranes has previously been 
described [Amin and Hirst, 1994], the yield of LTB recovered from the membranes 
approaching 73%. In the ultrafiltration procedure described here, it was estimated that 85- 
90% of LTB-Pk was recovered from tlie membrane.
As well as concentiating LTB-Pk from culture supernatants, the GF15 dialysis 
membrane could be utilised to dialyse LTB-Pk in situ against the buffer of choice. Such 
versatility in the use of the GF15 dialysis membranes highlights tlieir attractiveness for 
incorporation into purification regimes in which the proteins have to be concentrated from 
large culture volumes prior to purification. In addition to the above advantages, GF15 
membranes are extremely economical since they are readily re-usable [personal observations].
4. Purification o f LTB-Pk,
LTB has been reported to be purified to homogeneity by direct application of 
clarified E.coli lysates to gel filtration columns containing galactose as a constituent of the gel 
matrix [Clements and Finkelstein, 1979; Clements et ah, 1990]. The purified protein can be 
subsequently eluted by application of 0.2M galactose to the gel filtration column. This 
association of LTB with the gel matrix is probably a reflection on the ganglioside binding 
properties of LTB, since LTB binds to gangliosides (and for that matter certain other sugars) 
through the lactose derivative, galactose [Sixma et ah, 1992]. Initial attempts to purify LTB- 
Pk using a sephadex G-25 column, the column described in the original assay, were 
unsuccessful. Although LTB-Pk was seen to bind to the column, the protein failed to elute 
following application of galactose (data not shown). Interestingly the authors who described 
the original protocol have also experienced problems in eluting LTB-fusion proteins from 
such columns [Clements, 1990], tlie reason for this was unclear. Purification of cholera toxin 
and LTB from culture supernatants of Vibrio species, has also been successfully achieved 
using GMl-ganglioside affinity columns [Tayot et ah, 1980 ]. Thus, other attempts to purify 
LTB-Pk were based on the affinity chromatography approach. In the absence of available
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GMl-ganglioside an anti-Pk MAb SV5-P-k-linked to sepharose 4B was used instead as the 
immunoaffinity resin. However, although LTB-Pk clearly interacted with the resin support, 
protein elution was only achievable after the application of extensively denaturating buffers 
containing urea, that resulted in both the dénaturation of LTB-Pk and the MAb S V5-P-k (data 
not shown). Such conditions not only necessitated that LTB-Pk had to be re-natured in vitro, 
but could also, potentially lead to the dénaturation of the Pk-fusion epitope or other epitopes 
on LTB-Pk that could be important for the enterotoxin's adjuvanticity. In addition, the 
degradation of MAb S V5-P-k during the elution step would mean that for each subsequent 
purifications, new immunoaffinity columns would have to be constructed, which would 
increase both the time and cost of the purification procedure. Elution of LTB from GMl- 
ganglioside immunoaffinity columns normally relies on extensive denaturing conditions and 
in pail, this is thought to be a reflection on the pentameric nature of LTB. It is possible that 
the five Pk-epitopes present on one pentamer of LTB-Pk, resulted in multiple interactions 
with the anti-Pk antibody, and thus making elution of LTB-Pk more difficult. In addition, 
LTB-Pk was observed to irreversibly associate with a variety of sepharose-based resins, even 
in the absence of MAb SV5-P-k, a finding that was not too surprising considering the high 
affinity LTB-Pk had for the G25-sephadex column, since both columns contain the galactose- 
derivative, agarose.
From the above findings it was thought that alternative, more conventional 
purification strategies that did not employ agarose-based resins, may be more successful at 
purifying LTB-Pk. One such alternative was hydrophobic interaction chromatography, a 
process that sepaiates biomolecules by their degree of hydrophobicity. The first hydrophobic 
column investigated was phenyl superose, which had previously been reported to 
successfully purify LTB to homogeneity from Vibrio sp.60 culture medium [Amin and Hirst, 
1994]. The elution of LTB from a resin that contains a strongly hydrophilic matrix like 
agarose, was surprising in light of the previous difficulties with such supports. It is possible 
that the attachment of the phenyl group to the carbohydrate hindered the interaction of the 
putative agarose-binding domain of LTB with the agarose-based support. If this was the case, 
it follows that only hydrophobic interactions would facilitate interaction of LTB-Pk with
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phenyl superose, and as such, elution of LTB-Pk from the column could potentially be 
achieved by conventional means. Ultrafiltrated preparations of LTB-Pk were shown to bind 
to tlie phenyl superose under high salt conditions, with the vast majority of the contaminating 
material, that failed to form sufficient hydrophobic interactions with the phenyl superose, 
being removed in the early stages of the purification. Application of a decreasing salt 
concentration resulted in LTB-Pk being eluted at salt levels of approximately 0.65M which is 
slightly higlier than the reported salt concentration for eluting LTB [Amin and Hirst, 1994]. 
However, unlike the losults of Amin and Hirst, LTB-Pk was not eluted as a homogeneous 
preparation. This was first demonstrated by the evidence of a slight 'bur' in the hydrophobic 
interaction chromatography profile and confirmed when eluted samples of LTB-Pk were 
examinW by SDS-PAGE. Having said this, the actual level of contamination was small. 
Apart from tire failure to completely purify LTB-Pk, there are additional drawbacks to the use 
of phenyl superose. For example, the columns are expensive and are normally only employed 
for the purification of small amounts of protein.
The results shown here suggested that an inexpensive alternative to phenyl superose, 
is the Macro-prep.® t-butyl hydrophobic support t-butyl is principally successful at 
purifying proteins tirat have intermediate to weakly hydrophobicity, and is chemically stable. 
Purification of LTB-Pk on this latter hydrophobic matrix, resulted in the same efficiency of 
purification as that of the phenyl superose-based purification. However, in both instances, 
hydrophobic interaction chromatography could not purify LTB-Pk completely from Vibrio 
sp.60 protein contaminants.
In contrast to these findings, application of LTB-Pk to the sulphur-based cation 
exchange matrix and its subsequent elution, resulted in a highly purified preparation of LTB- 
Pk, with no apparent contaminating material, as determined by SDS-PAGE. Thus in terms of 
purity, ion-exchange chromatography is superior to hydrophobic chromatography for 
purifying LTB-Pk from crude culture medium. There are several other advantages to the ion- 
exchange teclinique. For example, unlike hydrophobic chromatography where protein 
samples are applied under high salt conditions, there is no need to introduce and subsequently 
remove, an extraneous substance (e.g. ammonium sulphate) to tlie material to be purified.
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Further, not only did the absence of ammonium sulphate during the ion-exchange procedure 
help preserve the Pk fusion, the retention of the oligomerisation and GMl-binding properties 
of LTB-Pk, suggests that the gentle conditions under which the purification was conducted, 
did not damage any epitopes that are important for the physiological properties of LTB-Pk. 
Combining these observations, with the fact that the Bio-rex 70 column is cheap, easy to 
store, easy to regenemte, readily available, does not need expensive equipment to operate, 
and is re-usable, highlights its potential to purify LTB-Pk on the industrial level.
5. Systemic Immunogenicity o f LTB-Pk,
LTB is a potent systemic (and mucosal) immunogen, and it is thought that this 
property may contribute to the adjuvanticity of the molecule. Initial studies on the 
immunogenicity of ammonium sulphate purified LTB-Pk were conducted in the murine 
Balb/c strain (H-2K‘*) which are reported to be high responders to LTB [source of personal 
communication]. It was suggested from these studies that LTB-Pk alone was a potent 
systemic immunogen, inducing high levels of serum immunity to itself following 
intraperitoneal administration. Although, the immunogenicity of LTB-Pk was slightly 
abrogated by complexing LTB-Pk to the Pk-specific MAb, SV5-P-k, the reduction in tlie 
response was slight There were two interesting observations firom these initial studies. The 
first being tliat the presence of additional adjuvant like alum, was not apparently necessary to 
potentiate tlie immune response to LTB-Pk. Secondly, the immunity generated to LTB-Pk 
was predominately directed at LTB and not the Pk-epitope. There have been previous reports 
on the poor serum immunity to the Pk-tag when the epitope was incorporated into 
immunogenic solid matrix-antibody-antigen (SMAA) complexes [Randall etaL, 1993; 1994]. 
This was thought to W beneficial, since it implied that the immune response was not directed 
at the irrelevant epitope.
One factor that had to be taken into consideration in these initial studies, was that the 
LTB-Pk preparation was not completely pure. Thus it was possible that contaminants in the 
LTB-Pk preparations may be responsible, or contribute, to the potency of LTB-Pk, e.g. by 
polyclonally activating B cells. However, there was evidence to suggest this was not the
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case. Firstly, analysis of the sera from vaccinated mice, demonstrated that the immune 
response was highly specific for LTB-Pk. Secondly, when later immunisation studies using 
highly purified LTB-Pk were conducted, very high levels of serum immunity specific for 
LTB-Pk were detectable (data not shown). This evidence suggests that LTB-Pk, like LTB, is 
a potent sys^mic immunogen.
6, Systemic immunogenicity o f  SIV^MAb-^LTE complexes^
Preliminary immunogenicity studies on the efficacy of LTB-Pk to promote immunity 
to conjugated SIV proteins, were concerned with analysing the immune response to the 
simian immunodeficiency virus (SIV) recombinant gag gene product, p 17 or to denatured 
SrV proteins from SIV-infect cell lysates. Such studies suggested that the conjugation of 
recombinant pl7 to LTB-Pk via MAb SV5-P-k could potentiate the immune response to 
recombinant pl7 4-8 fold more than immunisation with pl7-MAb complexes alone. Further, 
following immunisation with pl7-MAb-LTB complexes the resulting anti-pl7 titres, were 
similar in all immunised mice and also were almost equivalent to the response generated 
following immunisation with pl7-MAb complexes in the picsence of alum. The potency of 
pl7-MAb-LTB complexes could be slightly enhanced by the inclusion of a second adjuvant, 
alum. This difference in response to His-pl7-Pk, was not due to variability in doses of 
administered antigen in the different vaccines, since comparative SDS-PAGE analysis of the 
various vaccines prior to vaccination, demonstrated that all vaccines contained equivalent 
amounts of His-pl7-Pk and where appropriate LTB-Pk.
In an attempt to characterise the antibody response to His-pl7-Pk, the sera was 
re-assayed for antibodies of the IgG class and divided into Protein A-binding (IgG subclasses 
of IgG2a» IgCÎ2b IgGg) versus non Protein A binding (IgG subclass IgG^) antibodies. 
Although all immunogenic vaccines resulted in a demonstrable IgG response (data not 
shown), only LTB-containing vaccines induced antibodies that could interact with Protein A, 
suggesting that LTB-Pk can modulate the immune response to His-pl7-Pk.
Serum immunity to LTB-Pk was also demonstrable following immunisation with 
pl7-MAb-LTB complexes (either alone or with alum) and this antibody response was readily
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detectable with HRP-conjugated Protein A (data not ahown). The presence of IgG antibodies 
is indicarivc of the involvement of cell -mediated immunity, since the switch from IgM 
p ro d u c ts  to IgG production is govenied by (he presence of lymphokines [reviewed by 
Rnkelmiin et ai,, 1990]. Support for the induction of cell-mediated immune responses, was 
suggested when the spl^ocytes from immune mice were investigated in vitro for their ability 
to respond to His-pI7-Pk and LTB-Pk. Mixed lymphocyte proliferation assays demonstrated 
that mice immunised with pl7-MAb-LTB complexes in the presence or absence of alum, 
responded to stimulation with His-pl7-Pk with a more enhanced proliferation than mice 
immunised with pl7-MAb complexes adsorbed onto alum. In an attempt to identify 
proliferating cell type, the phenotype of the proliferating cells were determined by FACscan 
analysis. Such studies revealed that after a five day stimulation period, the vast proportion of 
cells detectable by FACscan analysis expressed the CD4 molecule on their cell surface (i.e. 
the cells were CD4+ T cells), there being little evidence of the presence of B cells. The lack of 
detectable B cells after a five day stimulation in vitro was not due to the absence of B cells in 
the initial lymphocyte samples since FACscan analysis of the original preparation revealed 
that an approximately equal number of B cells and CD4+ T cells were present. However, 
although the evidence would suggest that CD4+ T cells are responding in the assay, it is 
possible that the B cells died during the culture period, and thus the high level of CD4+T cell 
detection, was simply due to the CD4+T cells' ability to survive during the culture period. 
Thus, in a second attempt to determine whether T cells are responding to specific antigenic 
stimulation, the supernatants from stimulated cultures were assayed for the presence of 
cytokines.
Based on their production of cytokines murine (D4+ T cell clones have been 
divided into two groups; T^l cells that predominantly produce IL-2, IL-3, lymphotoxin, and 
IFN-y or Tfj2, producing IL-3, BL-4, IL-5 and BL-6 [Mosmann et ah, 1986]. Stimulation of 
immune cells from p 17-MAb/alum, p 17-MAb-LTB or p 17-MAb-LTB/alum immunised mice 
with His-pl7-Pk, resulted in very little IL-2 being detectable in the culture supernatants. This 
was not due to insensitivity of the cytokine-ELISA assay to detect IL-2, since high levels of 
IL-2 were loadily detectable in the cultures that had been mitogenically stimulated with PHA.
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The lack of detection of IL-2 in antigen-stimulated cultures has been observed by others [A. 
Mowat, personal communications], the explanation for which, is unknown. In contrast to 
these findings, high levels of IFN-y were secreted by His-p 17-Pk-specific immune cells firom 
mice vaccinated with pl7-MAb-LTB complexes (with or without alum), but IFN-y 
production detectable from lymphocytes from mice primed with pl7-MAb in association with 
alum was below background levels. Very minor levels of IL-5 could be detected from each 
culture, and was highest in tlie mice vaccinated with pl7-MAb-LTB complexes in association 
with alum. Tliis poor response to IL-5 from spleen cultures was also evident from PHA 
stimulated cultures, and has been reported by others [Wilson et al,, 1991], the reason for 
which is unknown. This evidence suggests that the presence of LTB-Pk in the vaccine 
formulations leads to the stimulation of T cells capable of secreting IFN-y, possibly CD4+ 
T|^l cells. Whether, CD4+ T^2 cells aie also stimulated can not be presumed since there is 
insufficient evidence that a T^2 profile was present Similar studies with cholera toxin [Vajdy 
and Lycke, 1993; Jackson et aL, 1993] have shown that intraperitoneal administration of the 
enterotoxin and unrelated antigen can lead to a characteristic T^l response to the unrelated 
antigen in the spleen, which would support the evidence presented here. However, it is 
important to point out that, the proliferation assay relied on unfractionated splenic 
populations. A major disadvantage of such an approach is that the relationship to the cell type 
producing the cytokine can only be made by indirect argument. In the present study, the 
FACscan assayed for the presence of the CD4-f T cell subset after antigenic stimulation, and 
not the CD8+ T cell subset. CD8+ T ceil, normally characterised as cytolytic T cells, have now 
been shown to be capable of secreting a cytokine pattern similar to that of T^l cells i.e. they 
can produce cytokines similar to that of T^l cells, like IFN-y and IL-2 [Fong and Mosmann, 
1990]. Thus in can not be ruled out that CD8+ T cells or some other IFN-y producing cell, 
were responsible for the high level of IFN-y production. For future work, the use of purified 
(ZD4+ T cells would ensure that the antigen effects noted were due to direct stimulation of 
CD4+ T cells and not due to stimulation of other cell types that could influence the cytokine 
pattern observed. In addition, in situ hybridisation assays that specifically probe for a certain
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cytokine RNA levels in cells that respond to antigen-specific stimulation, will also help to 
characterise the responding cells further.
These initial immunogenicity studies gave a strong indication on the efficacy of 
conjugating pl7-MAb complexes to LTB-Pk. Unfortunately, they failed to establish whether 
co-administration of His-p 17-Pk with LTB-Pk would similarly potentiate the response to His- 
pl7-Pk. Subsequent experiments that compared the efficacy of co-administration of LTB-Pk 
with His-p 17-Pk as opposed to pl7-MAb-LTB complexes to promote immunity to His-p 17- 
Pk, revealed that foUowng three intraperitoneal immunisations, co-administration of His- 
p 17-Pk with LTB-Pk was as efficient as pi 7-MAb-LTB complexes at potentiating the 
response to His-pl7-Pk (data not shown). This would suggest tliat the complexing of the 
recombinant pl7 to LTB-Pk via tlie monoclonal antibody bridge (and therefore the targeting 
of the complex onto GMl-ganglioside) is not a vital requirement for the LTB-Pk to adjuvant 
the response to His-p 17-Pk. However, a later series of systemic immunogenicity studies 
using recombinant His-p27-Pk as a target antigen, revealed that although three immunisations 
with His-p27-Pk co-adrainistered with LTB-Pk enhanced the immune response to His-p27- 
Pk in a similar manner to that seen following immunisation with p27-MAb-LTB complexes, 
the p27-MAb-LTB complexes were more potent. This was suggested by the evidence that 
two administrations of p27-MAb-LTB complexes induced a 8-10 fold enhancement in the 
response to His-p27-Pk, in compaiison to the response generated following co-administration 
of His-p27-Pk and LTB-Pk. Thus it would seem that, conjugation of His-p27-Pk to LTB-Pk 
via MAb SV5-P-k leads to a more efficient presentation of recombinant p27 to the immune 
system. Furthermore, these later studies employed highly purified preparations of LTB-Pk in 
the vaccine formulations, thus the adjuvant effects mediated by LTB-Pk were not due to 
impurities in tiie vaccine preparations.
These results highlight the efficacy of SIV-MAb-LTB complexes as systemic 
immunogens and suggest that targeting of recombinant SIV antigens onto GMl-ganglioside 
via LTB-Pk, is important at promoting a more efficient response to the recombinant SIV 
antigen.
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7. Mucosal immunogenicity o f  SFV-MAh-LTB complexes.
Intranasal administration of Ipg of His-p 17-Pk either alone, as part of an 
immime-complex (pl7-MAb), co administered with LTB-Pk or conjugated to LTB-Pk (pl7- 
MAb-LTB) did not induce any detectable anti-His-p 17-Pk specific humoral immunity in the 
serum or saliva of vaccinated mice. In contrast, both co-administration of His-p 17-Pk with 
LTB-Pk and vaccination with pl7-MAb-LTB complexes induced a significant serum antibody 
response to LTB-Pk demonstrating that LTB-Pk itself to be immunogenic in the nasal 
mucosae, a finding which was later supported by the identification of anti-LTB-Pk secretory 
antibody in the saliva of vaccinated mice. LTB, like CTB is thought to increase adsorption of 
protein antigens over the mucosal epithelium when co-administered with the protein, though 
this may not always be the case. For LTB-conjugates uptake of LTB by the mucosae 
epithelium should, in theory result in concomitant uptake of conjugated protein, and thus 
increase the chance of stimulating mucosal immunity. Thus, it was surprising and 
disappointing that pi 7-MAb-LTB complexes did not prime the mucosal system against His- 
pl7-Pk.
Several possibilities exist as to why LTB-Pk failed to potentiate the immune 
response to His-p 17-Pk. Firstly, protease activity in the intranasal cavity may result in the 
cleavage of the Pk epitope from both LTB-Pk and His-p 17-Pk, which would effectively 
destroy the linkage between the two recombinant antigens, or that His-p 17-Pk itself was 
rapidly degraded. Secondly, the antibcxly molecule itself, could have been subject to 
proteolytic attack, once again destroying the linkage of His-pl7-Pk and LTB-Pk. Thirdly, the 
affinity of LTB-Pk for GMl was reduced due to the linkage of antibody and antigen, and thus 
complexes did not form a strong interaction with the epithelial cells promoting their uptake.
In an attempt to understand which theory was the most likely explanation, the 
stabilities of LTB-Pk, MAb SV5-P-k and His-p 17-Pk upon exposure to mucosal proteases 
were investigated in vitro. Neither MAb SV5-P-k nor LTB-Pk were shown to be susceptible 
to proteolytic attack. In contrast, His-p 17-Pk was extremely vulnerable to proteolytic attack 
and could be rapidly degraded upon exposure to mucosal proteases. Although such a result
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dcies m î  fcmally prove ihal breakdown of His-pl7-Pk is responsible for tlie poor 
îmmun&smmîy exhibited by the His-pl74% vaccine formulations, the idea is attractive.
ÎI was therefore decided that only reccHnbinant SIV proteins that were more 
resilient %> proteolytic atmck should be used for the investigation into the m ucosal 
im m unogenicity of SIV-M Ab-LTB com plexes. One such recombinant SIV protein was His- 
p27-Pk, wliich like His-pl7-Pk is a recombinant gag gene product. Proteolysis experiments 
with His-p27-Pk demonstrated that even at minor concentrations, although some degradation 
was detectable in Western blot assays, the protein seemed to be fairly resistant to proteolytic 
degiadation. Further, when p27 -MAb-LTB complexes were incubated with mucosal 
pioteases, then mixed with Staphylococcus aureus, the whole complex was efficiently 
precipitated, providing additional support that such p27-MAb-LTB complexes are relatively 
stable and have the potential to be used as mucosal immunogens.
This theory was tested in immunisation studies using Balb/c mice given p27- 
MAb-LTB intranasally tliree times. Specific immunity to His-p27-Pk and LTB-Pk was 
readily detectable by ECL immune assays, in the sera of all vaccinated mice 10 days after the 
final immunisation. Little of the immune response was directed at the Pk epitope and when 
the sera was re-assayed for reactivity with Western-blotted viral proteins from SlV-infected 
cells, antibodies specific for both p27 and its precursor, p57, were identified. Such specific 
immunity in the sera, suggests that p27-MAb-LTB can be taken up by the nasal mucosae for 
presentation to mucosal B cells and (presumably) T cells.
His-p27-Pk specific immunity was evident in the lungs of intranasally vaccinated 
mice (as measured by ELISPOT assays) immunised with p27-MAb-LTB complexes, but no 
antibodies to His-p27-Pk could detected in the saliva. One of the interesting observations with 
regards the His-p27-Pk-specific antibody isotype distribution was that the IgG isotype was 
the dominant isotype in both the lungs and the spleen. High levels of IgA antibodies specific 
for His-p27-Pk were also readily detectable in the lungs but not in the spleen. Such high 
levels of IgA specific antibodies in the mucosa and minor levels in the periphery is consistent 
with mucosal priming of the immune response [Murphy et al. 1994]. In viral infections there 
is normally a correlation between serum IgG and protection against pulmonary virus growth
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[Hall et al., 1991; Walsh et a i, 1987] and this has been attributed to serum IgG transudating 
the !«ng epiihellum as exposed to the presence of IgG-secreting cells in the lungs. The data 
presented here, suggests that IgG-secreling B cells themselves can reside in the lung, though 
whether the presence of the IgG-secreting cells is a reflection of the trafficking of peripheral 
IgG -secreting cells into the lung or, whether the IgG-secreting cells are from a mucosal 
origin, is unknown. Studies by Jones and Ada, 1986 have quantitated the proportion of IgM, 
IgG and IgA secieting cells in the lungs of mice following virus infection and have noted that 
the IgG-screting B cells predominate. Whereas, similar studies on the isotype distribution in 
tlie small intestine have revealed that, following virus infection, IgA-secreting B cells 
predominate in the Peyers patches. Such evidence suggests that IgG-secreting cells may have 
a prominent role in the immune surveillance of the lung against viral infections or that factors 
in the lung microenvironment favours the generation of IgG-secreting B cells. Thus, the 
presence of His-p27-Pk-specific IgG-secreting cells in the lungs of p27-MAb-LTB vaccinated 
mice, may be a reflection on the presence of the viral antigen in the vaccine. Alternatively, the 
existence of IgG-secreting cells in the lungs, may be the result of an inflammatory response 
following p27-MAb-LTB administration. This needs further investigation.
Recent evidence by McGhee and colleagues (1993), suggests that in mucosal 
tissues, T^2 cells predominate and produce IL-5 which promotes the generation of IgA- 
secreting cells. Others support this observation [Beagley et al., 1988]. Thus, the presence of 
IgA-secreting B cells in the lungs of vaccinated mice, may indicate that intranasal 
administration of p27-MAb-LTB complexes can selectively prime T^2 cells in the mucosae.
The relevance of secretory IgA in the upper respiratory tract for preventing virus 
replication has also been recently advocated [Renegar and Small, 1991]. However, there was 
no evidence that intranasal administration of p27-MAb-LTB complexes induced His-p27-Pk 
specific IgA in the saliva, and only minor levels of anti-LTB-Pk IgA antibodies were 
detected Although this poor response may be a reflection on the time course of the 
experiment e.g. saliva was collected fairly soon after immunisation (11 days), even at later 
times (35 days post immunisation) only anti-LTB-Pk antibodies were detected (data not 
shown). Alternatively, the inability to detect IgA antibodies to His-p27-Pk and the detection
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of only low levels of anti-LTB-Pk IgA antibodies may be due to the insensitivity of the ECL- 
assay performed.
The induction of long teim memory, is obviously desirable in the design of 
vaccines. It has generally been assumed that tlie mucosal immune system does not display 
memory. However, this is now disputed [Lycke etaU, 1987; Lycke and Holmgren, 1986; 
1987; Vajdy and Lycke, 1993]. The ability of intranasal administration of p27-MAb-LTB 
complexes to induce memory to His-p27-Pk and LTB-Pk was examined in lymphocyte 
proliferation assays. Immune cells from mice that had been intranasally vaccinated three times 
with p27-MAb-LTB complexes, were stimulated in vitro witli His-p27-Pk and LTB-Pk, three 
months after the last immunisation. Both His-p27-Pk and LTB-P specific immune cells were 
shown to respond to antigenic challenge. Phenotypic analysis of the lymphocytes following a 
five day stimulation revealed that, CD4+ T cells predominated in LTB-Pk stimulated cultures. 
In His-p27-Pk stimulated cultures, although CD4+ T cells tended to predominate, there was 
also evidence that CD8+ T cells may be responding to antigenic stimulation as well. There 
was also evidence that B cell memory occurred following intranasal immunisation with p27- 
MAb-LTB complexes, since serum immunity to the recombinant antigens was detectable 
following a fourth intranasal boost, three months after the third immunisation (data not 
shown). Thus, both B-cell and T-cell memory may be generated by intranasal immunisation 
with p27-MAb-LTB complexes.
One question this study does not determine is whether intranasal co-administration 
of LTB-Pk and His-p27-Pk would promote similar levels of immunity to the recombinant 
antigens that were seen following immunisation with p27-MAb-LTB complexes. Preliminary 
studies have shown that two intranasal immunisations with His-p27-Pk co administered with 
LTB-Pk or administration of p27-MAb-LTB complexes, followed by one intraperitoneal 
immunisation with the respective vaccines, resulted in serum immunity to His-p27-Pk in mice 
vaccinated with p27-MAb-LTB complexes but not in mice given His-p27-Pk co-administered 
with LTB-Pk (data not shown). Such findings suggest that the linkage of His-p27-Pk to 
LTB-Pk is important for the recombinant SIV protein to be immunogenic by the mucosal 
route i.e. the ability to target His-p27-Pk onto GMl-ganglioside via the binding of LTB-Pk to
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the glycolipid, is crucial to promote immunity to the recombinant SIV protein in the mucosal 
system. In support of this observation, Dertzbaugh et al., 1990, have shown that CTB- 
peptide fusions that inhibit GMl-ganglioside binding, are not immunogenic by the mucosal 
route. Nevertheless, it still has to be confirmed that p27-MAb-LTB complexes are more 
immunogenic by the mucosal route than co-administration of His-p 17-Pk and LTB-Pk.
8. Areas o f Future Investigation.
One area of friture investigation is continuation of the studies into the efficacy of 
SrV-MAb-LTB complexes as immunogens, particularly their immunogenicity in the mucosal 
immune system. The mucosal immunogenicity results presented above, have concentrated on 
p27-MAb-LTB complexes containing ammonium sulphate purified LTB-Pk. It will need to be 
verified that liighly purified preparations of p27-MAb-LTB complexes have similar efficacies 
in the mucosal system.
Although these studies have centred on the administration of SIV-MAb-LTB 
complexes by the intranasal route, there have been problems with the administration of the 
complexes. In some instances the use of diethyl ether as the anaesthetic has lead to fatalities. 
An approach that is currently under evaluation is the administration of vaccines by 
nébulisation. In this instance, soluble vaccine formulations are vaporised under high 
pressure, the vapour is then readily inhaled by the mice. This procedure ensures that the 
vaccine reaches the lungs and since no anaesthetic is necessary, it is harmless to the 
experimental animals. Preliminary work with the nébulisation system has concentrated on 
analysing the ability of highly purified LTB-Pk to induce semm immunity to itself, following 
inti'anasal nébulisation. So far, the results have been promising, with mice exhibiting high 
levels of serum immunity to LTB-Pk following four nébulisations. However, it has still to be 
establish^ what is the ideal dose of antigen needed for efficient stimulation of the immune 
system following nébulisation. At present, high doses of antigen are being employed 
(approximately 50(ig of antigen per mouse) since the efficiency rate of antigen uptake by the 
mice following nébulisation is thought to be as low as 1/10th of the administered dose. 
Whether nébulisation will be a successful procedure for the administration of SIV-MAb-LTB
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complexes remains to be verified. Recent experiments have suggested that administration of 
the complexes in such a manner, did not lead to serum immunity to the recombinant SIV 
protein and only low levels of immunity to LTB-Pk. Whether, this poor response to the 
recombinant antigens was due to damage of the vaccine following vapourisation, or due to 
too low a dosage, remains to be investigated.
It has recently been established that immunisation with CTB and formalin 
inactivated influenza A virus can lead to virus specific CD8+ CTL.The level of immunity is 
similar to natural infection with live replicating virus [Mbawuike and Wyde, 1993]. 
Considering the important role cytotoxic CD8+ T cells have in the control of virus infections, 
it would be of interest to establish whether administi'ation of SIV-MAb-LTB complexes can 
lead to priming of this arm of the immune system.
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